Turner syndrome is a rare genetic condition affecting only females, caused by a missing or partially missing X chromosome, leading to short stature, underdeveloped ovaries, and a range of other health concerns that vary widely from person to person.

Epidemiology

Turner syndrome is not as rare as many people might think, though it remains an uncommon condition that affects only females. The disorder occurs in approximately one in every 2,000 to 2,500 live female births worldwide. This means that thousands of girls are born with Turner syndrome each year, yet many families have never heard of the condition until it touches their own lives.^[1][2]

What makes the statistics particularly striking is that Turner syndrome is far more common at conception than these numbers suggest. Research has shown that the condition is present in many more pregnancies than result in live births. In fact, it has been estimated that only about one percent of fetuses with Turner syndrome survive to term. The condition is believed to cause as many as 10 percent of all first-trimester miscarriages, meaning that most pregnancies affected by Turner syndrome end before the baby can develop fully.^[2]

Unlike some genetic conditions such as Down syndrome, Turner syndrome does not appear to be linked to the age of the parents. Advanced maternal or paternal age is not considered a significant contributor to the risk of having a child with Turner syndrome. The condition occurs randomly and sporadically, affecting families across all ethnic backgrounds, geographical regions, and socioeconomic groups. There are no clearly established environmental risk factors that increase the likelihood of Turner syndrome occurring.^[3]

Causes

Turner syndrome happens when genetic material is missing from one of the two sex chromosomes that typically determine a person’s biological characteristics. To understand this, it helps to know how chromosomes work in the human body. Every person normally has 46 chromosomes arranged in 23 pairs inside each cell of their body. These chromosomes carry genes, which are like instruction manuals that tell the body how to grow, develop, and function. Of these 23 pairs, 22 are called autosomes (numbered chromosomes), and one pair consists of sex chromosomes that determine whether someone is male or female.^[1]

Typically, females have two X chromosomes (XX), while males have one X and one Y chromosome (XY). In Turner syndrome, however, a female is born with only one complete X chromosome instead of two, or with one normal X chromosome and a second X chromosome that is partially missing or altered. This means that critical genetic information is absent, and this missing material affects how the body develops before and after birth.^[4]

There are two main ways this chromosomal change can occur. The first is called monosomy X, where one X chromosome is completely absent from every cell in the body. This typically happens because of an error during the formation of the egg or sperm cell from one of the biological parents. This error is known as nondisjunction, a mistake in cell division that results in a reproductive cell with an abnormal number of chromosomes. If that egg or sperm then contributes to conception, the resulting baby will have only one X chromosome in each cell. Monosomy X is generally the more severe form of Turner syndrome, with more recognizable physical features.^[1][4]

The second type is called mosaic Turner syndrome. In this form, the chromosomal abnormality occurs randomly during the very early stages of fetal development, after conception has already taken place. As the embryo’s cells divide and multiply, some cells end up with the typical two X chromosomes while others have only one. This creates a “mosaic” pattern where different cells in the body have different chromosomal makeup. Girls with mosaic Turner syndrome often have milder symptoms because some of their cells are functioning normally.^[1][4]

Scientists have not yet fully determined why these chromosomal errors happen. The condition is not caused by anything the parents did or did not do before or during pregnancy. It cannot be prevented, and it is not typically inherited or passed down through families. Instead, it occurs as a random event. Recurrence in subsequent pregnancies is extremely rare, giving parents reassurance that the chance of having another child with Turner syndrome is very low.^[11]

Risk Factors

Turner syndrome is unique among genetic conditions in that there are no well-established risk factors that increase the likelihood of a baby being born with the disorder. Unlike conditions such as Down syndrome, where advanced maternal age is a known risk factor, Turner syndrome occurs randomly and does not appear to be influenced by the age of either parent at the time of conception. Whether the mother is 20 years old or 40 years old, the risk remains essentially the same.^[3]

No environmental exposures, lifestyle factors, or behaviors during pregnancy have been identified as increasing the risk of Turner syndrome. Parents can take comfort in knowing that nothing they did or failed to do before or during pregnancy caused the condition. The chromosomal error happens by chance during the formation of reproductive cells or in the earliest stages of embryonic development.^[11]

Because Turner syndrome is not typically inherited, having a family history of the condition does not significantly increase risk. Most cases occur sporadically in families with no previous history of the disorder. Very rarely, the condition can be passed from a parent to a child, but this is extremely uncommon. For families who have had one child with Turner syndrome, the chance of having another affected child in a subsequent pregnancy is no higher than it would be for any other family in the general population.^[11]

Symptoms

Turner syndrome affects everyone differently, and the range of symptoms can vary dramatically from one person to another. Some girls show obvious signs shortly after birth, while others may not be diagnosed until they are teenagers or even adults. The timing and severity of symptoms depend partly on whether a girl has monosomy X or mosaic Turner syndrome, with mosaic forms generally causing milder features.^[1]

Sometimes, signs of Turner syndrome can be detected even before a baby is born. During routine pregnancy ultrasounds, doctors may notice certain features that raise suspicion. These prenatal signs include fluid collecting around the back of the fetus’s neck (called increased nuchal translucency or cystic hygroma), heart problems, or kidney and urinary tract abnormalities. When these features are seen on ultrasound, healthcare providers may recommend additional testing to check for Turner syndrome.^[1][8]

At birth or shortly after, some babies show physical features that may lead doctors to suspect Turner syndrome. These can include a short, wide neck with extra folds of skin (often called a “webbed neck”), a low hairline at the back of the neck, and ears that are low-set, unusually shaped, or rotated. Some babies are born with swelling of the hands and feet, known as lymphedema, caused by fluid buildup in the tissues. Other features might include a broad chest with nipples that are spaced farther apart than usual, arms that bend outward slightly at the elbows, flat feet, and narrow fingernails and toenails.^[1][6]

The two most common and consistent features of Turner syndrome are short stature and problems with ovary function. Almost everyone with Turner syndrome experiences slower growth than their peers. This usually becomes noticeable around age five, when affected girls are noticeably shorter than other children their age. Without treatment, girls with Turner syndrome typically do not experience the growth spurts that normally happen during childhood and adolescence. The average final adult height for women with untreated Turner syndrome is approximately 143 centimeters, or about 4 feet 7 inches, which is significantly shorter than the average height for women.^[1][2]

The ovaries are the female reproductive organs that produce egg cells and important hormones like estrogen. In girls with Turner syndrome, the ovaries often develop normally at first during fetal development, but the egg cells typically die prematurely, and most ovarian tissue breaks down before birth. This condition, called primary ovarian insufficiency, means that the ovaries produce little or no female sex hormones and contain few or no eggs. As a result, most girls with Turner syndrome do not go through puberty naturally. They may not develop breasts, start menstrual periods, or experience other changes associated with adolescence unless they receive hormone therapy. The vast majority of women with Turner syndrome are unable to become pregnant naturally, though some with mosaic forms may retain enough ovarian function to conceive, and assisted reproductive technologies can help some women have children.^[1][4]

Beyond growth and reproductive development, Turner syndrome can affect many other parts of the body. About 30 to 50 percent of individuals with the condition are born with heart defects. The most common heart problems include a narrowing of the aorta (the major blood vessel carrying blood from the heart to the body), called coarctation of the aorta, and abnormalities of the aortic valve (the valve connecting the aorta to the heart). Some people may also develop progressive dilation of the aortic root, which can be life-threatening if not monitored and managed properly. These cardiac complications are among the most serious health concerns associated with Turner syndrome.^[4][12]

Kidney problems are also common, affecting about one-third of girls with Turner syndrome. These may include structural abnormalities such as horseshoe kidney (where the two kidneys are fused together) or problems with how the kidneys are positioned or shaped. Hearing difficulties can occur due to repeated ear infections or structural problems with the inner ear, and many girls develop sensorineural hearing loss (hearing loss caused by damage to the inner ear or hearing nerves) as they get older. Vision problems, including drooping eyelids, lazy eye, or nearsightedness, are also more frequent in Turner syndrome.^[2][6]

Other health issues may include an underactive thyroid gland, which affects metabolism and energy levels; high blood pressure; a tendency to gain weight; an increased risk of developing diabetes; and bone thinning (osteoporosis), which makes bones more fragile and prone to fractures. Some girls also have a higher number of moles on their skin than usual.^[2][6]

Prevention

Unfortunately, there is currently no known way to prevent Turner syndrome from occurring. Because the condition results from a random error in chromosomal formation or division, it cannot be predicted or avoided through any lifestyle changes, dietary choices, or medical interventions before or during pregnancy. Parents cannot take any actions to reduce the risk of having a child with Turner syndrome, as the chromosomal abnormality happens spontaneously and is not linked to anything they did or did not do.^[11]

However, while Turner syndrome itself cannot be prevented, many of its complications and associated health problems can be prevented, minimized, or managed effectively with early intervention and appropriate medical care. This is where early diagnosis and proactive health management become crucial. Once Turner syndrome is identified, whether before birth, in infancy, or later in childhood, a comprehensive care plan can be put in place to address potential health issues before they become serious.^[5]

Regular health screenings are an essential part of preventing complications in girls and women with Turner syndrome. Cardiovascular problems, which are among the most serious risks, can be detected early through regular heart examinations and imaging tests. All individuals with Turner syndrome should have a thorough cardiac evaluation at the time of diagnosis, and those with heart abnormalities or high blood pressure should receive ongoing monitoring. These regular check-ups allow doctors to identify changes in the aorta or heart valves early, when interventions can be most effective and potentially life-saving.^[12]

Bone health is another area where preventive measures can make a significant difference. Because girls with Turner syndrome are at higher risk for osteoporosis, starting calcium and vitamin D supplementation during childhood can help build stronger bones. Healthcare guidelines recommend beginning calcium and vitamin D supplements around age 10. Weight-bearing exercises such as walking, running, and strength training also help maintain bone density throughout life. Estrogen replacement therapy, which is typically started during the teenage years, also plays an important role in protecting bone health.^[12]

Regular monitoring of blood pressure, kidney function, thyroid hormone levels, and bone density allows healthcare providers to catch problems early and start treatment before complications develop. Blood pressure should be checked regularly, as girls with Turner syndrome have a higher risk of developing hypertension. Thyroid function tests can detect an underactive thyroid early, allowing for hormone replacement before symptoms affect quality of life. Hearing and vision should also be checked periodically, with intervention provided as needed.^[5][11]

Growth hormone therapy and estrogen replacement are not preventive measures in the traditional sense, but they do prevent some of the developmental issues associated with Turner syndrome. Growth hormone treatment, typically started in early childhood, can help girls reach a more typical adult height, preventing the psychological and practical challenges associated with being significantly shorter than peers. Estrogen therapy, usually initiated during the preteen or early teenage years, allows girls to go through puberty and develop secondary sexual characteristics, supporting both physical and emotional development.^[9]

Pathophysiology

Understanding what happens in the body at a cellular and molecular level helps explain why Turner syndrome causes such varied symptoms. The fundamental problem lies in having only one functioning X chromosome instead of the usual two. While it might seem that having one X chromosome should be sufficient since one X chromosome is normally inactivated in females anyway, the reality is more complex. Not all genes on the second X chromosome are turned off during the normal X-inactivation process; some genes escape inactivation and continue to be expressed from both X chromosomes in typical females.^[3]

These genes that escape X-inactivation are crucial for normal development and function. When they are missing or present in reduced amounts due to Turner syndrome, the body cannot develop and function as it normally would. The loss of genetic material from the missing or abnormal X chromosome interferes with normal development, particularly affecting growth and the development and function of the ovaries. The degree of impact depends on how much genetic material is missing and whether all cells are affected (as in monosomy X) or only some cells (as in mosaic Turner syndrome).^[3]

One specific gene that scientists have identified as particularly important is called SHOX, which stands for short stature homeobox-containing gene. This gene is located on the X chromosome and plays a critical role in bone growth and development. When only one copy of the SHOX gene is functional instead of two, the result is impaired bone growth, leading to the short stature characteristic of Turner syndrome. The loss of the SHOX gene also contributes to some of the skeletal abnormalities seen in the condition, such as shortened bones in the hands and arms that bend outward at the elbows.^[4]

The problems with ovarian function in Turner syndrome also have a clear biological basis. During normal female fetal development, the ovaries start out with a large number of immature egg cells. In Turner syndrome, the ovaries may develop initially, but the egg cells undergo accelerated death, a process called atresia. By the time a girl with Turner syndrome is born, most or all of the ovarian tissue has deteriorated, leaving behind only streak gonads (thin strips of nonfunctional tissue where the ovaries should be). Without functioning ovaries, the body cannot produce adequate amounts of estrogen and other sex hormones naturally, leading to absent or delayed puberty and infertility.^[1]

The cardiovascular abnormalities seen in Turner syndrome are thought to result from disrupted development during the embryonic period when the heart and major blood vessels are forming. The exact mechanisms are not fully understood, but the missing genetic material appears to affect how these structures develop in the womb. The most common heart defects, such as coarctation of the aorta and bicuspid aortic valve (where the aortic valve has two leaflets instead of the normal three), develop during the early weeks of pregnancy when the cardiovascular system is taking shape.^[12]

The lymphatic system abnormalities that cause swelling of the hands and feet at birth, and may contribute to the webbed neck appearance, also reflect developmental disruption. During fetal development, the lymphatic system (which helps drain fluid from tissues) may not form properly, leading to fluid accumulation. This is particularly evident in the neck region, where excess fluid can cause the characteristic webbing or thickened appearance of the skin.^[12]

Many of the other features and health problems associated with Turner syndrome likely result from the complex interplay of multiple genes on the X chromosome. Researchers continue to study which specific genes are responsible for which features, but it is clear that the loss of genetic material affects multiple body systems in different ways. The variability in how Turner syndrome affects different individuals reflects differences in exactly which genes are affected and to what degree, as well as individual genetic backgrounds and environmental factors.^[4]

Ongoing Clinical Trials for Usher’s Syndrome

Currently, there are 2 clinical trials investigating new treatments for Usher’s syndrome, a genetic disorder affecting both hearing and vision. These trials are testing gene therapy approaches aimed at addressing the underlying genetic causes of the condition, particularly focusing on Type 1B. The trials are taking place in Italy and France.

Clinical trial locations

• France
  • Study on Long-Term Safety and Effects of SAR421869 for Patients with Usher Syndrome Type 1B
• Italy
  • Study of AAVB-081 and Prednisolone for Patients with Usher Syndrome Type 1B Retinitis Pigmentosa

Study of AAVB-081 and Prednisolone for Patients with Usher Syndrome Type 1B Retinitis Pigmentosa

This trial is investigating a gene therapy called AAVB-081 for people with Usher Syndrome Type 1B, a genetic condition that causes both severe hearing loss from birth and progressive vision loss due to retinitis pigmentosa. The treatment uses a specially designed virus to deliver a healthy copy of the MYO7A gene directly to the retina, the light-sensitive layer at the back of the eye.

Who can participate: Adults between 18 and 50 years old with a confirmed genetic diagnosis of Usher Syndrome Type 1B caused by mutations in the MYO7A gene. Participants must be willing to follow the study procedures and sign an informed consent form.

Who cannot participate: People who do not have Usher Syndrome Type 1B with retinitis pigmentosa, those younger than 3 years old, pregnant or breastfeeding women, and individuals with allergies to the study medication or certain eye conditions that could interfere with the treatment.

What the trial involves: The study evaluates the safety and tolerability of AAVB-081 when injected under the retina. Participants will also receive prednisone, an oral medication. Throughout the study, participants undergo regular health checks including eye exams, blood tests, and vision assessments to monitor their response to treatment and any side effects. The goal is to find the best dose that balances benefits and risks, and to determine if this gene therapy can help improve or stabilize vision. The study is expected to conclude by May 2030.

Investigational drug: AAVB-081 is administered through a subretinal injection using an AAV8 viral vector to deliver the healthy MYO7A gene. The treatment aims to correct the underlying genetic cause of vision loss in this condition.

Study on Long-Term Safety and Effects of SAR421869 for Patients with Usher Syndrome Type 1B

This is a long-term follow-up study examining the safety and effects of SAR421869, another gene therapy approach for Usher syndrome Type 1B. The treatment involves a subretinal injection containing a human gene designed to address the genetic cause of the condition.

Who can participate: This study is only open to patients who previously enrolled in an earlier trial (protocol TDU13600) and received a subretinal injection of SAR421869. Participants must provide written informed consent and any required local authorization, such as HIPAA compliance. Both males and females can participate, including those from vulnerable populations.

Who cannot participate: People who do not have Usher’s syndrome Type 1B, those who were not part of the previous trial, or those who do not fall within the specified age range for the study.

What the trial involves: The study focuses on monitoring the long-term safety and tolerability of SAR421869. Participants undergo regular assessments to evaluate any adverse events, changes in eye health and safety, and potential delays in retinal degeneration. The primary goal is to understand how well patients can tolerate the medication over an extended period and to observe its biological effects. The study is expected to continue until June 2031.

Investigational drug: SAR421869 is delivered as a suspension for injection, targeting specific pathways involved in the disease process. The exact mechanism is still being studied in these clinical trials.

Summary

Both ongoing trials for Usher’s syndrome focus specifically on Type 1B, using gene therapy approaches to address the underlying genetic causes of the condition. These studies represent different stages of clinical research: one is evaluating an initial treatment approach with AAVB-081 in Italy, while the other is a long-term follow-up study of SAR421869 in France for patients who previously received the treatment. Both trials use subretinal injections to deliver gene therapies directly to the eye, aiming to improve or stabilize vision by correcting genetic defects. The trials reflect the growing focus on gene therapy as a potential treatment strategy for rare genetic disorders affecting vision. Each study emphasizes careful monitoring of safety and tolerability, with follow-up periods extending several years to assess long-term effects.

Usher syndrome is a rare genetic disease that affects both hearing and vision, and sometimes balance. Because the symptoms appear at different stages of life and vary in severity, proper diagnosis requires a careful combination of hearing tests, vision exams, balance assessments, and genetic testing to distinguish it from other conditions.

Introduction: Who Should Get Tested for Usher Syndrome

If you notice that your child has hearing loss or deafness from birth, it is important to consider the possibility of Usher syndrome. Many children with this condition are born deaf or with significant hearing problems, but the vision issues may not become apparent until later in childhood or adolescence. This delay between the identification of hearing loss and the diagnosis of vision problems can sometimes stretch to 5 to 10 years, which is why early and comprehensive diagnostic testing is so important.^[5]

Parents should seek diagnostic evaluation if their child shows signs of hearing loss combined with difficulty seeing in the dark, trouble moving around in dimly lit spaces, or taking longer to adjust to changes in lighting. These are often the first signs of retinitis pigmentosa, the eye disease that causes progressive vision loss in people with Usher syndrome. Children may also trip over objects they don’t see in their path or struggle with tasks that require side vision.^[1]

In some cases, children with Usher syndrome type 1 may also have difficulty keeping their balance, which can delay milestones like sitting up independently or learning to walk. If a baby or young child is born deaf or with severe hearing loss and also struggles with balance, this combination of symptoms should prompt immediate medical attention.^[2]

Because Usher syndrome is inherited from both parents, genetic testing and early screening have become more common. Even if there is no known family history of the condition, both parents may be carriers of the gene mutation without showing any symptoms themselves. If you have a family member with combined hearing and vision loss, or if your child has unexplained sensory issues, it is advisable to consult with a doctor who can arrange for comprehensive diagnostic testing.^[8]

Diagnostic Methods: How Doctors Identify Usher Syndrome

Diagnosing Usher syndrome involves a combination of tests that assess hearing, vision, balance, and genetics. Because the condition affects multiple sensory systems, doctors need to look at the complete picture to distinguish Usher syndrome from other conditions that may cause hearing or vision problems on their own.

Hearing Tests

The first step in diagnosing Usher syndrome is usually a hearing test. Many children with this condition are born with moderate to profound hearing loss, depending on the type of Usher syndrome they have. Audiologists, who are specialists in hearing, use a variety of tests to measure how well a child can hear different sounds and frequencies.^[5]

Hearing tests for Usher syndrome typically assess the severity and type of hearing loss. The hearing loss in Usher syndrome is called sensorineural hearing loss, which means it is caused by problems in the inner ear or the nerve pathways that carry sound signals to the brain. This type of hearing loss is different from hearing problems caused by ear infections or blockages, which affect the outer or middle ear.^[3]

Because hearing loss can be a symptom of many different conditions, audiologists also look for patterns that might suggest Usher syndrome. For example, children with type 1 Usher syndrome are often born profoundly deaf, while those with type 2 have moderate to severe hearing loss that primarily affects high-frequency sounds, making it hard to hear soft speech sounds like “d” and “t.” Type 3 is rare and involves hearing that is normal at birth but gradually worsens over time.^[3]

Vision Tests

Vision testing is critical for diagnosing Usher syndrome because the condition always involves retinitis pigmentosa, a progressive eye disease. An eye doctor, also called an ophthalmologist, will perform a comprehensive dilated eye exam, which is a simple and painless procedure. During this exam, the doctor puts special eye drops into your child’s eyes to widen the pupils, allowing them to see the back of the eye more clearly.^[1]

The exam includes checking the retina, which is the light-sensitive tissue at the back of the eye. In people with Usher syndrome, the cells in the retina gradually break down over time. The doctor will look for signs of this breakdown, such as changes in the appearance of the retina or the presence of dark spots. These changes indicate that retinitis pigmentosa is present.^[2]

One important part of the vision exam is a visual field test, which checks your child’s side (peripheral) vision. In Usher syndrome, peripheral vision is often the first to be affected, leading to a condition called tunnel vision, where the person can only see what is directly in front of them. This test helps doctors understand how much vision has already been lost and how the condition is progressing.^[1]

Doctors may also use additional tests to get more detailed information about the retina. One such test is electroretinography (ERG), which measures how well the retina responds to light. This test involves placing a sensor near the eye to detect electrical signals produced by the retina when exposed to light. A weaker response can indicate that the retina is damaged.^[1]

Another test called optical coherence tomography (OCT) uses light waves to take detailed pictures of the retina. These images allow the doctor to see the different layers of the retina and identify any areas of thinning or damage. This test is especially useful for monitoring how the disease is progressing over time.^[1]

Balance Tests

For children with Usher syndrome type 1, balance problems are a key feature that helps distinguish this type from others. The balance system is located in the inner ear, in a part called the vestibular system. When this system is not working properly, children may have trouble sitting up, standing, or walking at the expected ages.^[8]

Doctors can test balance using a procedure called videonystagmography. This test checks for abnormal eye movements that occur when the balance system is not functioning correctly. It helps doctors determine whether the vestibular system is affected, which is a strong indicator of Usher syndrome type 1.^[1]

Balance testing is particularly important because not all children with hearing and vision loss have balance problems. Children with Usher syndrome type 2 and most with type 3 have normal balance, so the presence or absence of balance issues helps doctors narrow down which type of Usher syndrome a child has.^[3]

Genetic Testing

Genetic testing is the most definitive way to diagnose Usher syndrome and determine which specific type a person has. Because Usher syndrome is caused by changes (mutations) in specific genes, a genetic test can identify which gene is affected. Scientists have identified at least 9 to 11 different genes that can cause Usher syndrome, depending on the source.^[1][2]

Genetic testing involves taking a small sample of blood or saliva and analyzing it in a laboratory to look for mutations in the genes known to cause Usher syndrome. The test can confirm the diagnosis even before vision problems become obvious, which is especially helpful for families who want to start planning for the future as early as possible.^[3]

Knowing the specific genetic mutation can also provide information about how the disease is likely to progress and whether a child might be eligible for certain research studies or clinical trials. Different types of Usher syndrome progress at different rates, so genetic testing helps doctors and families understand what to expect.^[7]

Because Usher syndrome is inherited in an autosomal recessive pattern, both parents must carry a copy of the mutated gene for their child to develop the condition. This means that parents who are carriers do not have symptoms themselves, and they may not even know they carry the gene. Genetic testing can also help other family members understand their risk of being carriers, which can be useful for family planning decisions.^[8]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or therapies for diseases like Usher syndrome. To participate in a clinical trial, patients usually need to meet certain criteria, which often include specific diagnostic tests to confirm the diagnosis and measure the severity of their condition.

For Usher syndrome clinical trials, genetic testing is almost always required. Researchers need to know which specific gene mutation is causing the condition because many experimental treatments are designed to target specific genetic subtypes. For example, a gene therapy trial for type 1B Usher syndrome, caused by mutations in the MYO7A gene, would only be open to patients with that exact mutation.^[13]

Vision testing is also a standard part of clinical trial qualification. Researchers typically use tests like ERG and OCT to measure how much retinal damage has occurred and how much vision the patient still has. Some trials may only accept patients at certain stages of vision loss—for example, those who still have some central vision but have lost most of their peripheral vision. These measurements help researchers determine if a treatment is working by comparing vision before and after the intervention.^[1]

Hearing tests are used to assess the degree of hearing loss and determine whether a patient’s hearing is stable or worsening. Some clinical trials may focus specifically on vision treatments, while others may aim to preserve both hearing and vision. Understanding the baseline hearing level is important for tracking any changes during the trial.^[5]

In addition to these sensory tests, clinical trials may also require general health assessments, such as blood tests, to ensure that participants are healthy enough to receive the experimental treatment. Some trials also collect detailed medical histories and ask about the age when symptoms first appeared, as this information helps researchers understand how the disease progresses and which patients are most likely to benefit from a particular therapy.^[13]

Usher’s Syndrome

Usher’s syndrome is a rare genetic condition that affects both hearing and vision, and is the most common cause of combined deafness and blindness. People with this condition are born with it, though symptoms develop at different times depending on the type. While there is no cure, early identification and proper management can help people live full, independent lives.

Table of contents

• What is Usher’s syndrome?
• Types of Usher’s syndrome
• Symptoms
• What causes Usher’s syndrome?
• How is Usher’s syndrome diagnosed?
• Treatment and management
• Living with Usher’s syndrome
• Current research

What is Usher’s syndrome?

Usher–Hallgren syndrome, retinitis pigmentosa–dysacusis syndrome, dystrophia retinae dysacusis syndrome

Usher’s syndrome is a rare genetic disease that affects both hearing and vision, and sometimes balance.^[1] It is the most common condition that causes combined deafness and blindness.^[8] The condition gets its name from Charles Usher, a British eye doctor who first described how it is passed down in families in 1914.^[5]

People who have Usher’s syndrome are born with it, though they typically receive their diagnosis during childhood or teenage years.^[1] The condition causes deafness or hearing loss and an eye disease called retinitis pigmentosa (RP), which is a breakdown of light-sensing cells in the back of the eye.^[1] Some types of Usher’s syndrome also cause balance problems.

Worldwide, researchers estimate that about 400,000 people have Usher’s syndrome.^[7] The condition affects approximately 4 to 17 out of every 100,000 people.^[3] It accounts for about 50 percent of all cases where people inherit both deafness and blindness from their parents.^[8] Among children who are deaf or hard of hearing, about 3 to 6 percent have Usher’s syndrome.^[8]

• Inner ear (cochlea)
• Retina
• Vestibular system

Types of Usher’s syndrome

There are three main types of Usher’s syndrome, and each type causes a different mix of health problems that appear at different ages.^[1] Scientists have identified at least 9 to 11 different genes that can cause Usher’s syndrome, which has led to multiple subtypes within each main type.^[1][7]

Type 1

People with type 1 Usher’s syndrome have the most severe symptoms from the earliest age. They experience profound hearing loss or complete deafness from birth, meaning they can only hear very loud sounds or no sounds at all.^[1] Balance problems are present from birth because the inner ear structures that help maintain balance don’t develop properly. These balance issues can make it harder for babies to sit up on their own and for children to learn to walk.^[1]

Vision problems typically start in early childhood, usually by age 10. Children first notice difficulty seeing in the dark, and their vision continues to worsen over time, often leading to severe vision loss by middle age.^[1] Type 1 is more common among people of Ashkenazi Jewish ancestry (from central and eastern Europe) and in French-Acadian populations.^[6]

Type 2

Type 2 is one of the most common forms of Usher’s syndrome.^[1] People with this type are born with moderate to severe hearing loss in early childhood, but their hearing typically doesn’t get worse over time.^[6] The hearing loss mainly affects their ability to hear high-pitched sounds, such as soft speech sounds like the letters “d” and “t.”^[3]

Unlike type 1, people with type 2 do not have balance problems and develop motor skills like walking at the expected age.^[1] Vision loss typically begins during the teenage years or early adulthood and progresses more slowly than in type 1.^[1] Many people with type 2 retain some central vision throughout their lives.

Type 3

Type 3 is the rarest form of Usher’s syndrome, accounting for only about 2 percent of all cases overall.^[3] However, it occurs more frequently in Finnish populations, where it accounts for about 40 percent of cases, and among people of Ashkenazi Jewish heritage.^[3]

People with type 3 are usually born with normal hearing and vision. Hearing loss typically begins during late childhood or the teenage years, after the child has already learned to speak, and becomes more severe over time.^[3] By middle age, most people with type 3 have profound hearing loss. Vision loss caused by retinitis pigmentosa also develops in late childhood or during the teenage years. About half of people with type 3 develop balance problems.^[3]

Symptoms

The main symptoms of Usher’s syndrome are hearing loss and vision loss, but the specific symptoms and when they appear depend on which type a person has.^[1] All people with Usher’s syndrome eventually develop retinitis pigmentosa, which affects their vision.

Hearing loss

Hearing loss in Usher’s syndrome is called sensorineural, which means it is caused by problems in the inner ear.^[3] The hearing loss happens because genetic changes affect nerve cells in the cochlea, the sound-transmitting structure of the inner ear, so these cells don’t send sound signals properly.^[2][4]

Some children with Usher’s syndrome are born completely deaf or with severe hearing loss. Others experience moderate hearing loss that may start later in childhood or adolescence.^[8] About 30 percent of people with retinitis pigmentosa report some degree of hearing loss, and about half of them are diagnosed with Usher’s syndrome.^[4]

Vision loss

Vision loss in Usher’s syndrome is caused by retinitis pigmentosa, which affects the retina—the light-sensitive tissue at the back of the eye.^[1] The retina contains special cells called rods and cones that convert light into electrical signals that the brain interprets as vision.^[4] In Usher’s syndrome, genes that make up retina cells change or mutate, causing these light-sensing cells to gradually break down.^[2]

The first sign of retinitis pigmentosa is usually difficulty seeing in low light or darkness, called night blindness.^[4] Children may have trouble moving around in the dark, take longer to adjust when lighting changes, or trip over objects they can’t see.^[1] As the condition progresses, people develop blind spots in their side vision (peripheral vision). Over time, these blind spots grow larger and merge together, creating what is called tunnel vision—where only the central area of vision remains.^[3]

Sometimes, clouding of the lens of the eye (cataracts) or cysts in the central part of the retina called the macula can cause additional vision problems and an earlier decline in central vision.^[8] In adults, retinitis pigmentosa can make it difficult to do daily activities like walking, driving, and reading.^[1]

Balance problems

Balance problems occur mainly in type 1 Usher’s syndrome and affect about half of people with type 3.^[2] These problems are caused by abnormal development of the vestibular system, which is the part of the inner ear that helps maintain the body’s balance and sense of position in space.^[3] The vestibular system contains special sensory cells called vestibular hair cells that detect gravity and head movement.^[8]

Children with balance issues may take longer than usual to sit up independently, begin walking later than expected, and may have difficulty riding a bicycle or playing certain sports.^[3]

What causes Usher’s syndrome?

Usher’s syndrome is caused by changes (mutations) in specific genes that are inherited from both parents.^[1] Scientists have found at least 9 to 11 different genes that can cause Usher’s syndrome.^[1][3] For type 1, at least six genes can cause the condition, with mutations in the MYO7A gene being most common, followed by mutations in the CDH23 gene.^[3] Type 2 can result from mutations in three genes, with USH2A gene mutations accounting for most cases.^[3]

These genes play important roles in the development and function of structures in both the inner ear and the retina. In the inner ear, they help maintain structures called stereocilia—tiny hair-like projections on sensory cells that transmit sound and motion signals to the brain.^[6] They also help maintain the structure and function of rod and cone cells in the retina, as well as supporting cells called the retinal pigmented epithelium.^[6]

How the condition is inherited

Usher’s syndrome is inherited in an autosomal recessive pattern.^[3] “Autosomal” means that men and women are equally likely to have the disorder and equally likely to pass it on to a child of either sex. “Recessive” means that a child must receive a changed gene from both biological parents to develop the condition.^[8]

When both parents are carriers—meaning they each have one normal gene and one changed gene—they typically don’t have symptoms themselves. With each pregnancy, they have a 25 percent chance of having a child with Usher’s syndrome, a 50 percent chance of having a child who is a carrier like them, and a 25 percent chance of having a child with two normal genes.^[5]

Because there are many different genetic versions of Usher’s syndrome, families rarely have a history of the condition. Parents are often surprised by the diagnosis because it doesn’t appear to run in their family.^[5] Estimates suggest that 1 in 10 people carries some form of a gene that can cause Usher’s syndrome, but the chance of two specific carriers meeting and having children together is small.^[5]

How is Usher’s syndrome diagnosed?

Doctors diagnose Usher’s syndrome by asking questions about medical history and testing hearing, balance, and vision.^[1] Because newborn hearing screening has reduced the age at which children with hearing loss are identified—from 12 to 18 months down to 6 months or less—audiologists (hearing specialists) are often the first healthcare professionals to work with families.^[5] However, the diagnosis of Usher’s syndrome, with its vision loss component, typically comes 5 to 10 years after the hearing loss is identified.^[5]

Eye examination

An eye doctor can check for retinitis pigmentosa as part of a comprehensive dilated eye exam.^[1] During this simple and painless exam, the doctor gives eye drops to dilate (widen) the pupils and then examines the eyes for retinitis pigmentosa and other eye problems. The exam includes a visual field test to check peripheral (side) vision.^[1]

Additional eye tests may include:

• Electroretinography (ERG): This test measures how well the retina responds to light.^[1]
• Optical coherence tomography (OCT): This test uses light waves to take a detailed picture of the retina.^[1]

Hearing and balance tests

Hearing tests measure the type and degree of hearing loss. Balance testing may include videonystagmography, which checks for abnormal eye movements that can indicate vestibular problems.^[1] These tests help doctors determine which type of Usher’s syndrome a person has, since hearing loss alone cannot indicate Usher’s syndrome or clearly differentiate between the types.^[5]

Genetic testing

Genetic testing can identify the specific gene mutations causing Usher’s syndrome.^[1] This testing is the only reliable way to determine the exact genetic type and subtype. While clinical testing can suggest which type of Usher’s syndrome a person has based on symptoms, DNA testing provides definitive answers.^[7] Understanding the genetic cause can help predict how the condition might progress and inform decisions about treatment options and family planning.

Treatment and management

There is currently no cure for Usher’s syndrome, but there are many ways to manage its effects on hearing, balance, and vision.^[1] The most effective approach involves early identification and intervention through tailored programs that consider the severity of hearing and vision loss, as well as the person’s age and abilities.^[11]

Managing hearing loss

Treatment for hearing loss may include:^[11]

• Hearing aids: These devices amplify sounds and can be helpful for people with moderate hearing loss.
• Cochlear implants: These electronic devices can provide sound signals directly to the auditory nerve for people with severe to profound hearing loss.
• Assistive listening devices: These tools help people hear better in specific situations, such as talking on the phone or watching television.
• American Sign Language: Learning sign language provides an important communication method.
• Speech therapy: This can help develop or maintain speech skills.

Managing balance difficulties

Balance problems can be addressed through:^[11]

• Physical and occupational therapy: These therapies help strengthen muscles, particularly core muscles, to improve balance.
• Orientation and mobility (O&M) training: This training teaches people how to move safely from one place to another and helps them use their remaining vision and other senses more effectively.^[11]

Managing vision loss

Treatment for vision loss may include:^[11]

• Low-vision services: An optometrist can provide training to use optical and electronic devices correctly, help people use their remaining vision more effectively, and suggest improvements to lighting and contrast in the home and workplace.
• Vision aids: Devices such as magnifiers, portable electronic magnifiers that reverse contrast (white text on black background), and special lenses can help with reading and other tasks.^[1]
• Braille instruction: Learning Braille provides an important method for reading as vision declines.
• Auditory training: This helps people learn to rely more on their hearing as vision decreases.

Vitamin A supplementation

A long-term clinical trial supported by the National Eye Institute found that a high dose of vitamin A may slow retinitis pigmentosa, though it cannot cure the condition.^[11] Researchers recommend that most adult patients with common forms of retinitis pigmentosa take a daily supplement of 15,000 IU (international units) of vitamin A under the supervision of their eye care professional. However, because patients with type 1 Usher’s syndrome did not participate in this study, high-dose vitamin A is not recommended for them.^[11]

Protective measures

Protecting remaining vision is important. Research shows the value of wearing sunglasses to protect eyes with retinitis pigmentosa from sun damage.^[16] Starting this habit young and encouraging consistent use can help preserve vision longer.

Living with Usher’s syndrome

Living with Usher’s syndrome involves ongoing adjustments to accommodate changes in hearing, vision, and sometimes balance. The psychological impact of living with progressive sensory loss can be significant, as people must constantly adapt to what is changing while trying to maintain independence and quality of life.^[18]

Emotional and psychological support

Getting an Usher’s syndrome diagnosis isn’t a single moment—it’s a process that unfolds over time.^[18] The reality of the condition often reveals itself gradually through everyday challenges: struggling to read a menu in a dim restaurant, hesitating at a busy crosswalk, or missing parts of conversations in noisy rooms. Grief doesn’t just come after loss—it comes with it, even when a person is still functioning and showing up in daily life.^[18]

Many people experience prejudice, as others may not understand that vision and hearing loss are invisible disabilities. People with Usher’s syndrome sometimes report being treated as second-class citizens, with others talking to their helpers rather than directly to them.^[19] Mental health support, counseling, and connecting with others who have similar experiences can help people navigate these challenges.

Practical adjustments at home

Making modifications at home can improve safety and independence:^[16]

• Keep spaces free of clutter, especially on floors, since decreased peripheral vision makes it harder to see objects beside or below.
• Install nightlights throughout the home, particularly in hallways and rooms without natural light.
• Use rope lights along hallway floors to mark common pathways, similar to lights in movie theater aisles.
• Ensure good lighting in all areas, but avoid harsh glare that can make vision worse.
• Use contrasting colors to help objects stand out—for example, placing light-colored objects on dark surfaces.
• Consider wearing a flashlight headlamp for tasks in low-light conditions.

Education and career planning

Early identification allows educational programs to begin as soon as possible, preparing individuals for employment and independent living.^[12] Programs should be tailored to each person’s specific needs, taking into account the type and severity of their hearing and vision loss, their age, and their individual strengths.

Support services

Support Service Providers (SSPs) are professionals trained to work with people who have combined vision and hearing loss.^[17] They provide environmental information so that the person can make informed decisions or participate more fully in activities without having to rely only on friends or family. SSPs may assist with reading bills, shopping, participating in social activities, and attending family events. Some states offer free SSP services.

Connection and community

Connecting with others in the Usher’s syndrome community can provide valuable support, information, and understanding. Many people find that sharing experiences with others who face similar challenges helps reduce feelings of isolation and provides practical strategies for daily living.

Current research

Research into effective treatments for Usher’s syndrome is actively progressing in several areas, including gene therapy, stem cell therapy, drug-based treatments, and retinal implants.^[14]

Gene therapy

Gene therapy approaches aim to correct or replace the faulty genes that cause Usher’s syndrome. AAVantgarde Bio has moved a dual-vector gene therapy for Usher syndrome type 1B (caused by mutations in the MYO7A gene) into a Phase 1/2 clinical trial.^[13] This represents an important step toward developing treatments that address the underlying genetic cause of the condition.

RNA-based therapies

Sepul Bio is advancing RNA therapies (antisense oligonucleotides) for specific genetic mutations. The company has launched clinical trials for ultevursen, designed for people with exon 13 mutations in the USH2A gene—a common cause of type 2 Usher’s syndrome.^[13] These therapies work by targeting the genetic instructions that cells use to make proteins, potentially correcting the effects of specific mutations.

Drug therapies

Nacuity has reported promising results from a Phase 2 clinical trial of NACA, an oral antioxidant therapy for Usher’s syndrome. The trial found that NACA reduced the loss of light-sensing cells in the retina by 50 percent.^[13] This type of treatment aims to protect retinal cells from damage caused by oxidative stress, potentially slowing vision loss.

Research is also exploring whether certain drugs can counteract specific types of genetic mutations called nonsense mutations, which occur in a subset of people with Usher’s syndrome.^[14]

Retinal implants

Scientists are developing artificial retinas—electronic devices that can provide some visual perception for people who have lost most of their vision.^[14] These implants work similarly to cochlear implants, using a small camera mounted on glasses that sends signals to electrodes placed in or near the retina. While these devices don’t restore normal vision, they can help people perceive light, shapes, and movement, improving their ability to navigate their environment.

The ongoing research offers hope that treatments to slow or prevent the progression of Usher’s syndrome may become available in the future. People with Usher’s syndrome and their families are encouraged to stay informed about research developments and consider participating in clinical trials when appropriate.

Turner syndrome is a genetic condition affecting girls and women that requires careful medical attention throughout life. While there is no cure, modern treatment approaches focus on managing hormone levels, supporting growth and development, and monitoring for potential health complications to help affected individuals lead full, healthy lives.

Caring for Growth and Development: What Treatment Aims to Achieve

When a girl is diagnosed with Turner syndrome, treatment focuses on addressing the specific challenges that arise from having only one complete X chromosome instead of the usual two. The main goals of medical care include helping children reach a taller adult height than they would without treatment, supporting the development of normal female physical characteristics during the teenage years, and preventing long-term health problems such as weak bones, heart complications, and other conditions that can affect quality of life.^[1]

Because Turner syndrome affects each person differently, treatment plans are highly individualized. Some girls may have many physical differences and need extensive medical support, while others may have milder symptoms requiring less intensive care. The treatment approach depends on factors such as the person’s age at diagnosis, which specific features of the syndrome are present, and whether there are complications involving the heart, kidneys, or other organ systems. Medical care typically involves a team of specialists including endocrinologists (doctors who specialize in hormones and growth), cardiologists for heart monitoring, and other healthcare professionals who work together to address different aspects of the condition.^[9]

Treatment for Turner syndrome is lifelong, beginning in childhood and continuing into adulthood. Early intervention is essential for the best outcomes, particularly when it comes to maximizing growth potential and ensuring healthy bone development. The medical team monitors the patient regularly to detect and address any emerging problems before they become serious. This ongoing surveillance includes checking blood pressure, assessing bone density, evaluating how well the thyroid gland is functioning, and screening for other conditions that occur more frequently in people with Turner syndrome.^[11]

Standard Medical Treatment: Hormone Therapy as the Foundation

The cornerstone of Turner syndrome treatment involves two main types of hormone therapy: growth hormone to address short stature and estrogen replacement to promote the development of female sexual characteristics and protect bone health. These treatments are recommended by medical guidelines and have been shown to significantly improve outcomes for girls and women with this condition.^[14]

Growth Hormone Treatment

Growth hormone therapy is the standard approach for preventing the severe short stature that would otherwise occur in Turner syndrome. Without treatment, the average adult height is approximately 143 centimeters (about 4 feet 7 inches). Girls with Turner syndrome typically grow more slowly than their peers, usually becoming noticeable around age 5, and they don’t experience the normal growth spurts that occur during childhood and adolescence.^[2]

Treatment with growth hormone injections typically begins in childhood, though the ideal age to start has not been firmly established. Many doctors recommend beginning treatment as soon as the growth delay becomes apparent. The medication is given as daily injections under the skin, and treatment continues until the girl reaches a bone age of approximately 14 years or until the growth plates in the bones close. The longer the duration of treatment before puberty starts, the greater the potential for achieving a taller adult height. Studies have shown that growth hormone therapy can help girls gain several inches in height compared to what they would have reached without treatment.^[15]

During growth hormone treatment, children need regular monitoring by a pediatric endocrinologist, typically every three to six months. The doctor checks how well the child is responding to treatment, adjusts the medication dose as needed, and watches for any side effects. Growth hormone is generally well-tolerated, though some children may experience temporary reactions at the injection site or, rarely, other effects that require medical attention.^[15]

Estrogen Replacement Therapy

Estrogen replacement is crucial for girls with Turner syndrome because their ovaries typically don’t produce adequate amounts of female sex hormones. The ovaries in Turner syndrome usually develop normally at first, but egg cells die prematurely and most ovarian tissue breaks down before birth. This leads to primary ovarian insufficiency, meaning the ovaries function poorly or not at all, resulting in absent or incomplete puberty and infertility in most cases.^[4]

Estrogen therapy is typically initiated between ages 12 and 15 years, though some specialists recommend starting with very low doses as early as age 5 to support gradual, natural-appearing development. The timing is carefully balanced: starting too early or using doses that are too high can cause the growth plates in bones to close prematurely, which would compromise the final adult height achieved with growth hormone therapy. Starting too late, however, can lead to delayed development and increased risk of bone thinning.^[15]

Treatment usually begins with continuous low-dose estrogen, which can be given as pills or patches applied to the skin. Transdermal estrogens (patches) are often preferred because they deliver more natural, physiologic levels of the hormone and may be better tolerated. After six to eighteen months of estrogen-only treatment, the regimen is often changed to a cycling pattern (three weeks on, one week off), and a second hormone called progestin is added to protect the lining of the uterus and establish a monthly cycle similar to menstruation.^[15]

Ongoing estrogen therapy is essential not just for sexual development but also for maintaining bone strength and cardiovascular health. Women with Turner syndrome who stop taking estrogen after initially starting it face increased risks of osteoporosis (weak, brittle bones) and heart disease. Therefore, hormone replacement typically continues at least until the age when natural menopause would normally occur, and often beyond that point.^[14]

Treatment for Additional Health Conditions

Beyond hormone therapy, girls and women with Turner syndrome often require treatment for associated medical problems. Approximately one-third have heart defects that may need surgical correction, such as narrowing of the aorta (coarctation) or abnormalities of the aortic valve. Those with heart valve problems may need antibiotics before dental or surgical procedures to prevent bacterial infections of the heart. Blood pressure must be monitored regularly, as high blood pressure is common and increases the risk of serious cardiovascular complications.^[3]

Many girls with Turner syndrome develop thyroid problems, particularly an underactive thyroid gland (hypothyroidism). This condition requires treatment with thyroid hormone replacement medication taken daily. Hearing problems, including frequent ear infections in childhood and progressive hearing loss later in life, are also common and may require treatment with antibiotics for infections, placement of ear tubes, or use of hearing aids.^[12]

Some girls and women with Turner syndrome experience learning difficulties, particularly with tasks requiring spatial awareness such as mathematics or reading maps. While intelligence is usually normal, specialized educational support may be beneficial. Psychological counseling or therapy can help address issues related to self-esteem, body image, and social skills, which some individuals with Turner syndrome find challenging, particularly during adolescence.^[11]

Exploring New Possibilities: Treatment Approaches in Clinical Trials

While standard treatment with growth hormone and estrogen replacement has been established for decades, researchers continue to investigate new approaches that might improve outcomes for individuals with Turner syndrome. Clinical trials are exploring ways to enhance growth, optimize hormone delivery, and better understand the underlying mechanisms of the condition.

Combined Hormone Approaches

One area of active research involves combining growth hormone with very low doses of estrogen earlier in childhood than traditionally recommended. A double-blind, placebo-controlled clinical trial examined whether adding ultra-low-dose estrogen to growth hormone therapy in young girls could improve final adult height. The concept behind this approach is that small amounts of estrogen might support bone growth and maturation in a way that complements growth hormone, potentially leading to better height outcomes without causing premature closure of growth plates.^[15]

These trials typically enroll girls in early childhood, often beginning treatment around age 5 or 6 years. Participants receive daily growth hormone injections along with either ultra-low-dose estrogen or placebo, with researchers carefully monitoring growth velocity, bone maturation, and eventual adult height. The ultra-low doses are designed to mimic the small amounts of estrogen that would naturally circulate in prepubertal girls. Early results from some studies suggest this combination may improve growth compared to growth hormone alone, though more research is needed to confirm these findings and determine optimal dosing strategies.

Androgen Therapy Investigation

While not currently standard treatment, some researchers have investigated whether low doses of male hormones (androgens) might benefit girls with Turner syndrome. The rationale is that androgens can promote muscle development and may have positive effects on bone density, potentially complementing estrogen’s benefits. Small clinical studies have examined whether very low doses of androgens like oxandrolone (an anabolic steroid) might enhance growth when added to growth hormone therapy.^[15]

These trials carefully monitor for masculinizing side effects such as facial hair growth or voice deepening, using doses low enough to minimize such risks while potentially providing metabolic benefits. Results have been mixed, and androgen therapy remains experimental rather than part of routine care. Some studies suggest possible improvements in growth velocity or body composition, but concerns about side effects and limited long-term data have prevented widespread adoption of this approach.

Assisted Reproduction Research

Almost all women with Turner syndrome are infertile due to ovarian failure, though a small percentage retain some ovarian function through young adulthood. Research in reproductive medicine has explored various approaches to help women with Turner syndrome have biological children. Clinical trials have investigated the use of donated eggs from other women combined with in vitro fertilization (IVF), where embryos are created outside the body and then transferred to the woman’s uterus.^[11]

These trials focus on optimizing hormone preparations to prepare the uterus for pregnancy and determining the safest protocols given the cardiovascular risks associated with Turner syndrome. Women with certain heart conditions, particularly those with dilated or abnormal aortas, bicuspid aortic valves, or coarctation, face substantially increased risks during pregnancy and may be advised against attempting it even with assisted reproduction. Research continues to better identify which women can safely consider pregnancy and how to minimize complications.

Studies on Cardiovascular Protection

Given that cardiovascular complications are a leading cause of serious health problems in Turner syndrome, some clinical research focuses on preventive strategies beyond standard blood pressure management. Trials are examining whether specific medications or lifestyle interventions can prevent progressive enlargement of the aorta, which can lead to life-threatening rupture or dissection (tearing of the vessel wall).^[14]

These studies typically involve regular imaging of the heart and aorta using echocardiography or magnetic resonance imaging to track changes over time. Some trials investigate whether medications like beta-blockers or other drugs used to treat aortic disease in other conditions might slow aortic root dilatation in Turner syndrome. Participants undergo frequent cardiovascular assessments, and researchers analyze whether certain genetic variants or other factors predict who will develop progressive aortic problems.

Genetic and Molecular Research

At a more fundamental level, researchers are working to better understand exactly which genes on the X chromosome are responsible for the various features of Turner syndrome. One gene called SHOX has been identified as likely responsible for short stature and certain skeletal abnormalities when only one copy is present instead of two. This knowledge opens possibilities for more targeted future therapies.^[4]

Some research groups are investigating whether there are ways to compensate for the missing genetic material or enhance the function of the single X chromosome that is present. While such approaches remain experimental and are in early phases of investigation, they represent potential future directions for treatment that might address the condition at a more fundamental biological level rather than simply managing symptoms.

Surgical Interventions When Needed

Some girls with Turner syndrome require surgical procedures to correct structural problems or address complications. Heart defects such as coarctation of the aorta or severe valve abnormalities may need surgical repair, typically performed in childhood. These operations can be life-saving and significantly improve long-term cardiovascular health. Women who develop progressive aortic root dilatation may eventually require surgical replacement of the affected portion of the aorta to prevent rupture.^[12]

Cosmetic surgery for features like webbed neck or prominent ears is sometimes considered, though this is a personal decision that should be made carefully. Individuals with Turner syndrome are thought to have a higher risk of developing thick, raised scars called keloids after surgery, so any cosmetic procedure must weigh potential benefits against this risk.^[15]

If testing reveals the presence of Y chromosome material (which occurs in some cases), doctors strongly recommend surgical removal of the underdeveloped ovarian tissue. This is because Y chromosome material in someone with Turner syndrome carries a significantly increased risk of developing a type of tumor called a gonadoblastoma. The procedure, called prophylactic gonadectomy, is typically performed laparoscopically (through small incisions using a camera and special instruments) to minimize recovery time.^[14]

Comprehensive Monitoring Throughout Life

Regardless of which treatments are used, ongoing medical surveillance is essential for everyone with Turner syndrome. Regular check-ups should occur throughout childhood and continue into adulthood, though many adult specialists may have less experience with this relatively rare condition. A well-planned transition from pediatric to adult medical care is important to ensure continuity of monitoring and treatment.^[14]

Recommended screening includes cardiovascular evaluation at diagnosis and periodically thereafter, typically every three to five years even if the initial assessment is normal. This surveillance helps detect problems like progressive aortic enlargement or the development of high blood pressure before they cause serious complications. Blood tests to check thyroid function, glucose metabolism (diabetes screening), and lipid levels (cholesterol and related fats) should be performed regularly, as Turner syndrome increases risks for these conditions.^[12]

Bone density scans are recommended to monitor for osteoporosis, and hearing tests should be conducted periodically to detect progressive hearing loss. Regular eye examinations help identify vision problems that may be more common in Turner syndrome. For women who retain some ovarian function into adulthood, monitoring of hormone levels helps determine if and when complete ovarian failure occurs.^[9]

Most Common Treatment Methods

• Hormone Therapy
  • Growth hormone injections given daily in childhood to increase adult height, typically continued until bone age reaches approximately 14 years
  • Estrogen replacement started in early adolescence (ages 12-15) to promote development of breasts and other female characteristics
  • Progestin added to estrogen after initial treatment period to protect the uterine lining and establish monthly cycles
  • Thyroid hormone replacement for those who develop hypothyroidism
  • Ongoing estrogen therapy continued into adulthood to maintain bone strength and cardiovascular health
• Cardiovascular Management
  • Regular blood pressure monitoring and treatment with antihypertensive medications if high blood pressure develops
  • Periodic imaging of the heart and aorta with echocardiography or MRI to monitor for enlargement or abnormalities
  • Surgical repair of heart defects such as coarctation of the aorta or severe valve problems
  • Antibiotic prophylaxis before dental or surgical procedures in those with certain heart valve conditions
• Bone Health Support
  • Calcium and vitamin D supplementation starting by age 10 years
  • Encouragement of weight-bearing exercise throughout life
  • Regular bone density scanning to monitor for osteoporosis
  • Treatment with bone-strengthening medications if severe osteoporosis develops
• Supportive Care
  • Educational support for learning difficulties, particularly in mathematics and spatial tasks
  • Psychological counseling to address self-esteem, body image, and social skills
  • Hearing evaluation and treatment including ear tubes for recurrent infections or hearing aids for hearing loss
  • Regular eye examinations and treatment of vision problems
• Fertility Treatment
  • Egg donation combined with in vitro fertilization for women who wish to become pregnant
  • Thorough cardiovascular evaluation before attempting pregnancy to assess risks
  • Careful counseling about pregnancy risks in those with certain heart conditions

Usher syndrome is a rare genetic condition that affects both hearing and vision, and sometimes balance, leading to a progressive dual sensory loss that shapes how individuals experience and navigate the world around them.

Understanding the Prognosis of Usher Syndrome

When families first learn about Usher syndrome, one of their most pressing concerns is what the future holds. It’s important to understand that Usher syndrome is a progressive condition, which means symptoms develop and often worsen over time. However, this progression varies greatly depending on the type of Usher syndrome a person has.^[1]

The most reassuring aspect of the prognosis is that Usher syndrome does not affect life expectancy. People with this condition can live full, normal lifespans.^[2] What changes is how they interact with their environment as their hearing and vision gradually decline. This means that while the condition presents significant challenges, it does not shorten life itself.

For individuals with Type 1 Usher syndrome, the progression tends to be more rapid and severe. These individuals are born with profound hearing loss or complete deafness and begin experiencing vision loss by around age 10. By midlife, many will have severe vision impairment.^[1] Type 2 follows a somewhat gentler course, with moderate to severe hearing loss present from birth but vision problems typically not appearing until the teenage years. People with Type 2 may maintain some useful vision into middle age.^[1]

Type 3 is the rarest form and has the most variable progression. Individuals with Type 3 are born with normal hearing and vision, but both senses begin to deteriorate during late childhood or adolescence. The rate of decline can vary significantly from person to person.^[3]

While statistics about progression timelines exist, it’s crucial to remember that each person’s journey is unique. Some individuals may maintain functional vision longer than expected, while others may experience faster decline. This unpredictability can be emotionally challenging, as it makes long-term planning more difficult.

How Usher Syndrome Progresses Without Treatment

Understanding the natural progression of Usher syndrome helps families and patients prepare for the changes ahead. Without intervention, the condition follows a predictable pattern, though the exact timeline varies by type.

In Type 1 Usher syndrome, children are born with severe to profound hearing loss. Without hearing aids or cochlear implants, they may never develop spoken language naturally. The vision loss component begins in early childhood, typically before age 10. The first sign is usually difficulty seeing in dim light, a condition called night blindness. This happens because the rod cells in the retina, which are responsible for vision in low light, are the first to deteriorate.^[8]

As time passes, the person begins to lose peripheral vision, also known as side vision. This loss progresses inward, creating what is often described as tunnel vision. Imagine looking through a narrow tube—that’s what the world begins to look like for someone with advancing retinitis pigmentosa (RP), the eye disease that causes vision loss in Usher syndrome.^[1] Eventually, only a small area of central vision may remain, and in some cases, complete blindness can occur.

Type 1 also involves balance problems from birth because the vestibular system in the inner ear, which helps maintain balance and spatial orientation, doesn’t develop normally. Children with Type 1 often sit up and walk later than their peers. They may struggle with activities requiring balance, such as riding a bicycle or playing certain sports.^[3]

For Type 2 Usher syndrome, hearing loss is present from birth but is less severe than Type 1. The vision loss typically begins in adolescence rather than early childhood. Because balance is usually normal in Type 2, children reach developmental milestones like sitting and walking at typical ages.^[1]

Type 3 presents the most variable course. Individuals are born with normal hearing and vision, but both begin to deteriorate during late childhood or early teenage years. The hearing loss is progressive, meaning it gets worse over time, and by middle age, many individuals have profound hearing loss. Vision loss also progresses, though the timeline is less predictable.^[3]

Without treatment or supportive interventions, individuals with Usher syndrome face increasing isolation as their ability to communicate and navigate independently diminishes. The combined loss of hearing and vision—known as deaf-blindness—creates unique challenges that affect nearly every aspect of daily life.

Possible Complications of Usher Syndrome

Beyond the primary symptoms of hearing and vision loss, Usher syndrome can lead to several complications that affect overall health and quality of life. Understanding these potential issues helps families and healthcare providers monitor for warning signs and intervene when necessary.

One significant complication involves the eyes. In addition to retinitis pigmentosa, some people with Usher syndrome develop cataracts, which are cloudy areas in the lens of the eye. Cataracts further impair vision, particularly central vision, which may be the only remaining functional vision for someone with advanced RP. The combination of cataracts and RP can accelerate vision loss.^[8] Additionally, some individuals develop cysts in the macula, the central part of the retina responsible for sharp, detailed vision. These cysts can cause an early decline in central vision, which is particularly devastating because central vision is often the last to be affected by RP.^[8]

Balance problems, particularly in Type 1, can lead to an increased risk of falls and injuries. Children who struggle with balance may avoid physical activities, which can affect their physical fitness, social development, and self-confidence. Adults with balance issues may find it increasingly difficult to navigate unfamiliar environments safely.^[2]

The psychological impact of Usher syndrome can be profound and is sometimes overlooked as a complication. The progressive nature of the condition means that individuals face repeated losses—each new limitation represents a form of grief. Many people with Usher syndrome experience anxiety, depression, or feelings of isolation as their condition progresses.^[18] The constant adjustments required to adapt to diminishing sensory abilities can be emotionally exhausting.

Social complications are also common. As hearing and vision worsen, communication becomes increasingly difficult. This can lead to withdrawal from social activities, strained relationships, and loneliness. The condition is often described as an “invisible disability” because others may not immediately recognize the challenges faced by someone with Usher syndrome, leading to misunderstandings and social awkwardness.^[19]

Employment complications may arise as the condition progresses. Jobs that require driving, detailed visual work, or communication in noisy environments become increasingly difficult or impossible. This can affect financial stability and career advancement, adding another layer of stress to an already challenging situation.

Impact on Daily Life

Usher syndrome affects nearly every aspect of daily life, from the moment a person wakes up until they go to sleep. The dual sensory loss creates unique challenges that require constant adaptation and creative problem-solving.

Navigating physical spaces becomes increasingly difficult as vision narrows. Simple tasks like walking down a hallway can be challenging because peripheral vision helps us detect obstacles to our sides and below our feet. People with Usher syndrome may trip over objects they don’t see in their limited field of vision. Moving through dimly lit environments—like restaurants, movie theaters, or outdoor spaces at dusk—becomes particularly hazardous due to night blindness.^[16]

Reading becomes progressively more difficult. As peripheral vision narrows, it becomes harder to scan lines of text. Letters may need to be magnified significantly, and eventually, standard print may become impossible to read. Many people transition to using assistive devices like electronic magnifiers or learn to read Braille.^[11]

Communication presents unique challenges. For someone with hearing loss who previously relied on lip reading, declining vision makes this increasingly difficult. Similarly, those who use sign language may struggle as their visual field narrows and they can no longer see the signer’s hands and face simultaneously. This creates a profound sense of isolation, as the two primary methods of communication become compromised.^[4]

Social gatherings become exhausting and sometimes overwhelming. Imagine trying to follow a conversation in a noisy, dimly lit restaurant when you can barely hear and your vision is limited. Many people with Usher syndrome report feeling left out of group conversations or social events because they simply cannot keep up with what’s happening around them.^[18]

Independence is often deeply affected. Activities that most people take for granted—driving, grocery shopping, preparing meals, managing finances—can become difficult or impossible without assistance. This loss of independence can be emotionally devastating, particularly for young adults who are trying to establish their autonomy.

However, many people with Usher syndrome develop effective coping strategies. They learn to advocate for their needs, such as asking for better lighting or quieter spaces for conversations. They use assistive technology like smartphones with accessibility features, special lighting setups at home, and mobility aids. Some individuals use support service providers (SSPs), professionals trained to work with people who have combined hearing and vision loss, who provide environmental information and support during activities.^[17]

Practical adaptations at home can significantly improve safety and independence. These include using nightlights throughout the house, installing rope lights along hallways, reducing clutter, using high-contrast markers to identify important items, and organizing belongings in consistent locations so they can be found by memory rather than sight.^[16]

Career choices and educational paths are often influenced by Usher syndrome. Some individuals choose careers that they can pursue despite sensory limitations, while others race against time to accomplish goals while they still have functional vision. This awareness of a ticking clock can be both motivating and stressful.^[15]

Support for Families: Understanding Clinical Trials

For families affected by Usher syndrome, clinical trials represent hope for better treatments and possibly even a cure. Understanding what clinical trials are and how they work can help families make informed decisions about whether participation might be right for them.

Clinical trials are research studies that test new treatments, therapies, or interventions to see if they are safe and effective. For Usher syndrome, ongoing research focuses on several approaches, including gene therapy, which aims to correct or replace the faulty genes that cause the condition; drug-based therapies that may slow the progression of vision or hearing loss; and retinal implants that could restore some visual function.^[14]

Recent advances in research have been promising. Some trials are testing therapies that specifically target certain genetic subtypes of Usher syndrome. For example, gene therapies for Usher syndrome type 1B have entered clinical trials, and RNA-based therapies for certain mutations are being developed.^[13] Other research focuses on protecting retinal cells from further damage using antioxidant treatments.^[13]

Families considering clinical trial participation should understand both the potential benefits and risks. Benefits may include access to cutting-edge treatments before they’re widely available, close monitoring by medical experts, and the satisfaction of contributing to research that may help future generations. However, experimental treatments may have unknown side effects, may not work as hoped, and participation requires a significant time commitment for appointments and follow-up visits.

Before enrolling in a trial, families should ask important questions: What is the purpose of the trial? What are the potential risks and benefits? What will participation involve in terms of time and procedures? Will treatment costs be covered? Can we withdraw from the trial if we change our minds? Understanding these details helps families make informed decisions.

Family members can support their loved one’s participation in several practical ways. They can help research available trials by checking registries of clinical studies for Usher syndrome. Many research institutions and advocacy organizations maintain databases of current trials. They can assist with transportation to appointments, help keep track of medication schedules or trial requirements, and provide emotional support throughout the process.

It’s important to note that genetic testing is often required to determine the specific subtype of Usher syndrome before enrolling in certain trials, as many new therapies target specific genetic mutations. Families should discuss genetic testing with their healthcare providers to understand which subtype they have and which trials might be appropriate.^[7]

Even if participation in a clinical trial isn’t possible or appropriate right now, families can stay informed about research progress. Subscribing to newsletters from Usher syndrome advocacy organizations, attending webinars or conferences about current research, and maintaining regular contact with specialists who treat Usher syndrome can help families stay up to date on new developments.

Organizations dedicated to Usher syndrome research and support often have data collection programs where families can register and share information about their experience with the condition. These registries help researchers understand the disease better and may connect families with future clinical trial opportunities when they become available.^[7]

Family involvement in advocacy can also support research efforts. By raising awareness about Usher syndrome, participating in fundraising events, and connecting with other affected families, relatives can help ensure that research continues and that the Usher syndrome community remains visible to researchers, clinicians, and funding organizations.

Usher’s syndrome is a rare inherited condition that quietly steals both sight and sound, often beginning in childhood and progressing through a person’s lifetime, making it the most common genetic cause of combined deafness and blindness.

Understanding Usher’s Syndrome

Usher’s syndrome is a genetic disease that affects both hearing and vision at the same time. People who have this condition are born with it, even if the symptoms don’t show up right away. The syndrome causes deafness or hearing loss along with an eye disease called retinitis pigmentosa, which is the breakdown of light-sensing cells in the back of the eye. Sometimes, the condition also causes balance problems, making it harder for children to walk steadily or ride a bike.^[1]

The condition is named after Charles Usher, a British eye doctor who studied and described how the disease worked and how it passed from parents to children back in 1914. Since then, researchers have learned much more about the genetic changes that cause this syndrome and how it affects people’s lives.^[6]

There is currently no cure for Usher’s syndrome. However, many treatments and support services exist to help people manage their vision, hearing, and balance challenges. Early identification of the condition is crucial because it allows families and healthcare teams to start helpful interventions as soon as possible, giving children the best chance to learn communication skills and adapt to changes before vision loss becomes severe.^[1]

How Common Is Usher’s Syndrome

Usher’s syndrome is considered a rare disease. It affects somewhere between 3 and 17 out of every 100,000 people, depending on which part of the world you look at. While these numbers might seem small, this condition is responsible for about half of all cases where people inherit both deafness and blindness together.^[8]

The syndrome is thought to account for 3 to 6 percent of all children who are born deaf, and another 3 to 6 percent of children who are hard of hearing. When you look at people who have retinitis pigmentosa, about 30 percent report some degree of hearing loss, and roughly half of those are eventually diagnosed with Usher’s syndrome.^[4]

Certain types of Usher’s syndrome are more common in specific populations. For example, Type 1 appears more frequently among people of Ashkenazi Jewish heritage, which includes families with roots in central and eastern Europe, and among French Acadian populations, particularly in Louisiana. Type 3 is very rare worldwide but occurs more often in Finnish populations and among Ashkenazi Jewish communities. Worldwide, researchers estimate that as many as 400,000 people live with Usher’s syndrome.^[3][4]

What Causes Usher’s Syndrome

Usher’s syndrome is caused by changes in genes, which are the instructions our bodies use to build and maintain themselves. These genetic changes are inherited, meaning they get passed down from parents to children. Scientists have discovered at least nine to eleven different genes that can cause Usher’s syndrome when they contain mutations.^[1][3]

The syndrome follows what geneticists call an autosomal recessive pattern of inheritance. This means that a child must receive a changed copy of the gene from both parents to develop the condition. Each parent carries one copy of the mutated gene but typically does not have symptoms themselves because their other gene copy works normally. When both parents are carriers, they have a 25 percent chance with each pregnancy of having a child with Usher’s syndrome.^[8]

Because the syndrome is inherited in this recessive way, families are often surprised by the diagnosis. Parents may not know they carry the gene because there is usually no family history of the condition. Research suggests that about 1 in 10 people carries some form of a recessive gene for Usher’s syndrome, but because there are many different genetic versions, the chance of two carriers of the same mutation meeting and having children together is relatively small.^[5]

Risk Factors for Usher’s Syndrome

The primary risk factor for Usher’s syndrome is having two parents who both carry a mutation in one of the genes associated with the condition. Because the syndrome is inherited in an autosomal recessive pattern, it affects men and women equally. Neither sex is more likely to develop the condition or pass it on to their children.^[8]

Certain ethnic and geographic populations have higher rates of carrying specific Usher’s syndrome gene mutations. People of Ashkenazi Jewish descent have higher rates of certain mutations that cause Types 1 and 3. French Acadian populations, particularly those in Louisiana, also show higher rates of Type 1. Finnish populations have notably higher rates of Type 3, where it accounts for about 40 percent of all Usher’s cases in that country, compared to just 2 percent worldwide.^[3]

Families with one child who has Usher’s syndrome have a 25 percent chance of having another affected child with each subsequent pregnancy, since both parents are confirmed carriers. Siblings of a person with Usher’s syndrome have a 50 percent chance of being carriers themselves, even if they don’t have symptoms.^[5]

Symptoms of Usher’s Syndrome

The main symptoms of Usher’s syndrome are hearing loss and vision loss, though how severe these are and when they begin depends on which type of the syndrome a person has. All people with Usher’s syndrome eventually develop retinitis pigmentosa, which causes the breakdown of cells in the retina, the light-sensitive tissue at the back of the eye.^[1]

Hearing loss in Usher’s syndrome is described as sensorineural, which means it’s caused by problems with the inner ear rather than the outer or middle ear. Depending on the type, some children are born profoundly deaf, unable to hear anything except very loud sounds, while others are born with moderate to severe hearing loss or develop hearing loss later in childhood or adolescence.^[3]

Retinitis pigmentosa typically begins with difficulty seeing in low light or darkness, a symptom called night blindness. Parents might notice their child struggles to move around in dim rooms, takes a long time to adjust when going from bright light to darkness, or trips over objects they can’t see in their path. As the condition progresses, people lose their side vision, also called peripheral vision. Blind spots develop on the sides and gradually expand inward, creating what’s known as tunnel vision, where only the center of the visual field remains clear.^[1]

Balance problems occur because Usher’s syndrome can affect the vestibular system, which is the part of the inner ear that helps maintain balance and tells us which way is up. Children with balance issues, particularly those with Type 1, may have trouble sitting up independently, may walk later than other children their age, and might struggle with activities that require good balance, like riding a bicycle or playing certain sports.^[8]

Some people with Usher’s syndrome may also develop other eye problems as they get older, including clouding of the lens called cataracts or cysts in the central part of the retina called the macula. These additional problems can contribute to earlier loss of central vision in some cases.^[8]

Types of Usher’s Syndrome and Their Symptoms

There are three main types of Usher’s syndrome, and they differ in when symptoms begin and how severe they are. Understanding these types helps doctors and families know what to expect and plan accordingly.^[2]

Type 1 is the most severe form. Children with Type 1 are born with profound hearing loss or complete deafness. They can only hear very loud sounds or nothing at all. They also have balance problems from birth because the vestibular system doesn’t work properly, which can delay when they learn to sit up and walk. Vision problems appear in the first decade of life, usually by age 10, with rapid progression to severe vision loss by middle age.^[1]

Type 2 is the most common form. Babies with Type 2 are born with moderate to severe hearing loss, but they can typically hear some sounds, especially with hearing aids. Their hearing stays relatively stable over time rather than getting worse. They usually have normal balance and don’t have trouble learning to walk. Vision problems caused by retinitis pigmentosa typically start in the teenage years or early adulthood and progress more slowly than in Type 1. By midlife, they may have severe vision loss, but the rate of decline varies from person to person.^[3]

Type 3 is the rarest form. People with Type 3 are born with normal hearing and vision. They begin to develop hearing loss during late childhood or adolescence, after they’ve already learned to speak, and the hearing loss becomes more severe over time. By middle age, most have profound hearing loss. Vision problems from retinitis pigmentosa also develop in late childhood or adolescence. About half of people with Type 3 also develop balance problems, though not as severe as in Type 1.^[1][3]

How Vision Loss Progresses

Understanding how vision changes in Usher’s syndrome helps people and families prepare for what’s ahead. The vision loss follows a predictable pattern, though the speed can vary significantly from person to person. The earliest sign is almost always difficulty seeing in dim light or darkness. A child might bump into furniture when the lights are turned down, hesitate before entering a dark room, or have trouble finding their way at dusk.^[4]

As retinitis pigmentosa progresses, the field of vision gradually narrows. Imagine looking through a tube or tunnel where you can see straight ahead clearly but can’t see anything to the sides, above, or below. This tunnel vision makes it difficult to notice things in peripheral vision, like a car approaching from the side, a step down from a curb, or a person waving from across the room. Daily tasks like walking through crowded spaces, driving, and reading become increasingly challenging.^[1]

Many people with retinitis pigmentosa do retain some central vision throughout their lives, which allows them to see details directly in front of them even when their peripheral vision is gone. However, the progression and amount of remaining vision varies greatly between individuals, even within the same family.^[3]

Prevention of Usher’s Syndrome

Because Usher’s syndrome is an inherited genetic condition, there is no way to prevent someone who has the gene mutations from developing it. However, genetic testing and counseling can help families understand their risks and make informed decisions.^[3]

For families who already have one child with Usher’s syndrome, genetic testing can identify the specific mutations involved. This information helps confirm the diagnosis and can be useful for other family members who may be carriers. Siblings of someone with Usher’s syndrome can be tested to see if they carry one copy of the mutated gene, which would mean they could pass it to their own children.^[5]

For couples who are both known carriers, prenatal testing options exist. These include amniocentesis and chorionic villus sampling, which can detect whether a developing baby has inherited two copies of the mutated gene. These tests allow couples to understand the genetic status of their pregnancy, though they come with their own risks and ethical considerations that should be discussed thoroughly with genetic counselors and healthcare providers.^[3]

While the syndrome itself cannot be prevented, protecting remaining vision and hearing is crucial. People with Usher’s syndrome should wear sunglasses that block harmful ultraviolet rays, as research suggests that protecting eyes with retinitis pigmentosa from sun exposure is important. The bill of a baseball cap can also provide protection from unseen objects from above as peripheral vision decreases.^[16]

How the Body Is Affected: Understanding the Science

Usher’s syndrome affects the body because the genes that are mutated normally produce proteins essential for the proper function of hair cells in the inner ear and light-sensing cells in the retina. When these genes don’t work correctly, the cells can’t function properly or maintain themselves over time.^[2]

In the inner ear, hearing depends on tiny hair cells in a spiral structure called the cochlea. These hair cells contain microscopic hair-like projections called stereocilia that bend in response to sound vibrations. When they bend, they send electrical signals to the brain, which interprets them as sound. In Usher’s syndrome, mutations affect the structure and function of these hair cells, preventing them from transmitting sound signals properly. Depending on the specific gene involved and the type of mutation, this can result in profound deafness from birth or progressive hearing loss over time.^[8]

The same genes also affect the vestibular hair cells, which are sensory cells that detect gravity and head movement. When these cells don’t work correctly, people have trouble with balance and spatial orientation. This explains why some people with Usher’s syndrome, particularly those with Type 1, have significant balance difficulties.^[8]

In the eye, the retina contains two types of light-sensing cells called rods and cones. Rods are responsible for vision in low light and for peripheral vision, while cones handle color vision and sharp central vision. In Usher’s syndrome, the genetic mutations affect the structure and function of these photoreceptor cells and the supporting tissue called the retinal pigmented epithelium. Over time, these cells gradually break down and die, starting with the rods. This explains why night blindness is the first symptom and why peripheral vision is lost before central vision.^[6]

At least ten different genes can cause Usher’s syndrome, and researchers continue to discover new ones. The most common genes involved in Type 1 include MYO7A and CDH23. Type 2 is most often caused by mutations in the USH2A gene. Type 3 can result from mutations in the CLRN1 gene among others. Each of these genes produces proteins that play crucial roles in the development and maintenance of hair cells in the inner ear and photoreceptor cells in the retina.^[3][6]

The proteins encoded by these genes are involved in various cellular functions. Some help maintain the structure of stereocilia on hair cells, allowing them to bend properly in response to sound. Others are involved in transporting molecules within cells or maintaining connections between cells. When mutations prevent these proteins from working correctly, the cells cannot function normally, and over time they degenerate and die. This cellular breakdown is what causes the progressive nature of the syndrome, particularly the vision loss from retinitis pigmentosa.^[6]

Turner syndrome diagnostics involve a range of tests that can identify this chromosomal condition at different stages of life, from before birth through adulthood. Understanding when and how testing is performed helps families and patients access timely treatment and support for managing the various health aspects associated with the condition.

Introduction: Who Should Undergo Diagnostics

Turner syndrome can be identified at many different points in a person’s life, and knowing when to seek diagnostic testing is important for ensuring early intervention and appropriate care. The timing of diagnosis varies widely, which means that healthcare providers need to remain alert to signs and symptoms that might suggest the condition at any age.^[1]

During pregnancy, diagnostic testing may be recommended if routine ultrasound scans reveal certain concerning features in the developing baby. These warning signs include an increased thickness at the back of the neck (called increased nuchal translucency), a fluid-filled sac on the neck (cystic hygroma), problems with the heart (especially on the left side), or issues with the kidneys. When these features appear on ultrasound, doctors may suggest further testing to confirm whether Turner syndrome is present.^[2]

At birth, certain physical characteristics may prompt healthcare providers to order diagnostic tests. Newborns with Turner syndrome might have swelling in their hands and feet, extra folds of skin on the neck (webbed neck), ears that are positioned lower than usual or shaped differently, a low hairline at the back of the head, or a broad chest with widely spaced nipples. If a doctor notices these features, they will typically recommend blood tests to check the baby’s chromosomes.^[3]

During childhood, parents and doctors should consider Turner syndrome testing if a girl is growing much more slowly than her peers. Most girls with Turner syndrome will show noticeable differences in height by around age five, as they tend to be shorter than other children their age and may not experience the usual growth spurts that happen during childhood and adolescence. This lack of expected growth is often one of the first clear signs that prompts diagnostic testing.^[1]

In teenage years and young adulthood, diagnostic testing should be considered if a young woman does not begin puberty at the expected time or experiences primary amenorrhea (meaning she never starts having menstrual periods). Most girls typically begin developing breasts and start menstruation between ages 10 and 14, so if these milestones do not occur, healthcare providers should investigate the possibility of Turner syndrome. Some women are not diagnosed until adulthood, when they seek medical help because they are unable to become pregnant.^[4]

Diagnostic Methods

The definitive way to diagnose Turner syndrome involves analyzing a person’s chromosomes through laboratory testing. The primary diagnostic test is called a karyotype analysis, which examines the chromosomes in a person’s cells. Normally, females have two complete X chromosomes in each cell, but in Turner syndrome, one X chromosome is either completely missing or partially absent. The karyotype test can identify this chromosomal difference and confirm the diagnosis.^[5]

To perform a karyotype analysis, healthcare providers typically collect a blood sample from the patient. The blood contains cells that can be examined in a laboratory to count and assess the structure of the chromosomes. Sometimes, instead of blood, doctors may collect cells from the inside of the cheek (called a buccal smear) or take a small skin sample. The cells are then sent to a specialized genetics laboratory where technicians prepare and examine them under a microscope to create a detailed picture of the chromosomes.^[8]

There are different patterns that can be identified through karyotype testing. About half of girls with Turner syndrome have monosomy X, which means every cell in their body has only one X chromosome instead of two (written as 45,X). This is usually the more recognizable form of the condition with more obvious symptoms. Other girls have what is called mosaic Turner syndrome, where some cells have the normal two X chromosomes while other cells have only one X chromosome. Girls with mosaic Turner syndrome often have milder symptoms and may be more difficult to diagnose based on physical appearance alone.^[1]

In addition to confirming the diagnosis, doctors will perform other tests to assess the various health conditions that can occur alongside Turner syndrome. These screening tests help healthcare providers understand the full picture of a patient’s health and identify any complications that need treatment or monitoring.

Heart evaluations are essential for all patients at the time of diagnosis. Doctors will perform a physical examination to listen to the heart and check blood pressure. An echocardiogram (an ultrasound of the heart) is typically ordered to look for structural problems with the heart, such as a narrowed aorta (the major blood vessel carrying blood from the heart), a bicuspid aortic valve (a valve with two flaps instead of the normal three), or other heart defects. About one-third to one-half of individuals with Turner syndrome are born with some type of heart problem, making cardiovascular screening a critical part of the diagnostic process.^[4]

Kidney assessment is also important because some people with Turner syndrome have kidney abnormalities. A kidney ultrasound or other imaging tests can reveal structural problems with the kidneys or urinary system that might not cause obvious symptoms but could affect health over time.^[2]

Hearing tests should be conducted as part of the diagnostic evaluation because hearing problems are more common in people with Turner syndrome. These may include recurrent ear infections that can lead to hearing loss, as well as sensorineural hearing loss (a type of hearing problem caused by damage to the inner ear or the nerve pathways to the brain). Regular hearing assessments help identify problems early so appropriate interventions can be implemented.^[6]

Eye examinations are recommended to check for vision problems and structural issues with the eyes, such as drooping eyelids or other features that might affect sight. Regular eye tests help ensure any vision problems are corrected with glasses or other treatments.^[3]

Thyroid function tests are important because individuals with Turner syndrome have an increased risk of developing thyroid problems. Blood tests can measure thyroid hormone levels and identify conditions like hypothyroidism (when the thyroid gland does not produce enough hormone), which can affect growth, development, and overall energy levels.^[11]

Bone density testing may be performed, especially in older children and adults, to assess bone strength. People with Turner syndrome are at higher risk for developing weak bones (osteoporosis), particularly if they have not received appropriate hormone replacement therapy.^[12]

Healthcare providers will also assess developmental and learning abilities. While most people with Turner syndrome have normal intelligence, some may experience specific learning challenges, particularly with spatial awareness, mathematics, and certain social skills. Psychological and educational assessments can help identify areas where additional support might be beneficial.^[2]

Prenatal Diagnostic Testing

When Turner syndrome is suspected before birth, two main procedures can be used to test the baby’s chromosomes while the mother is still pregnant. These tests are more invasive than ultrasound and carry a small risk, so they are typically offered only when there is a specific reason to suspect a chromosomal condition.

Chorionic villus sampling (CVS) involves taking a small sample of tissue from the placenta, which is the organ that nourishes the developing baby. The placenta contains the same genetic material as the baby, so examining its cells can reveal whether Turner syndrome is present. This test is usually performed between 11 and 14 weeks of pregnancy. A doctor inserts a thin tube through the cervix or uses a needle through the abdomen to collect the tissue sample, which is then sent to a laboratory for chromosome analysis.^[8]

Amniocentesis is another prenatal testing option that involves collecting a sample of the amniotic fluid that surrounds the baby in the womb. The developing baby sheds cells into this fluid, and these cells can be examined to determine the baby’s chromosomal makeup. Amniocentesis is typically performed after 14 weeks of pregnancy. During the procedure, a doctor uses ultrasound guidance to insert a thin needle through the mother’s abdomen and into the amniotic sac to withdraw a small amount of fluid.^[8]

In recent years, newer screening tests have become available that analyze the baby’s DNA circulating in the mother’s bloodstream. These tests, called prenatal cell-free fetal DNA screening or noninvasive prenatal screening, can indicate an increased risk of Turner syndrome without requiring an invasive procedure. However, these screening tests cannot provide a definitive diagnosis, so if results suggest Turner syndrome, doctors will recommend confirmatory testing through CVS or amniocentesis.^[8]

Diagnostics for Clinical Trial Qualification

When individuals with Turner syndrome are being considered for participation in clinical trials, additional diagnostic criteria and tests may be required beyond those used for standard diagnosis. Clinical trials often have specific inclusion and exclusion criteria that help researchers ensure they are studying the condition in a consistent and scientifically valid way.

The fundamental requirement for clinical trial enrollment is confirmed diagnosis of Turner syndrome through karyotype analysis. Researchers typically require documentation showing the specific chromosomal abnormality, whether it is complete monosomy X (45,X) or a mosaic pattern. Some clinical trials may focus on specific chromosomal variants, so the exact karyotype results become important for determining eligibility.^[14]

For clinical trials studying growth hormone therapy, baseline measurements are essential. Researchers will document the participant’s current height, weight, and growth velocity (how quickly they are growing over time). Bone age assessment, typically done through an X-ray of the left hand and wrist, helps determine skeletal maturity and predict remaining growth potential. Many trials require participants to be still growing, which means they cannot have reached full skeletal maturity (usually defined as a bone age of 14 years or less).^[15]

Cardiovascular assessment is typically required for clinical trial participation, particularly for trials involving hormone therapies. Detailed heart imaging, including echocardiography, helps identify any structural heart problems or aortic complications that might make certain treatments risky or inappropriate. Researchers need to document blood pressure readings and any history of cardiovascular issues.^[14]

Hormone level testing is crucial for trials examining puberty induction or fertility treatments. Blood tests measuring follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen, and other reproductive hormones help researchers understand ovarian function and determine appropriate treatment protocols. These baseline hormone levels also serve as comparison points to assess whether trial treatments are having the desired effects.^[3]

For trials examining specific health complications associated with Turner syndrome, additional specialized testing may be required. This could include detailed kidney function tests, comprehensive thyroid panels, hearing assessments, or cognitive and psychological evaluations depending on what the clinical trial is investigating.

Quality of life assessments and standardized questionnaires often form part of the diagnostic workup for clinical trial participation. These tools help researchers measure not only the physical effects of Turner syndrome but also the psychological, social, and emotional impacts, allowing them to evaluate whether interventions improve overall wellbeing alongside specific medical outcomes.

Ongoing Clinical Trials for Turner’s Syndrome

There are currently 6 clinical trials ongoing for Turner’s syndrome, a genetic condition affecting females characterized by the partial or complete absence of one X chromosome. These trials are investigating growth hormone therapies, hormone replacement treatments, and new approaches to managing symptoms associated with the condition. Studies are taking place across multiple European countries and are exploring treatments including vosoritide, estrogen replacement therapy in different forms, testosterone replacement therapy, and somapacitan.

Clinical trial locations

• Austria
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Belgium
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Bulgaria
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Croatia
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Denmark
  • Study on Estrogen Treatment (Oral vs. Transdermal) for Women with Turner Syndrome
  • Study on Long-Term Effects of Oral and Transdermal Estradiol Therapy in Women with Turner Syndrome
  • Study on Testosterone and Isopropyl Myristate for Women with Turner Syndrome
• Finland
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• France
  • Study of Vosoritide for Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome Not Responding to Growth Hormone
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Germany
  • Study of Vosoritide for Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome Not Responding to Growth Hormone
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Greece
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Italy
  • Study of Vosoritide for Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome Not Responding to Growth Hormone
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Latvia
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Lithuania
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Netherlands
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
  • Study on the Safety and Effectiveness of Somapacitan for Children with Short Stature Due to Noonan Syndrome, Turner Syndrome, Small for Gestational Age, or Idiopathic Short Stature
• Poland
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
  • Study on the Safety and Effectiveness of Somapacitan for Children with Short Stature Due to Noonan Syndrome, Turner Syndrome, Small for Gestational Age, or Idiopathic Short Stature
• Portugal
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Slovenia
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
• Spain
  • Study of Vosoritide for Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome Not Responding to Growth Hormone
  • Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature
  • Study on the Safety and Effectiveness of Somapacitan for Children with Short Stature Due to Noonan Syndrome, Turner Syndrome, Small for Gestational Age, or Idiopathic Short Stature

Study of Vosoritide for Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome Not Responding to Growth Hormone

This trial is investigating vosoritide as a potential treatment for children with growth-related conditions who have not responded adequately to human growth hormone therapy. The study compares different doses of vosoritide with continued hGH treatment.

Who can join: Children must be at least 3 years old and younger than 10 years for females or 11 years for males. They need a genetically confirmed diagnosis of Turner syndrome, SHOX deficiency, or Noonan syndrome. Participants must have a height Z-score of -2.00 or lower, be at Tanner Stage 1, and have received continuous hGH treatment for at least 1 year before joining. Importantly, they must have shown an inadequate response to previous hGH treatment.

Who cannot join: Children without one of the specified genetic conditions cannot participate. The trial is open to both males and females within the specified age ranges.

Study focus: The trial evaluates how different doses of vosoritide affect growth in children compared to continued hGH treatment. After an initial assessment and baseline growth phase, participants are randomly assigned to either continue hGH or switch to one of three doses of vosoritide. The treatment phase lasts six months initially, with an extended phase of up to 24 months. Regular assessments monitor growth, height Z-scores, and potential side effects.

Investigational drugs: Vosoritide is administered through subcutaneous injection. It works by targeting a specific pathway in the body that regulates bone growth. Human growth hormone continues to be used as the comparison treatment.

Study on Estrogen Treatment (Oral vs. Transdermal) for Women with Turner Syndrome

This Danish trial compares two different forms of estradiol hormone therapy to determine which is more effective for managing symptoms in women with the condition.

Who can join: Women must be between 18 and 50 years old with a confirmed diagnosis. They must already be receiving estrogen treatment. Healthy female controls are also needed who are previously healthy, not taking any medication or contraceptive pills, and have no mental or psychiatric disorders.

Who cannot join: Men cannot participate. Only females within the specified age range are eligible.

Study focus: The trial compares oral estradiol taken as Estrofem tablets with transdermal estradiol applied as Divigel gel. Both contain the same active substance but are administered differently. The study monitors hormone levels, particularly luteinizing hormone and follicle-stimulating hormone, to assess how the body responds to each treatment form. The study lasts up to 14 days.

Investigational drugs: Estradiol is tested in both oral and transdermal forms. This hormone is crucial for female development and reproductive health, binding to estrogen receptors to regulate various body functions.

Study on Long-Term Effects of Oral and Transdermal Estradiol Therapy in Women with Turner Syndrome

Another Danish study examines the long-term effects of two forms of estrogen replacement therapy on various health aspects including hormone levels, heart health, and overall physical well-being.

Who can join: Women aged 18 to 50 with a confirmed diagnosis who are already receiving estrogen treatment. Healthy female controls are also recruited who must be previously healthy, not taking medications or contraceptive pills, and free from mental or psychiatric disorders.

Who cannot join: Men are not eligible. Only females within the specified age range can participate.

Study focus: This longer-term study compares oral Estrofem tablets with transdermal Divigel gel over six months for each treatment type. After an initial assessment and washout period, participants receive oral estrogen therapy for six months, followed by mid-study assessment, then switch to transdermal therapy for another six months. The trial monitors body composition, cardiovascular status, muscle strength, bone density, and quality of life.

Investigational drugs: Both oral and transdermal estradiol are being evaluated for their long-term effects on metabolism, cardiovascular health, and overall well-being.

Study on Testosterone and Isopropyl Myristate for Women with Turner Syndrome

This Danish trial studies testosterone replacement therapy alongside estrogen replacement therapy to understand its effects on various health parameters.

Who can join: Women aged 18 to 50 with any type of the syndrome who are currently receiving estrogen replacement therapy and can speak Danish.

Who cannot join: Men cannot participate. Women outside the specified age range are not eligible.

Study focus: The study examines how testosterone replacement therapy, used alongside estrogen therapy, impacts hormone levels, heart health, brain function, and overall physical well-being. Participants use Androgel, a transdermal gel applied to the skin, for up to 12 months. The trial includes regular monitoring through DXA scans measuring body composition, along with assessments of quality of life, inflammatory markers, and other health indicators. Some participants receive a placebo for comparison.

Investigational drugs: Testosterone delivered through a transdermal patch allows gradual hormone entry into the bloodstream, mimicking natural release patterns.

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

This large multinational study across 16 European countries tests whether once-weekly somapacitan is as effective as daily Norditropin for promoting growth in children with various growth-related conditions.

Who can join: Children must not have had previous growth-promoting therapy. For those born small for gestational age, boys must be 2 years 26 weeks to younger than 11 years with testis volume below 4 mL, while girls must be 2 years 26 weeks to younger than 10 years without breast development. For those with Turner syndrome, girls must be 2 years 26 weeks to younger than 10 years with confirmed diagnosis and no breast development. For Noonan syndrome, boys and girls follow similar age and development criteria as SGA patients. For idiopathic short stature, children must be prepubertal with specific bone age requirements.

Who cannot join: Children without the specified short stature conditions, those outside the age ranges, those with interfering medical conditions, those on growth-affecting medications, those with previous growth hormone therapy, those with medication allergies, or those unable to comply with study procedures.

Study focus: After initial assessment and baseline measurements, participants are randomly assigned to receive either once-weekly somapacitan or continue with daily Norditropin. The primary evaluation occurs at six months, with an extended treatment phase lasting up to 24 months. Growth is carefully monitored through height velocity measurements, bone age changes, and various blood markers related to growth.

Investigational drugs: Somapacitan is given once weekly via subcutaneous injection using a pre-filled pen. Norditropin is administered daily, also by injection. Both are growth hormone therapies designed to stimulate growth in children.

Study on the Safety and Effectiveness of Somapacitan for Children with Short Stature Due to Noonan Syndrome, Turner Syndrome, Small for Gestational Age, or Idiopathic Short Stature

This trial in Poland, Spain, and the Netherlands focuses specifically on evaluating the safety and effectiveness of somapacitan for children with growth difficulties.

Who can join: Children born small for gestational age according to national standards, or girls with confirmed Turner syndrome, or children with Noonan syndrome diagnosed according to local clinical practice, or children with idiopathic short stature. All participants must be within specific age ranges at screening and have open epiphyses, meaning their bone growth plates are still open and allow for continued growth.

Who cannot join: Children with significant medical conditions that could interfere with the study, those who have had growth hormone treatment within the last 6 months, those with allergies to the study medication, those currently in another trial, those with a history of cancer or serious illness, those unable to comply with procedures, or those deemed unsuitable by the investigator.

Study focus: After an initial visit with physical examination, participants receive weekly somapacitan injections under the skin at a dose of 15 mg in 1.5 ml of solution. Weekly follow-ups monitor response and check for side effects. A comprehensive mid-study evaluation occurs at approximately 26 weeks, with long-term follow-up continuing until 156 weeks. The study carefully tracks the number of adverse events and measures growth progress throughout the treatment period.

Investigational drugs: Somapacitan is given once weekly to help children grow taller. It mimics natural growth hormone and is being tested in children who are shorter than usual for their age due to various conditions.

Summary

The six ongoing clinical trials for Turner’s syndrome reflect two distinct research priorities: growth promotion in children and hormone replacement therapy optimization in adult women.

Three trials focus on Denmark, examining different aspects of hormone replacement therapy in adult women. These studies compare oral versus transdermal estrogen delivery and explore testosterone supplementation alongside estrogen therapy. This concentration suggests Denmark is a center of expertise for hormone management in this condition.

Growth-focused trials are more geographically diverse. The vosoritide study spans Germany, France, Spain, and Italy, while the large somapacitan comparison trial operates across 16 European countries. A smaller somapacitan safety study takes place in Poland, Spain, and the Netherlands.

Somapacitan, a once-weekly growth hormone, features in two trials, reflecting significant interest in this newer therapy. Traditional daily growth hormone and the experimental drug vosoritide are also under investigation. All growth trials include children with Turner syndrome alongside other growth-related conditions, allowing researchers to gather broader evidence while studying this specific population.

The hormone replacement trials exclusively focus on women with Turner syndrome, examining how different delivery methods affect cardiovascular health, bone density, metabolism, and quality of life. These studies address lifelong health management needs for women with the condition.

Turner syndrome is a genetic condition affecting females that occurs when one X chromosome is missing or partially absent, leading to a range of health challenges that vary widely from person to person. With proper medical care, ongoing monitoring, and appropriate treatments, individuals with this condition can lead fulfilling, productive lives.

Understanding the Outlook for Turner Syndrome

When a girl or woman receives a diagnosis of Turner syndrome, understanding what the future holds becomes an important concern for both patients and their families. The outlook for individuals with this condition has improved significantly over recent decades thanks to advances in medical care and a better understanding of how to manage associated health issues^[11].

Turner syndrome can slightly reduce life expectancy compared to the general population, but the vast majority of people with the condition should be able to live relatively normal, healthy lives. The key to achieving the best possible outcome lies in receiving regular health checks and early treatment for any health problems that arise^[5]. This means working closely with a team of healthcare professionals who understand the condition and can monitor for complications before they become serious.

The prognosis varies considerably depending on several factors. The type of chromosomal abnormality matters—whether the X chromosome is completely missing (monosomy X) or only partially missing (mosaic Turner syndrome). Those with mosaic Turner syndrome often experience milder symptoms and may have a better overall outlook^[1]. Additionally, the presence and severity of heart defects significantly impact long-term health outcomes, as cardiovascular complications are among the most serious concerns for individuals with Turner syndrome.

It’s important to understand that statistical information about life expectancy represents averages across many individuals. Each person’s experience with Turner syndrome is unique, and many factors influence individual outcomes, including access to quality healthcare, early diagnosis, appropriate treatment, and management of associated conditions. With comprehensive medical care that includes regular monitoring of blood pressure, bone density, thyroid function, and cardiovascular health, many women with Turner syndrome enjoy active, fulfilling lives well into adulthood^[11].

How Turner Syndrome Progresses Without Treatment

Understanding the natural course of Turner syndrome—how it develops when medical interventions are not provided—helps illustrate why early diagnosis and treatment are so important. Without appropriate medical care, individuals with this condition face several predictable patterns of development that differ significantly from typical female development.

The most noticeable feature that emerges without treatment is short stature. Girls with Turner syndrome grow more slowly than their peers, typically becoming noticeable around age five. Without growth hormone therapy, they experience a lack of the normal growth spurts that occur during childhood and adolescence. The average final adult height without treatment is approximately 143 centimeters (4 feet 8 inches), significantly shorter than the typical female adult height^[2].

Puberty presents another major area where natural progression differs markedly from typical development. The ovaries in girls with Turner syndrome typically develop normally at first, but the egg cells usually die prematurely, and most ovarian tissue breaks down before birth^[4]. This means that without hormone replacement therapy, most girls with Turner syndrome will not undergo puberty naturally. They will not develop breasts, will not begin menstruating, and will experience primary amenorrhea—the absence of menstrual periods. Only a small percentage retain normal ovarian function through young adulthood, and even in these cases, function is typically limited.

Beyond growth and sexual development, untreated Turner syndrome leads to various other health consequences. The absence of naturally produced estrogen affects bone health, increasing the risk of developing osteoporosis at a younger age than would typically occur. Without estrogen, bones become thinner and more fragile, making fractures more likely. Cardiovascular problems that are present from birth may worsen over time without proper monitoring and intervention. Blood pressure problems can develop or worsen, particularly in individuals with certain heart defects.

Metabolic changes also occur as part of the natural progression. Without appropriate hormone treatment, individuals may develop an increased risk of obesity, diabetes, and an unhealthy lipid profile—a combination of factors that further increases cardiovascular risk^[3]. The thyroid gland may also develop problems, as Turner syndrome is associated with an increased likelihood of hypothyroidism, a condition where the thyroid doesn’t produce enough hormone.

Possible Complications That May Arise

Turner syndrome is associated with a wide range of potential complications affecting multiple body systems. While not every individual will experience all of these complications, understanding what might occur helps with early detection and prompt treatment.

Cardiovascular complications represent some of the most serious concerns. Congenital heart defects occur in approximately 30 to 50 percent of individuals with Turner syndrome. The most common defects include coarctation of the aorta, where the major blood vessel leaving the heart becomes narrowed, and bicuspid aortic valve, where the valve connecting the heart to the aorta has only two leaflets instead of the normal three^[4]. These structural abnormalities can lead to several dangerous complications, including high blood pressure, heart failure, and most seriously, aortic dissection or rupture—a life-threatening emergency where the wall of the aorta tears.

Progressive aortic root dilatation, where the aorta gradually enlarges at its connection to the heart, can occur even in individuals who had normal heart examinations at birth. This risk is particularly elevated in those with a bicuspid aortic valve, coarctation, or untreated high blood pressure^[12]. Because of these risks, individuals with Turner syndrome require regular cardiac monitoring throughout their lives, even if initial cardiovascular examinations were normal.

Kidney and urinary tract abnormalities affect a significant proportion of individuals with Turner syndrome. These can include structural malformations such as horseshoe kidney, where the two kidneys are fused together, or problems with how the kidneys collect and drain urine. While many kidney abnormalities don’t cause symptoms, some can lead to recurrent urinary tract infections or, in more severe cases, affect kidney function over time.

Hearing problems become increasingly common with age in Turner syndrome. Recurrent middle ear infections during childhood can lead to decreased hearing. Additionally, progressive sensorineural hearing loss—where the inner ear or nerve pathways to the brain are damaged—often develops. This type of hearing loss typically worsens gradually over time and requires monitoring and potential intervention with hearing aids^[3].

Bone health complications include not only osteoporosis from lack of estrogen but also an increased risk of fractures and altered bone development. Some individuals experience unusual bone formation patterns, such as cubitus valgus (where the arms angle outward at the elbows) or problems with bone development in the hands and wrists. Skeletal abnormalities, while often not causing functional problems, may require monitoring.

Metabolic and endocrine complications extend beyond ovarian insufficiency. Many individuals with Turner syndrome develop thyroid problems, most commonly hypothyroidism, requiring lifelong thyroid hormone replacement. The risk of developing type 2 diabetes is elevated, particularly with increasing age. Many individuals also develop an atherogenic lipid profile—unfavorable cholesterol and triglyceride levels that increase the risk of cardiovascular disease^[12].

Autoimmune conditions occur more frequently in Turner syndrome than in the general population. Beyond autoimmune thyroid disease, some individuals develop celiac disease (an immune reaction to gluten) or inflammatory bowel disease. Regular screening for these conditions helps ensure early detection and treatment.

Vision problems include an increased risk of strabismus (crossed or misaligned eyes), drooping eyelids, and other eye abnormalities. Some individuals are also at higher risk for developing high pressure within the eye, which can lead to glaucoma if not treated.

Impact on Daily Life and Activities

Living with Turner syndrome affects various aspects of daily life, though the degree of impact varies considerably from person to person. Understanding these effects helps individuals and families plan appropriate support and develop strategies for managing challenges.

Physical activities and sports participation require some consideration, particularly for those with cardiovascular abnormalities. Individuals with significant heart defects, aortic dilation, or uncontrolled high blood pressure may need to avoid certain high-intensity activities or contact sports that could potentially trigger cardiovascular complications. However, many people with Turner syndrome can participate safely in a wide range of physical activities with appropriate medical guidance. Regular exercise remains important for maintaining bone health, cardiovascular fitness, and overall wellbeing.

Short stature, while not a health problem in itself, can create practical challenges in daily life. Everyday tasks that others take for granted—reaching items on high shelves, using standard-height counters or equipment, driving a car with standard pedal positioning—may require adaptations or assistive devices. These physical adaptations are usually straightforward to implement, but they represent an ongoing aspect of managing life with the condition.

Learning and cognitive function in Turner syndrome typically involve specific patterns rather than overall intellectual disability. Most individuals have normal intelligence and normal language and reading skills^[5]. However, some people experience challenges with certain types of learning, particularly involving spatial awareness, mathematics, and nonverbal skills. These learning differences can affect performance in school subjects like geometry or subjects requiring strong visual-spatial processing. Some individuals also experience difficulties with attention, organization, or executive function skills—the mental processes that help with planning, focusing attention, and managing multiple tasks.

Social and emotional aspects of living with Turner syndrome can be challenging, particularly during adolescence and young adulthood. The visible differences in height and delayed puberty can affect self-esteem and social interactions during teenage years when fitting in with peers feels especially important. Not developing at the same time as friends can lead to feelings of being different or left behind. Some individuals experience social anxiety or have difficulty reading social cues, which may relate to the nonverbal learning challenges associated with Turner syndrome^[6].

Coming to terms with infertility represents a significant emotional challenge for many women with Turner syndrome. While assisted reproductive technology has made biological motherhood possible for some through egg donation and in vitro fertilization, the inability to conceive naturally can be a source of grief and loss. This reality often becomes more emotionally significant during young adulthood when peers are starting families.

Managing the medical aspects of Turner syndrome requires ongoing attention and coordination. Regular medical appointments for monitoring various health parameters—cardiovascular checks, bone density scans, hearing tests, blood tests for thyroid and metabolic function—become a routine part of life. Taking daily medications, particularly hormone therapies, requires consistency and attention. This level of medical management can sometimes feel burdensome, particularly for adolescents and young adults seeking independence.

Employment and career development are generally not significantly limited by Turner syndrome for most individuals. People with the condition work successfully in a wide range of fields and professions. However, those who experience learning difficulties may benefit from additional educational support or career guidance to find roles that match their strengths. Physical limitations from short stature rarely restrict career options but may require workplace accommodations in some situations.

Despite these challenges, many coping strategies and supports can help individuals thrive. Early intervention for learning differences through specialized educational support can help children develop strategies to work around their challenges. Counseling or therapy can provide valuable support for managing the emotional and social aspects of the condition, particularly during adolescence. Support groups connecting individuals with Turner syndrome allow them to share experiences and strategies with others who understand their situation. Focusing on individual strengths and abilities, rather than limitations, helps build confidence and resilience.

Supporting Families Through Clinical Research

For families affected by Turner syndrome, understanding clinical trials and research studies becomes an important consideration. These studies play a crucial role in advancing knowledge about the condition and developing improved treatments, but navigating the world of clinical research can feel overwhelming without proper guidance.

Clinical trials for Turner syndrome typically focus on several key areas. Research may investigate new approaches to growth hormone therapy to optimize height outcomes, study different estrogen replacement strategies to better mimic natural puberty and protect bone health, or explore treatments that might help preserve ovarian function. Some studies examine ways to prevent or manage specific complications, such as cardiovascular problems or metabolic issues. Others investigate the cognitive and psychological aspects of Turner syndrome to develop better support strategies.

Families considering clinical trial participation should understand what these studies involve. Clinical trials are research studies designed to answer specific questions about medical treatments, procedures, or diagnostic approaches. They follow strict protocols to ensure participant safety and collect reliable information. Trials typically have specific eligibility criteria, meaning not every individual with Turner syndrome will qualify for every study. Criteria might include specific age ranges, particular symptoms or complications, previous treatments received, or other health factors.

The benefits of participating in clinical research extend beyond potential individual advantages. Participants often receive very close medical monitoring and access to cutting-edge treatments before they become widely available. They contribute to advancing scientific knowledge that will help future generations affected by Turner syndrome. Many families find meaning and purpose in contributing to research that may eventually improve care for others facing similar challenges.

However, clinical trial participation also involves considerations and potential downsides. Trials may require additional time commitments for extra visits, testing, or procedures beyond standard care. There may be uncertainty about whether a particular treatment will prove beneficial, particularly in studies comparing new treatments to standard approaches. Some trials involve placebos—inactive treatments—though studies addressing serious aspects of Turner syndrome typically ensure all participants receive at least standard care. Families need to weigh these factors carefully based on their individual circumstances.

Finding appropriate clinical trials requires knowing where to look. Healthcare providers specializing in Turner syndrome often know about relevant studies and can make referrals. Online registries maintain searchable databases of clinical trials, allowing families to search for studies related to Turner syndrome in their geographic area or that accept participants remotely. Patient advocacy organizations focused on Turner syndrome often maintain information about ongoing research and can help connect families with appropriate studies.

Relatives can provide crucial support for patients considering or participating in clinical trials. Families can help by researching potential studies and discussing options together. Understanding the details of a study—what it involves, potential risks and benefits, time commitments required—allows for informed decision-making. Accompanying the patient to study visits provides both practical and emotional support. Helping maintain any records or complete any at-home requirements of the study assists with successful participation. Perhaps most importantly, respecting the individual’s decision about whether to participate, while providing guidance and support, empowers patients to take an active role in their healthcare decisions.

When evaluating a clinical trial, certain questions can help families make informed decisions. What is the purpose of the study? What exactly will participation involve in terms of visits, tests, and treatments? What are the potential risks and discomforts? What are the possible benefits, both to the participant and to future patients? How long will participation last? What happens after the study ends? Will the participant be able to continue receiving the treatment if it proves beneficial? Is there any cost associated with participation, or will the study cover related expenses? Asking these questions helps families understand what they’re agreeing to and make choices aligned with their values and circumstances.

Usher’s syndrome is a rare genetic condition that affects both hearing and vision, and sometimes balance, posing unique challenges that evolve throughout a person’s life. While there is currently no cure, advances in medical care and ongoing research offer hope for managing symptoms and improving quality of life for those living with this condition.

Understanding the Goals of Managing Usher’s Syndrome

When a person is diagnosed with Usher’s syndrome, the focus shifts to helping them live as fully and independently as possible despite the progressive nature of the condition. Treatment is not about curing the disease, but about preserving function, slowing decline, and supporting adaptation to changes in hearing and vision. The approach varies significantly depending on which type of Usher’s syndrome someone has, when symptoms appear, and how quickly they progress.^[1]

Medical professionals work with patients to create individualized plans that address hearing loss, vision problems, and balance difficulties. The earlier these interventions begin, the better the outcomes tend to be, particularly for children who are still developing language and learning skills. Early identification allows families to make informed decisions about communication methods, educational support, and assistive technologies that can make a meaningful difference in daily life.^[2]

There are established treatments approved by medical societies that have been used for decades to help people with Usher’s syndrome manage their symptoms. At the same time, scientists around the world are exploring innovative therapies through clinical trials, including gene therapy (a technique that aims to correct faulty genes), specialized drug treatments, and advanced technologies like retinal implants. These emerging approaches represent the cutting edge of research and may one day transform how Usher’s syndrome is treated.^[13][14]

Standard Treatment Approaches

Managing hearing loss in Usher’s syndrome typically begins with devices that amplify sound. Hearing aids are electronic devices worn in or behind the ear that make sounds louder, helping people with moderate hearing loss communicate more effectively. For individuals with severe or profound hearing loss, especially those with Type 1 Usher’s syndrome who are born deaf or nearly deaf, cochlear implants may be recommended. These are surgically placed devices that bypass damaged parts of the inner ear and directly stimulate the hearing nerve, allowing the brain to perceive sound signals.^[11][12]

The decision between hearing aids and cochlear implants depends on the degree of hearing loss and how well a person responds to amplification. Cochlear implants work best when placed early in childhood, particularly for Type 1 patients, because the developing brain is more adaptable to learning how to interpret the signals from the device. Many families also choose to teach their children American Sign Language alongside spoken communication, creating multiple pathways for connection with others throughout life.^[8]

For balance problems that occur particularly in Type 1 Usher’s syndrome, physical and occupational therapy play crucial roles. These therapies help strengthen core muscles and improve coordination. Orientation and mobility training teaches people how to navigate safely from one place to another, which becomes increasingly important as vision declines. This specialized instruction helps individuals maintain independence by learning techniques for traveling confidently in familiar and unfamiliar environments.^[11][17]

Vision support involves several complementary strategies. Low vision services provided by optometrists include training with optical and electronic magnification devices, techniques for using remaining vision more effectively, and environmental modifications such as improved lighting and enhanced contrast in the home. As vision declines, people may learn Braille, a tactile reading and writing system using raised dots, which allows continued access to written information even when sight is severely limited.^[11][12]

These standard interventions are ongoing rather than time-limited. A person with Usher’s syndrome may use hearing aids or cochlear implants throughout their entire life, upgrading technology as it improves. Vision services adapt as needs change, with different tools and strategies becoming relevant at different stages of vision loss. The goal is continuous support that evolves alongside the condition itself.^[2]

Innovative Therapies in Clinical Trials

The landscape of potential treatments for Usher’s syndrome has expanded dramatically in recent years as researchers have identified the specific genetic mutations responsible for different types of the condition. This knowledge has opened the door to therapies that target the underlying causes rather than just managing symptoms. While none of these experimental treatments are yet approved for general use, they represent promising directions that may fundamentally change the future of Usher’s syndrome care.^[14]

Gene therapy represents one of the most exciting frontiers in Usher’s syndrome research. This approach involves delivering correct copies of faulty genes directly to cells in the retina or inner ear. For Usher syndrome Type 1B, caused by mutations in the MYO7A gene, AAVantgarde Bio has initiated a Phase 1/2 clinical trial using a dual-vector gene therapy approach. The trial, called LUCE-1, is taking place at the University Hospital of Campania in Naples, Italy, with additional sites planned in the United Kingdom. This represents the first-in-human testing of this specific gene therapy strategy.^[13]

Phase 1/2 trials are early-stage studies that primarily assess safety while also beginning to gather information about whether the treatment shows any beneficial effects. Participants in these trials are carefully monitored for any adverse reactions, and researchers measure whether the therapy reaches its target tissues and produces the intended biological changes. These trials typically involve small numbers of participants and provide crucial data that guides decisions about whether to proceed to larger studies.^[14]

Another promising avenue involves antisense oligonucleotide therapies, which are specialized molecules that can modify how genes are expressed. Sepul Bio, a new business unit of Théa, is advancing two such treatments through clinical trials. One is called ultevursen, designed for people with Usher syndrome Type 2A who have specific mutations (exon 13 mutations) in the USH2A gene. This therapy is being studied in a Phase 2b trial called LUNA. The other is sepofarsen, for people with Leber congenital amaurosis Type 10 caused by a particular mutation in the CEP290 gene, which is being tested in a Phase 3 trial called HYPERION. Both of these RNA-based therapies had shown promising results in earlier clinical studies.^[13]

Phase 2 trials are designed to determine whether a treatment has beneficial effects and to identify the optimal dose. Phase 3 trials are larger studies that compare the new treatment to current standard care or placebo to definitively establish whether the therapy should be approved for widespread use. The fact that these trials are progressing through these stages suggests the treatments have demonstrated acceptable safety profiles and enough preliminary effectiveness to warrant continued investigation.^[14]

An oral antioxidant medication called NACA (N-acetylcysteine-amide) is being studied for its potential to protect retinal cells from damage. Nacuity, a Dallas-based company, reported that in a Phase 2 clinical trial conducted in Australia for people with Usher syndrome, NACA reduced photoreceptor cell loss by 50 percent. Photoreceptors are the cells in the retina that capture light and begin the process of vision. The Foundation Fighting Blindness has invested up to $7.5 million to advance this drug for retinitis pigmentosa, Usher syndrome, and related conditions. The mechanism of NACA involves reducing oxidative stress, a harmful process where unstable molecules damage cells. By providing antioxidant protection, NACA may slow the gradual death of photoreceptor cells that causes progressive vision loss.^[13]

For some types of Usher syndrome, researchers are exploring drugs that can overcome specific types of genetic mutations. A medication called Ataluren (originally known as PTC 124) has been developed to address nonsense mutations, a particular kind of genetic error where the instructions for making a protein are cut off prematurely. While this drug has been tested primarily in other genetic diseases like Duchenne muscular dystrophy and cystic fibrosis, researchers in Germany have been evaluating it in mouse models of Usher syndrome Type 1C. A similar approach involves modified antibiotics called aminoglycosides, with researchers at the Technion in Israel developing a modified version called NB54 specifically designed to be safe for long-term human use in treating Usher syndrome Type 1F, which is relatively common among Ashkenazi Jewish populations.^[14]

Beyond medications and gene therapies, researchers are developing retinal implants that function somewhat like cochlear implants for the eye. The Argus artificial retina system, funded by the U.S. Department of Energy, has progressed from 16-electrode to 60-electrode versions (Argus I and II) in clinical trials, with even more advanced versions in development. These devices use a small camera mounted on glasses that sends signals to an electrode array implanted on the retina, bypassing damaged photoreceptor cells to stimulate remaining nerve cells directly. Similarly, researchers at the Massachusetts Institute of Technology are developing an implant system with electrodes attached to the retina and the main chip implanted outside the eye. Clinical trials for this approach are expected to begin within a few years.^[14]

The journey of a therapy from laboratory research to approved treatment typically takes many years. Even treatments now in Phase 2 or Phase 3 trials may require several more years of study and regulatory review before becoming available to patients outside of research settings. Scientists must demonstrate not only that treatments work, but that they work safely across diverse populations and that their benefits outweigh any risks. This rigorous process protects patients while ensuring that new therapies represent genuine advances in care.^[14]

Most Common Treatment Methods

• Hearing Management
  • Hearing aids amplify sound for people with moderate hearing loss, helping them communicate more effectively in daily life
  • Cochlear implants are surgically placed devices that directly stimulate the hearing nerve, particularly beneficial for profound hearing loss in Type 1 Usher’s syndrome
  • American Sign Language provides an alternative communication method that remains effective even as hearing declines
  • Assistive listening devices enhance sound in specific situations like classrooms or meetings
• Vision Support Services
  • Low vision services include training with magnification devices, techniques for using remaining vision efficiently, and environmental modifications
  • Braille instruction provides access to reading and writing through a tactile system of raised dots
  • Orientation and mobility training teaches safe and independent navigation skills as vision declines
  • Protective eyewear including sunglasses helps shield eyes from potentially damaging ultraviolet light
  • Vitamin A supplementation at 15,000 IU daily may slow retinitis pigmentosa progression in some adult patients under medical supervision
• Balance and Mobility Interventions
  • Physical therapy strengthens core muscles and improves coordination, particularly important for Type 1 patients with vestibular dysfunction
  • Occupational therapy helps develop strategies for daily activities and maintaining independence
  • Mobility aids and environmental modifications improve safety in home and community settings
• Experimental Therapies in Clinical Trials
  • Gene therapy approaches for Type 1B (MYO7A mutations) delivering correct gene copies to retinal cells in Phase 1/2 trials
  • Antisense oligonucleotide therapies (ultevursen for USH2A mutations, sepofarsen for CEP290 mutations) modifying gene expression in Phase 2b and Phase 3 trials
  • Oral antioxidant NACA reducing photoreceptor cell loss through protection from oxidative stress in Phase 2 trials
  • Medications targeting specific mutation types like Ataluren for nonsense mutations and modified aminoglycosides like NB54 in laboratory and early testing phases
  • Retinal implant systems (Argus II and others) using camera-and-electrode technology to bypass damaged photoreceptors and stimulate retinal nerves directly

Still’s disease is a rare inflammatory condition that causes the body’s immune system to attack its own tissues, leading to high fevers, a distinctive rash, and painful joints. This puzzling disorder can appear suddenly in adults or children, and its unpredictable nature makes living with it a unique challenge for each person affected.

Understanding Still’s Disease

Still’s disease belongs to a group of conditions known as inflammatory arthritis, which means inflammation affects not only the joints but often the entire body. The disease exists in two main forms. When it affects children, it is called systemic juvenile idiopathic arthritis, often abbreviated as SJIA. When symptoms first appear in adults, typically after age 16, it is known as adult-onset Still’s disease, or AOSD.^[1] Both forms share similar symptoms, including fatigue, fever, joint pain, and inflammation, though the severity and duration can vary greatly from one person to another.^[4]

The condition was first described over a century ago by English physician Sir George Frederic Still, who observed children with unusual symptoms that did not fit the pattern of typical rheumatoid arthritis. Today, doctors recognize that Still’s disease can strike at any age, though it most commonly emerges in young adults between 16 and 35 years old.^[2] The disease follows an unpredictable course, which makes it particularly challenging for both patients and their healthcare providers to manage.

Epidemiology: How Common Is Still’s Disease?

Still’s disease is classified as a rare condition, meaning it affects only a small portion of the population. The exact number of people living with this disease is difficult to determine because many cases may be misdiagnosed or diagnosed late due to the condition’s rarity and complexity.^[4] Understanding how many people are affected helps researchers and healthcare systems better prepare for diagnosis and treatment needs.

For adult-onset Still’s disease, studies estimate that between 0.16 and 0.4 cases occur per 100,000 adults each year in Europe.^[3] This translates to roughly one or two people developing AOSD for every half million adults annually. For the childhood form, systemic juvenile idiopathic arthritis affects approximately 3.5 per 100,000 children.^[4] These numbers underscore just how uncommon this disease truly is.

The disease shows a distinctive pattern in when it strikes. Age distribution follows what doctors call a bimodal pattern, meaning there are two age ranges when the disease is most likely to appear. The first peak occurs between ages 15 and 25, while a second, smaller peak happens between ages 36 and 46.^[3] Interestingly, approximately three-quarters of patients experience their first symptoms between ages 16 and 35.^[3]

When it comes to gender distribution, Still’s disease affects men and women at roughly equal rates, though some studies suggest a slight tendency for more females to develop the condition.^[4][6] This near-equal distribution across genders is somewhat unusual among autoimmune and inflammatory conditions, many of which show a stronger female predominance.

Causes: Why Does Still’s Disease Happen?

Despite decades of research, the exact cause of Still’s disease remains a mystery to medical science. What doctors do know is that the condition involves the body’s immune system behaving abnormally, generating continuous inflammation even when there is no infection or injury to fight.^[2] This malfunction leads to the various symptoms that patients experience, but understanding why this malfunction occurs in the first place continues to puzzle researchers.

The leading theory suggests that Still’s disease may be what doctors call a reactive syndrome. This means the disease might be triggered when certain infectious agents—such as viruses or bacteria—interact with a person who has a genetic tendency to develop the condition.^[3] In other words, an infection might act as a spark that ignites an abnormal immune response in someone whose genetic makeup makes them vulnerable. However, not all patients with Still’s disease have clear evidence of a recent infection, so this theory does not explain every case.

Several specific infectious organisms have been proposed as possible triggers. These include bacteria like Yersinia enterocolitica (which can cause intestinal infections) and Mycoplasma pneumoniae (which causes certain types of pneumonia).^[3] Various viruses have also been suggested as potential culprits. However, researchers have not been able to consistently identify the same infectious agent in all patients, which suggests that if infections do play a role, different organisms might trigger the disease in different people.

Genetics appears to play some role in who develops Still’s disease, though the disease is not directly inherited from parents to children. A French research study involving 62 patients found associations between AOSD and specific variations in human leukocyte antigen (HLA) genes, particularly the subtypes B17, B18, B35, and DR2.^[3] HLA genes help the immune system distinguish the body’s own proteins from foreign invaders. Variations in these genes might predispose some individuals to develop abnormal immune responses. There have even been documented cases of the disease occurring in twins, which further suggests a genetic component.^[3]

Research also points to specific molecules in the immune system that appear to drive the disease process. Interleukin-1 (IL-1), a protein that promotes inflammation, seems to play a particularly important role.^[5] This discovery has proven valuable because medications that block IL-1 have become effective treatments for many patients. Another inflammatory molecule, interleukin-18, is also found at high levels in people with Still’s disease.^[5]

Risk Factors: Who Is More Likely to Develop Still’s Disease?

Identifying clear risk factors for Still’s disease has proven challenging because the condition is so rare and its causes remain poorly understood. However, certain patterns have emerged from studying groups of patients that may help identify who faces a higher likelihood of developing this condition.

Age stands out as one of the most consistent factors. Young adults in their late teens to mid-thirties represent the age group most commonly affected by adult-onset Still’s disease.^[2][6] For the childhood form, SJIA most frequently begins in children between birth and five years old.^[4] While the disease can technically appear at any age, these specific age ranges carry the highest risk.

Having certain genetic variations may increase susceptibility, particularly specific HLA gene types. People who carry the HLA-B17, B18, B35, or DR2 variants may face somewhat higher risk, though possessing these genetic markers certainly does not mean someone will definitely develop the disease.^[3] Most people with these genetic variations never develop Still’s disease, and genetic testing is not routinely used to predict who might get the condition.

Recent infections might act as triggers in genetically susceptible individuals. Some research suggests that bacterial or viral infections occurring shortly before symptom onset could potentially activate the abnormal immune response that characterizes Still’s disease.^[3][6] However, many patients do not recall having any significant infection before their symptoms began, so this connection remains uncertain.

Unlike many other autoimmune and inflammatory conditions, Still’s disease does not show a strong gender preference. Both males and females appear to be affected at roughly similar rates, so being male or female does not significantly change one’s risk.^[4] This differs from conditions like lupus or rheumatoid arthritis, which predominantly affect women.

It is important to note that Still’s disease cannot be prevented through lifestyle changes, vaccinations, or dietary modifications because researchers do not yet understand its causes well enough to develop prevention strategies. The unpredictable nature of the disease means that most people who develop it have no identifiable risk factors at all.

Symptoms: How Still’s Disease Affects the Body

The symptoms of Still’s disease can vary considerably from person to person, but certain hallmark features appear frequently enough that doctors look for them when making a diagnosis. Most people experience a combination of symptoms that affect multiple parts of the body simultaneously, which is why Still’s disease is considered a systemic condition—meaning it affects the whole body rather than just one organ or area.^[2]

Fever represents one of the most characteristic symptoms of Still’s disease. Unlike the steady low-grade fever that might accompany a common cold, the fever in Still’s disease follows a distinctive pattern. It typically spikes to at least 102 degrees Fahrenheit (38.9 degrees Celsius) or higher, and these spikes occur in a predictable daily rhythm.^[1] Most people experience one or two fever spikes each day, often with one peak in the morning and another in the evening.^[2] Between these spikes, body temperature may return to normal or near-normal levels. The fever can persist for a week or longer during active disease periods.

A distinctive rash often accompanies the fever spikes. This rash has a characteristic appearance that doctors describe as salmon-pink or salmon-colored. The rash typically appears as flat or slightly raised patches that come and go, usually showing up when the fever is spiking and then disappearing when temperature drops.^[1] The rash most commonly affects the trunk (chest and abdomen), arms, and legs, though it may spread to other areas.^[2][6] The temporary nature of this rash—appearing and disappearing—helps distinguish Still’s disease from other conditions with more persistent rashes.

Joint pain and inflammation cause significant discomfort for most people with Still’s disease. The joints may feel achy, stiff, swollen, and painful, making everyday movements difficult. This joint involvement usually lasts at least two weeks.^[1] The knees and wrists are most commonly affected, but the ankles, elbows, shoulders, hands, and other joints may also become involved.^[1][6] In some people, only a few joints are affected initially, but over time, more joints may develop symptoms. The chronic form of the disease can cause progressive joint damage, particularly to the wrists, which may lead to lasting disability if not properly treated.^[2]

Muscle pain often accompanies the other symptoms, typically coming and going along with the fever spikes. The muscular aching can become severe enough to interfere with daily activities and may make people feel as though they have severe flu.^[1][2]

Many people experience a sore throat as one of the first symptoms of Still’s disease. The lymph nodes in the neck may also become swollen and tender.^[1][6] This combination of fever, rash, and sore throat can easily be mistaken for a viral infection, which is one reason why Still’s disease often goes undiagnosed initially.

Fatigue and general malaise—a feeling of overall unwellness and exhaustion—affect most people with active Still’s disease. This exhaustion can be profound, making it difficult to carry out normal daily activities or maintain regular work schedules.^[2][4] Some people also experience abdominal pain during disease flares.^[2]

In the early stages, adult-onset Still’s disease often feels remarkably similar to influenza or another viral infection. The combination of high fever, body aches, and sore throat mimics many common illnesses. Healthcare providers typically become more suspicious of Still’s disease when these symptoms persist for two or three weeks without improvement—much longer than a typical viral infection would last.^[2]

Less commonly, Still’s disease can affect internal organs. Some people develop enlargement of the liver or spleen, inflammation around the heart (pericarditis) or within the heart muscle itself (myocarditis), or inflammation of the lining around the lungs (pleuritis).^[4][5] These complications can cause chest pain, difficulty breathing, or other serious symptoms.

Disease Patterns: How Still’s Disease Behaves Over Time

One of the most unpredictable aspects of Still’s disease is how it behaves over time. Healthcare providers have observed that the condition typically follows one of three main patterns, though it can be difficult to predict which pattern any individual patient will experience.^[2][4]

The first pattern is called monophasic Still’s disease. In this form, a person experiences a single episode of symptoms lasting anywhere from a few weeks to several months, but typically less than a year. Then, just as suddenly as it appeared, the disease goes away and does not return. The person experiences complete remission without ongoing symptoms or need for continued treatment. About one-third of people with adult-onset Still’s disease follow this pattern.^[2]

The second pattern is known as polyphasic or intermittent Still’s disease. People with this pattern experience multiple episodes of symptoms separated by periods when they feel completely well. These symptom-free intervals might last weeks, months, or even years. When symptoms do return, doctors call these periods “flares.” The good news is that flare episodes usually become shorter and less severe as time goes on. Like the monophasic form, about one-third of patients follow this pattern.^[2][4]

The third pattern is chronic Still’s disease, in which symptoms persist over time or flares occur so frequently that the person rarely feels completely well. This form is more likely to cause progressive damage to joints, similar to what happens in rheumatoid arthritis. The wrists are particularly vulnerable to joint destruction in chronic Still’s disease.^[1][2] Approximately one-third of patients develop chronic disease.

For children with systemic juvenile idiopathic arthritis, studies show that up to 30 percent still experience symptoms ten years after their initial diagnosis, and symptoms can persist into adulthood.^[4] This long-term persistence highlights the potentially chronic nature of the disease when it begins in childhood.

What makes Still’s disease particularly challenging is that doctors cannot reliably predict at the beginning which pattern a person will follow. Sometimes what initially appears to be monophasic or polyphasic disease later develops into the chronic form.^[2] This uncertainty means that people with Still’s disease must remain vigilant for symptom recurrence even after long periods of feeling well.

Complications: When Still’s Disease Becomes Dangerous

While many people with Still’s disease manage their symptoms reasonably well with treatment, the condition can lead to serious complications, particularly if it is not diagnosed quickly or if treatment is inadequate. Understanding these potential complications emphasizes the importance of proper diagnosis and aggressive treatment when needed.

Joint damage represents one of the most common long-term complications. Persistent inflammation in the joints can gradually destroy cartilage and bone, leading to permanent deformity and disability. The wrists are especially vulnerable, and chronic wrist arthritis can become severely disabling.^[1][4] People who develop chronic Still’s disease with ongoing arthritis face the highest risk for this type of joint destruction.

The liver and spleen may become enlarged during active disease, a condition doctors can detect through physical examination or imaging tests. While organ enlargement often resolves with treatment, it indicates significant systemic inflammation that requires attention.^[4]

One of the most serious complications is macrophage activation syndrome, abbreviated as MAS. This life-threatening condition involves excessive activation of certain immune cells called macrophages, which then cause widespread inflammation throughout the body. MAS can lead to extremely high fevers, organ dysfunction, and dangerous drops in blood cell counts. It requires emergency medical treatment.^[4][5] Fortunately, MAS is relatively rare, but doctors monitor patients carefully for signs of this complication.

Heart complications can occur when inflammation affects the pericardium (the sac surrounding the heart) or the heart muscle itself. Pericarditis causes chest pain and can potentially lead to fluid accumulation around the heart. Myocarditis—inflammation of the heart muscle—can result in chest pain, abnormal heart rhythms, and in severe cases, heart failure.^[4]

Lung involvement may manifest as pleuritis—inflammation of the lining around the lungs—which causes chest pain and difficulty breathing. In rare cases, people develop fluid accumulation in the chest or more serious lung complications.^[4][5]

Rarely, people with long-standing Still’s disease may develop amyloidosis, a condition in which abnormal protein deposits accumulate in various organs and interfere with their function.^[4] Other uncommon complications include kidney problems, blood cell abnormalities, and neurological issues.^[5]

Prevention: Can Still’s Disease Be Prevented?

Unfortunately, because the exact causes of Still’s disease remain unknown, there are currently no proven strategies to prevent the condition from developing. Unlike infectious diseases that can be prevented through vaccination or lifestyle-related conditions that can be avoided through healthy habits, Still’s disease appears to arise from a complex interaction of genetic susceptibility and unknown environmental or infectious triggers that cannot yet be controlled or avoided.^[3]

No dietary changes, vitamins, supplements, or lifestyle modifications have been shown to reduce the risk of developing Still’s disease. Similarly, because the disease is not directly inherited in a predictable pattern, genetic counseling does not typically help families assess risk for future generations. The sporadic nature of the disease means that most cases occur without any family history of the condition.

However, while primary prevention—stopping the disease before it starts—is not yet possible, people who have been diagnosed with Still’s disease can take important steps to prevent complications and reduce the severity and frequency of flare-ups. These secondary prevention strategies focus on managing the disease once it has developed.

Early and aggressive treatment of active disease represents the most important way to prevent long-term complications, particularly joint damage. Keeping inflammation under control through appropriate medications can preserve joint function and prevent the progressive destruction that occurs with chronic, untreated arthritis.^[6] This may require continuing medications even after symptoms improve, a strategy called maintenance therapy.

Regular follow-up with healthcare providers helps catch complications early when they are most treatable. Routine monitoring through physical examinations, blood tests, and other evaluations can detect problems like liver inflammation, heart involvement, or signs of macrophage activation syndrome before they become severe.

For people with polyphasic or chronic disease, learning to recognize the early warning signs of a flare can help them seek treatment quickly, potentially reducing the severity and duration of symptom episodes. Stress management, adequate rest, and general health maintenance may also help optimize overall wellbeing, though these measures have not been specifically proven to prevent Still’s disease flares.

Researchers continue working to understand what causes Still’s disease with the hope that future discoveries might eventually lead to prevention strategies. Until then, the focus remains on early diagnosis and effective treatment to minimize the disease’s impact on people’s lives.

Pathophysiology: What Goes Wrong in the Body

Understanding what happens inside the body during Still’s disease helps explain why the symptoms occur and why certain treatments work. At its core, Still’s disease involves abnormal activation and regulation of the immune system, leading to excessive and inappropriate inflammation throughout the body.

In a healthy immune system, inflammation serves as a protective response. When the body detects an infection or injury, immune cells release chemical messengers called cytokines that trigger inflammation. This inflammation helps fight invading microorganisms and promotes healing. Once the threat is eliminated, the immune system normally shuts down the inflammatory response and returns to a resting state.^[2]

In Still’s disease, this carefully controlled system malfunctions. The immune system generates continuous inflammation even though there is no ongoing infection or injury to fight. It is as if the body’s inflammatory response becomes stuck in the “on” position, unable to turn itself off. This persistent, inappropriate inflammation damages the body’s own tissues and produces the various symptoms people experience.

Specific immune system proteins play key roles in driving this abnormal inflammation. Interleukin-1 (IL-1) appears to be particularly important in Still’s disease. This powerful inflammatory molecule is produced in excess amounts, and its overactivity seems to fuel many of the disease’s manifestations.^[5] The discovery of IL-1’s central role has proven valuable because it led to the development of medications that specifically block this molecule’s effects, which have become effective treatments for many patients.

Another cytokine, interleukin-18 (IL-18), is also expressed at unusually high levels in people with Still’s disease.^[5] Researchers continue studying how these and other immune molecules interact to produce the disease’s characteristic symptoms.

The distinctive fever pattern in Still’s disease—with its predictable daily spikes—reflects the rhythmic release of inflammatory cytokines. When these molecules surge in the bloodstream, they act on the brain’s temperature control center, causing fever. The salmon-colored rash appears to result from inflammation affecting small blood vessels in the skin, and it tends to coincide with fever spikes because both result from the same inflammatory surge.

Joint inflammation occurs when immune cells infiltrate the joint spaces and release inflammatory molecules that damage cartilage and bone. In acute disease, this inflammation may be reversible with treatment. However, in chronic disease, repeated or continuous inflammation can cause permanent structural damage to joints. The wrists seem particularly vulnerable to this progressive destruction, though doctors do not fully understand why certain joints are more susceptible than others.

The elevated ferritin levels frequently seen in Still’s disease blood tests reflect the body’s inflammatory state. Ferritin is a protein that stores iron, and its blood levels typically increase during inflammation. In Still’s disease, ferritin can reach extremely high levels—often exceeding 1000 nanograms per milliliter—which helps doctors distinguish Still’s disease from other conditions.^[3][5]

Blood tests during active disease typically reveal a high white blood cell count, particularly an increase in neutrophils, a type of white blood cell involved in inflammation. This laboratory finding reflects the immune system’s overactivity.^[5] Interestingly, tests for rheumatoid factor and antinuclear antibodies—blood markers often positive in other autoimmune diseases like rheumatoid arthritis or lupus—are usually negative in Still’s disease, which helps doctors distinguish it from these other conditions.^[1][5]

The liver often shows signs of inflammation during active disease, with blood tests revealing elevated liver enzymes. Multiple organs can be affected because the inflammatory process is systemic—meaning it circulates throughout the entire body rather than remaining localized to one area. This explains why people experience such diverse symptoms affecting joints, skin, throat, internal organs, and overall energy levels simultaneously.

Scientists continue researching whether Still’s disease should be classified primarily as an autoimmune disease (where the immune system attacks specific body tissues) or an autoinflammatory disease (where excessive inflammation occurs without the specific self-targeting seen in autoimmune conditions). Most experts now view it as having characteristics of both types, though the autoinflammatory features appear more prominent.^[6] This distinction matters because it influences how researchers think about the disease and which types of treatments might work best.

Clinical Trials for Tourette’s Disorder

Five clinical trials are currently underway across Europe to study new treatments for Tourette’s disorder, a neurological condition characterized by repetitive, involuntary movements and vocalizations called tics. These studies are testing several investigational medications, including ecopipam, gemlapodect, dronabinol with palmidrol, and aripiprazole, in children, adolescents, and adults. Trials are being conducted in multiple countries including Germany, France, Spain, Poland, Hungary, and others.

Clinical trial locations

• Belgium
  • Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome
• Bulgaria
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
• Denmark
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
• France
  • Study on Impulsivity Control in Adults with Tourette Syndrome Using [18F]-Altanserin and Aripiprazole
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
  • Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome
• Germany
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Dronabinol and Palmidrol for Adults with Tourette Syndrome
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
  • Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome
• Hungary
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
  • Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome
• Italy
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
• Poland
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
  • Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome
• Romania
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
• Spain
  • Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder
  • Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder
  • Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome

Study on Impulsivity Control in Adults with Tourette Syndrome Using [18F]-Altanserin and Aripiprazole

This study, conducted in France, explores how the brain’s serotonergic system is involved in controlling impulsive behavior in adults with Tourette’s disorder. The research focuses on understanding the relationship between certain brain receptors and changes in impulsivity levels.

Main inclusion criteria: Participants must be adults aged 18 to 65 years with a confirmed diagnosis of Tourette’s disorder according to DSM-5 criteria. They must already have treatment with aripiprazole planned as part of their routine care. Both men and women can participate, and all participants must be members of the French social security system and provide written informed consent. Female participants must use effective contraception during the study.

Main exclusion criteria: Individuals without a confirmed diagnosis of Tourette’s disorder cannot participate. Those outside the specified age range are also excluded.

Focus and goal: The study aims to investigate whether changes in the availability of serotonergic 5-HT2A receptors in the brain correlate with improvements in impulsivity in people with Tourette’s disorder. Participants undergo brain imaging using specialized techniques to observe how the brain responds to treatment. Regular assessments measure changes in impulsivity levels and clinical scores throughout the study period.

Investigational drug: The study uses aripiprazole, taken orally as tablets, along with [18F]-altanserin administered by injection for imaging purposes. Aripiprazole is an atypical antipsychotic that works by modulating dopamine and serotonin receptors in the brain, particularly the 5-HT2A receptor believed to play a role in controlling impulsivity.

Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette’s Disorder

This international trial, conducted across eight European countries including Spain, Denmark, Italy, France, Poland, Hungary, Germany, and Bulgaria, evaluates the long-term safety and tolerability of ecopipam tablets over an extended period of up to 105 days.

Main inclusion criteria: Participants must have completed one of three previous studies involving ecopipam (EBS-101-TD-301, EBS-101-OL-001, or PSY-302A). The study doctor must believe that the participant benefited from ecopipam and would continue to benefit from ongoing treatment. Participants must have a confirmed diagnosis of Tourette’s disorder with both motor and vocal tics that interfere with daily activities. Female participants of childbearing potential must use highly effective contraception, and male participants must also use appropriate birth control methods. For those under 18, parental consent is required along with the participant’s assent.

Main exclusion criteria: Those who have not participated in the specified previous studies cannot join. Individuals without a diagnosis of Tourette’s disorder or those outside the eligible age range are excluded.

Focus and goal: The primary objective is to monitor the long-term safety profile of ecopipam in managing symptoms of Tourette’s disorder. Participants continue taking ecopipam tablets at varying doses based on their individual needs and previous study participation. Regular follow-up visits track any side effects or health changes over time.

Investigational drug: Ecopipam is a dopamine receptor antagonist taken orally in tablet form. Doses range from 11.2 mg to 89.6 mg. The medication works by blocking certain dopamine receptors in the brain that are involved in regulating movement and behavior, potentially helping to reduce tic symptoms.

Study on the Effects of Dronabinol and Palmidrol for Adults with Tourette Syndrome

This German trial tests a new treatment called SCI-110, which combines two active substances in a soft capsule form, for adults with Tourette’s syndrome over a 12-week period.

Main inclusion criteria: Participants must be adults between 18 and 65 years old with a DSM-5 diagnosis of Tourette’s syndrome. They must have a total tic score greater than 14 on the YGTSS-R scale and a severity score of 4 or higher on the CGI-S scale. Any existing medications for tics or other conditions must be at a stable dose for at least six weeks before joining and remain stable throughout the study. Women of childbearing potential must have a negative pregnancy test and use highly effective contraception. Men must use condoms and agree not to donate sperm for three months after the study ends.

Main exclusion criteria: Those outside the 18-65 age range or not receiving outpatient care are excluded. Individuals without a confirmed diagnosis of Tourette’s syndrome cannot participate.

Focus and goal: The study evaluates the safety, tolerability, and effectiveness of SCI-110 compared to a placebo in reducing tic severity. It is a double-blind study, meaning neither participants nor researchers know who receives the active medication or placebo. Regular assessments monitor vital signs, health metrics, and any adverse events throughout the treatment period.

Investigational drug: SCI-110 contains dronabinol, a cannabis-like compound, and palmidrol, which may help reduce inflammation and pain. The medication is taken daily as a soft capsule and is classified as a central nervous system agent. It works by modulating neurotransmitter activity in the brain to potentially reduce tic symptoms.

Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette’s Disorder

This multi-country trial across Spain, France, Denmark, Italy, Poland, Hungary, Romania, Bulgaria, and Germany investigates how well ecopipam maintains its effectiveness in treating young people with Tourette’s disorder over a 12-week treatment period followed by a randomized withdrawal phase.

Main inclusion criteria: Participants must be at least 6 years old and weigh at least 18 kg. They must have a diagnosis of Tourette’s disorder with both motor and vocal tics that interfere with normal daily routines. A minimum score of 20 on the YGTSS-TTS scale is required at both screening and baseline visits. Female participants who can become pregnant must use highly effective contraception plus a barrier method, with hormonal contraception stable for at least four weeks before screening. For participants in the EU, non-drug therapies must have been tried without success before joining.

Main exclusion criteria: Children younger than 6 years old or individuals without a confirmed diagnosis of Tourette’s disorder cannot participate. Those unable to follow study instructions, pregnant or breastfeeding women, and those who recently participated in another clinical trial are excluded.

Focus and goal: The study assesses whether ecopipam can maintain symptom control over time by comparing it to placebo. After the initial 12-week treatment period, participants enter a randomized withdrawal phase where some continue medication while others receive placebo. This helps determine how long the benefits of ecopipam last and whether symptoms return when medication is stopped.

Investigational drug: Ecopipam tablets are taken orally at doses ranging from 11.2 mg to 89.6 mg daily. As a dopamine receptor antagonist, ecopipam blocks certain brain signals thought to be involved in causing tics, potentially reducing symptom severity.

Study on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome

This trial, conducted in Hungary, Poland, Belgium, France, Spain, and Germany, evaluates a novel medication called gemlapodect in adults and adolescents over a 12-week period using a double-blind, placebo-controlled design.

Main inclusion criteria: Participants must be at least 18 years old (or 12-17 if regional approval for adolescents is granted) with moderate to severe Tourette syndrome. They can be new to treatment or previously treated but requiring a different approach. All medications used to treat Tourette syndrome must be stopped for at least 14 days before starting the study, though other stable mental health medications can be continued if they have been at the same dose for at least 30 days. Participants must have a Body Mass Index between 18 and 35 kg/m². Women of childbearing potential must confirm a negative pregnancy test and use appropriate contraception.

Main exclusion criteria: Individuals without Tourette syndrome or those outside the eligible age ranges cannot participate. Those who do not meet the BMI requirements are also excluded.

Focus and goal: The study aims to determine whether gemlapodect can effectively reduce tic severity scores compared to placebo. Regular assessments throughout the 12 weeks monitor changes in symptoms, body weight, blood glucose, lipids, and other health indicators. The trial also evaluates the medication’s safety profile through laboratory tests, ECGs, and vital sign monitoring.

Investigational drug: Gemlapodect is a novel PD10A inhibitor taken orally as hard capsules. It is currently in Phase IIb clinical research and works by modulating neurotransmitter activity in the brain to help control the involuntary movements and vocalizations associated with Tourette syndrome. It is classified as a central nervous system agent.

Summary

The five ongoing clinical trials for Tourette’s disorder represent diverse approaches to managing this neurological condition. Three trials focus on ecopipam, a dopamine receptor antagonist, with studies examining both its effectiveness in maintaining symptom control and its long-term safety profile. These ecopipam trials have the widest geographic reach, spanning up to nine European countries and including participants ranging from children as young as 6 years to adults.

Two other trials explore different therapeutic mechanisms: one investigates gemlapodect, a novel PD10A inhibitor, across six countries, while another tests SCI-110, a combination of dronabinol and palmidrol, exclusively in Germany. The French study takes a unique approach by examining the neurobiological underpinnings of impulsivity in Tourette’s disorder using brain imaging techniques alongside aripiprazole treatment.

Most trials are concentrated in major European research centers, with Germany, France, Spain, Poland, and Hungary hosting multiple studies. The trials primarily target moderate to severe cases and emphasize the importance of stable medication regimens before enrollment. All studies incorporate rigorous safety monitoring and use standardized scales to measure tic severity, ensuring consistent evaluation across different treatment approaches.

Tourette’s disorder is a neurological condition that begins in childhood and causes sudden, uncontrollable movements and sounds known as tics. While living with this condition presents unique challenges, understanding its progression and available support can help individuals and families navigate the journey with greater confidence and hope.

Understanding the Outlook: What to Expect Over Time

When a child receives a diagnosis of Tourette’s disorder, parents and families naturally wonder what the future holds. The outlook for this condition is often more encouraging than many people initially expect. While Tourette’s disorder is a chronic neurological condition, the path it takes varies greatly from person to person, and for many, the journey leads to significant improvement over time.^[1]

Most individuals with Tourette’s disorder experience their most severe tic symptoms during their early teenage years, typically around age 12. This period can be particularly challenging as children navigate school, social relationships, and the normal stresses of adolescence. However, the intensity and frequency of tics typically begin to lessen as young people move through their late teens and into early adulthood. For many, by the time they reach their late teens to early twenties, tics become much more manageable and controlled.^[1][2]

Research shows that the majority of patients will find that their symptoms improve within approximately ten years of onset. Many people experience such significant reduction in their tics that they no longer require medication or intensive management strategies. However, it’s important to understand that approximately one in three patients may continue to experience symptoms throughout their lifetime, though even in these cases, the severity typically decreases as they age.^[23]

The prognosis for Tourette’s disorder also depends on the severity of symptoms and the presence of other conditions. Most cases are mild, and many people learn to manage their tics effectively through various coping strategies and, when needed, medical interventions. The variability in how Tourette’s disorder affects different individuals means that some people may have tics that barely interfere with daily life, while others may face more significant challenges that require ongoing support and treatment.^[3][5]

How the Condition Develops Without Treatment

Understanding the natural course of Tourette’s disorder helps families make informed decisions about when and whether to pursue treatment. Without any medical or therapeutic intervention, the condition typically follows a predictable pattern, though with individual variations that make each person’s experience unique.

Tics usually begin to appear between the ages of 5 and 10 years, with the average onset occurring around age 6. The first symptoms most commonly appear in the head and neck area, such as eye blinking, facial grimacing, or head jerking. These initial manifestations are often simple motor tics that involve just a few muscle groups and occur as sudden, brief, repetitive movements.^[1][5]

As time progresses, motor tics may spread to other parts of the body, potentially affecting the muscles of the torso, arms, and legs. The pattern and complexity of tics tend to evolve over months and years. What begins as simple movements may develop into more complex tics involving coordinated patterns of movement that engage several muscle groups in different parts of the body. For example, a child who initially only blinked excessively might later develop a complex tic that combines facial grimacing with head twisting and shoulder shrugging.^[1]

Motor tics generally appear before vocal tics emerge. When vocal tics do develop, they typically start as simple sounds such as throat clearing, sniffing, grunting, or barking. Over time, these may progress to more complex vocal expressions, including the repetition of one’s own words or phrases, or in rare cases, the involuntary utterance of obscene or inappropriate words, a symptom called coprolalia. It’s worth noting that despite media portrayals, coprolalia is actually quite rare and occurs in only a small percentage of people with Tourette’s disorder.^[2][3]

Throughout the natural progression of untreated Tourette’s disorder, the types of tics and their frequency can change dramatically over time. Symptoms may appear, disappear completely, and then reappear later. This fluctuating nature is a hallmark of the condition and can make it difficult to predict when tics will be more or less bothersome. Even though the presentation varies, the underlying condition remains chronic, meaning it persists over extended periods.^[2]

For most individuals, even without treatment, tics tend to decrease significantly during adolescence and early adulthood. In some fortunate cases, tics may disappear entirely as a person matures. However, a subset of individuals will continue to experience tics into adulthood, and in certain cases, symptoms may actually intensify during the adult years. The reasons for these different trajectories are not fully understood, but they likely involve complex interactions between brain development, environmental factors, and individual biology.^[1][2]

Potential Complications and Challenges

While Tourette’s disorder itself is not life-threatening, it can lead to various complications that significantly impact a person’s health, safety, and overall well-being. Understanding these potential difficulties helps families and healthcare providers work together to prevent or address them early.

One of the most serious physical complications involves self-injurious behaviors. Some individuals with Tourette’s disorder develop tics that cause them to harm themselves, such as head banging, punching themselves in the face, or repetitive scratching. These self-directed tics can result in actual physical injury, bruising, and in severe cases, more significant trauma. Research indicates that at least one-third of patients with Tourette’s disorder exhibit some form of tic-related self-injurious behavior, and these symptoms can be present even in relatively mild cases of the condition.^[13]

The repetitive nature of tics can lead to muscle fatigue and chronic pain. When the same muscle groups contract repeatedly throughout the day, it creates tension and discomfort. Some individuals experience joint problems or muscle strain from the constant physical movements their tics require. This physical toll can add another layer of difficulty to an already challenging condition.^[10]

Mental health complications represent another significant concern for individuals with Tourette’s disorder. The presence of other psychiatric conditions alongside Tourette’s is extremely common, with most people experiencing at least one additional diagnosis. Attention-deficit/hyperactivity disorder, or ADHD, occurs in approximately 54 percent of individuals with Tourette’s disorder. Obsessive-compulsive disorder, known as OCD, affects about half of all patients. Depression, anxiety disorders, learning disabilities, and behavioral problems such as oppositional defiant disorder also occur at higher rates among those with Tourette’s disorder compared to the general population.^[10][12]

These co-occurring conditions often have a more significant impact on daily functioning than the tics themselves. Sometimes, treating these additional conditions becomes the primary focus of care because they interfere more substantially with learning, relationships, and quality of life. The interaction between multiple conditions can be complex, and addressing one problem may help reduce symptoms of another.^[9][17]

Social and emotional complications arise from the visible and audible nature of tics. Children and adolescents with Tourette’s disorder may become targets of bullying or social exclusion because their tics make them appear different from their peers. The experience of being stared at, questioned, or teased can lead to social anxiety, withdrawal, and feelings of isolation. These social challenges occur during a critical period of development when forming friendships and building self-esteem are particularly important.^[10][7]

Educational complications can emerge when tics interfere with learning. Some children find it difficult to concentrate on schoolwork when they are trying to suppress their tics or dealing with the premonitory urges that precede tic episodes. The physical act of ticcing during class can be distracting both to the student and to classmates. Additionally, if a child spends significant mental energy controlling tics during conversations or classroom activities, they may have less capacity to focus on the actual content being taught.^[10]

Impact on Daily Life and Functioning

Living with Tourette’s disorder affects nearly every aspect of daily life, from the most routine activities to major life decisions. The extent of impact varies considerably depending on the severity of symptoms, but even mild cases create challenges that require adaptation and resilience.

In educational settings, children with Tourette’s disorder face multiple obstacles. The need to suppress tics during class time can be mentally exhausting, leaving students with less energy for actual learning. If vocal tics are present, they may cause disruptions that draw unwanted attention from teachers and classmates. Physical tics that involve large movements may make it difficult to sit still at a desk for extended periods. Writing or completing timed tests can be particularly challenging if tics involve the hands and arms. Despite these difficulties, many students with Tourette’s disorder perform well academically when provided with appropriate accommodations and support.^[10][18]

Social relationships require navigation of complex dynamics when you have Tourette’s disorder. Making and maintaining friendships can be difficult when peers don’t understand why someone makes unusual movements or sounds. The fear of having a tic during social situations may lead some individuals to avoid gatherings, parties, or other social activities where they might feel self-conscious. Dating and romantic relationships introduce additional layers of vulnerability, as individuals must decide when and how to explain their condition to potential partners.^[15]

Work and career considerations become relevant as individuals with Tourette’s disorder reach adulthood. Some professions may be more challenging than others depending on the nature of a person’s tics. Jobs requiring extended periods of stillness or silence might be particularly difficult. However, many adults with Tourette’s disorder find fulfilling careers and learn to manage their symptoms in professional settings. The decision of whether to disclose their condition to employers and coworkers is a personal one that each individual must make based on their circumstances.^[19]

Physical activities and hobbies can be affected by motor tics, though interestingly, many people find that engaging in highly focused activities actually reduces their tics. Playing musical instruments, participating in competitive sports, or pursuing other absorbing interests may provide temporary relief from symptoms. These activities also offer important opportunities for building self-esteem and finding areas where Tourette’s disorder doesn’t define a person’s abilities.^[23]

Emotional well-being requires constant attention and care. The unpredictability of tics can create ongoing stress and anxiety. Many individuals with Tourette’s disorder describe feeling frustrated by their inability to control their own bodies. The cumulative effect of managing symptoms, dealing with social challenges, and coping with any co-occurring conditions can take a significant emotional toll. Depression is not uncommon, particularly during the teenage years when tics may be at their most severe and social pressures are most intense.^[13]

Sleep can be disrupted by tics that continue even during rest periods. Some individuals experience tics during sleep, which can interfere with getting adequate, quality rest. Poor sleep then exacerbates tic symptoms during waking hours, creating a challenging cycle. Fatigue from inadequate sleep also makes it harder to cope with the daily demands of managing the condition.^[15]

Managing stress becomes a crucial life skill for individuals with Tourette’s disorder because stress is a major trigger that can worsen tics. Learning to recognize stressful situations and developing effective coping strategies helps reduce the frequency and intensity of tic episodes. This might include practicing relaxation techniques, ensuring adequate sleep, limiting caffeine intake, maintaining a healthy diet, and engaging in regular exercise. Building a lifestyle that minimizes unnecessary stress while building resilience for unavoidable stressors is an important part of living well with Tourette’s disorder.^[15][20]

Supporting Families Through Clinical Trials and Research

Families affected by Tourette’s disorder should understand the role of clinical trials and research in advancing treatment options and improving outcomes for future generations. While managing the day-to-day challenges of Tourette’s disorder, families may also want to consider how they can contribute to the broader understanding of this condition.

Clinical trials are research studies that test new treatments, medications, or approaches to managing Tourette’s disorder. These studies help scientists and doctors determine which interventions are safe and effective. Participating in clinical trials is completely voluntary, and families should never feel pressured to enroll. However, for those who choose to participate, clinical trials offer access to cutting-edge treatments that are not yet widely available and contribute valuable information that benefits the entire community of people affected by Tourette’s disorder.

When considering clinical trial participation for a child or adolescent with Tourette’s disorder, families should gather comprehensive information about the study. Important questions include: What is being tested? What are the potential benefits and risks? How long will participation last? What procedures or tests will be required? Will there be any costs, or will compensation be provided? Understanding these details helps families make informed decisions that align with their values and circumstances.

Finding appropriate clinical trials requires knowing where to look. Healthcare providers who specialize in treating Tourette’s disorder often know about ongoing research studies and can provide referrals. National organizations dedicated to Tourette’s disorder maintain registries of current clinical trials and can help match interested families with appropriate studies. Online databases of clinical trials also provide searchable information about research opportunities.

Before enrolling in a clinical trial, families should discuss the opportunity thoroughly with their child’s regular healthcare team. The primary doctor or neurologist can help evaluate whether a particular study is appropriate given the individual’s specific symptoms, medical history, and treatment goals. They can also help families understand how participation might affect current treatments or require modifications to existing care plans.

Family members can support their loved one during clinical trial participation by maintaining clear communication with research staff, keeping careful records of symptoms and any changes observed, ensuring that all appointments and procedures are attended as scheduled, and providing emotional support throughout the process. It’s also important to remember that participants have the right to withdraw from a clinical trial at any time if they feel it is no longer in their best interest.

Beyond formal clinical trials, families can support research in other ways. Some research studies focus on understanding the natural history of Tourette’s disorder, identifying risk factors, or learning about how families cope with the condition. These studies may involve surveys, interviews, or genetic testing rather than experimental treatments. Every type of research contributes to the growing body of knowledge about Tourette’s disorder.

Relatives of someone with Tourette’s disorder can assist in the search for clinical trials and research opportunities by staying informed about current research through reputable organizations and websites, helping to identify trials that match their family member’s age, symptoms, and location, and assisting with the practical aspects of participation such as transportation to study appointments or help with paperwork.

Preparing for possible clinical trial participation involves organizing medical records and documentation of symptoms, making sure all questions about the study are answered before enrollment, understanding the time commitment required, and discussing expectations with all family members who will be affected. Being well-prepared helps families feel more confident in their decision and contributes to successful study participation if they choose to proceed.

The broader impact of clinical research on Tourette’s disorder cannot be overstated. Current treatment options, including both medications and behavioral therapies, exist because previous generations of patients and families participated in research studies. Each new study builds upon earlier findings, gradually improving our understanding of what causes Tourette’s disorder, how to diagnose it accurately, and most importantly, how to help people manage their symptoms and live full lives. By supporting research efforts, families become part of a larger community working toward better outcomes for everyone affected by this condition.

Turner’s Syndrome

Turner’s syndrome is a genetic condition that affects only females, occurring when one of the X chromosomes is partially or completely missing. While there is no cure, early diagnosis and treatment can help girls and women with this condition lead healthy, productive lives.

Table of contents

• What is Turner’s syndrome?
• What causes Turner’s syndrome?
• Signs and symptoms
• How is it diagnosed?
• Associated health problems
• Treatment and management
• Living with Turner’s syndrome

TS, monosomy X, 45X, Ullrich-Turner syndrome

What is Turner’s syndrome?

Turner’s syndrome is a genetic condition that only affects females. It happens when one of the X chromosomes (the structures in cells that carry genetic information) is partially or completely missing. Typically, females have two X chromosomes, but in Turner’s syndrome, one of these chromosomes is absent or abnormal.^[1]

The condition affects approximately 1 in 2,000 to 2,500 female babies born. However, this abnormality is much more common in pregnancies that do not survive to term. It has been estimated that only one percent of fetuses with this chromosomal abnormality survive to term, and as many as 10 percent of miscarriages have this chromosomal abnormality.^[2]

Turner’s syndrome affects everyone differently. The most common features include short stature and problems with ovary function, but the severity and range of symptoms can vary widely from person to person.^[1]

What causes Turner’s syndrome?

Humans typically have 23 pairs of chromosomes (structures that hold genes), for a total of 46 in each cell. This includes 22 pairs of numbered chromosomes and one pair of sex chromosomes. You inherit one chromosome of each pair from each biological parent. The sex chromosomes determine whether someone is male or female: typically, females have two X chromosomes (XX), while males have one X chromosome and one Y chromosome (XY).^[1]

Turner’s syndrome occurs when one of the X chromosomes is missing or altered. There are two main types of Turner’s syndrome. In monosomy X, each cell in the body has only one copy of the X chromosome instead of the usual two. This happens due to an error with either the sperm or the egg from the biological parent, and is typically the more severe form of the condition.^[1]

In mosaic Turner syndrome, the X chromosome is partially missing in only some cells of the body. This happens randomly during fetal development. People with mosaic Turner syndrome often have milder signs and symptoms than those with the complete form.^[4]

Turner’s syndrome is not caused by anything the parents did or did not do. It happens by chance and is not usually passed down in families. Advanced parental age is not considered a significant factor, and there are no clearly established environmental risk factors.^[3]

Signs and symptoms

The symptoms of Turner’s syndrome can vary greatly between individuals. Some girls have noticeable symptoms early in life, while others might not show signs until later. Symptoms can be mild and develop gradually during childhood, or they can be significant and noticeable shortly after birth. Some people don’t receive a diagnosis until adulthood.^[1]

Healthcare providers may suspect Turner’s syndrome before birth based on prenatal genetic testing or pregnancy ultrasound. Signs that may appear during pregnancy include the fetus having heart problems, kidney or urinary problems, or fluid collecting around the back of the neck.^[1]

Physical features that may appear at birth or shortly after include:^[1]

• Extra folds of skin on the neck (webbed neck)
• Low hairline at the back of the neck
• Low-set, misshapen, elongated, or cup-shaped ears with thick ear lobes
• Small and receding lower jaw
• Broad chest with nipples that are spaced far apart
• Arms that point out slightly at the elbows
• Puffy hands and feet (lymphedema)
• Flat feet
• Narrow fingernails and toenails

Almost everyone with Turner’s syndrome experiences short stature and problems with ovary function. Girls with the condition typically grow more slowly than their peers, with this difference usually becoming noticeable by age 5. They often lack growth spurts as children or teenagers.^[1]

Without treatment, the average adult height for women with Turner’s syndrome is about 143 centimeters (4 feet 8 inches).^[2]

Reduced functioning of the ovaries (the female reproductive organs that produce egg cells and hormones) is very common. The ovaries may develop normally at first, but egg cells usually die prematurely and most ovarian tissue breaks down before birth. Many females with Turner’s syndrome do not undergo puberty unless they receive hormone therapy. This means they may not develop breasts or start menstrual periods at the expected age. Most are unable to become pregnant naturally, although a small percentage retain normal ovarian function through young adulthood.^[4]

Other features that may be present include multiple pigmented moles on the skin and difficulty straightening the elbows completely.^[2]

How is it diagnosed?

Turner’s syndrome can be diagnosed at various life stages. Sometimes it is identified before birth through prenatal screening tests or ultrasound. In other cases, diagnosis happens at birth due to physical features, during childhood when a girl doesn’t grow at a similar rate to her peers, during teenage years when puberty fails to arrive, or even in adulthood during investigations for infertility.^[2]

If Turner’s syndrome is suspected during pregnancy, two procedures can be used to test for the condition before birth. Chorionic villus sampling (CVS) involves taking a small piece of tissue from the developing placenta, usually between 11 and 14 weeks of pregnancy. Amniocentesis involves taking a sample of the amniotic fluid from the uterus, typically after 14 weeks of pregnancy. Both tests allow examination of the baby’s chromosomes.^[8]

After birth or at any age, Turner’s syndrome is diagnosed using a blood test to analyze chromosomes. This test, called a karyotype, examines the number and structure of chromosomes in cells. Occasionally, a cheek scraping or skin sample may also be used.^[8]

The diagnosis may be prompted by clinical suspicion based on physical features, growth delay, or other symptoms. A complete evaluation also typically includes:^[2]

• Clinical history
• Physical examination
• Psychological and educational assessment
• Blood tests

Associated health problems

Turner’s syndrome can affect many different body systems. Understanding these potential complications helps ensure early detection and proper management.^[1]

Heart problems are among the most serious concerns. About 30 to 50 percent of individuals with Turner’s syndrome are born with a heart defect. Common problems include narrowing of the large artery that leaves the heart (coarctation of the aorta) or abnormalities of the valve that connects the aorta to the heart (bicuspid aortic valve). Some people may develop progressive enlargement of the aortic root or, rarely, life-threatening aortic dissection or rupture. All patients should have a cardiovascular evaluation at diagnosis, and those with heart abnormalities need long-term follow-up care.^[4]

Kidney problems are also common. About 30 percent of individuals have kidney malformations or urinary system abnormalities.^[1]

Hearing problems occur frequently. These may include recurrent ear infections and decreased hearing, particularly sensorineural hearing loss.^[2]

Bone health can be affected. Women with Turner’s syndrome are at higher risk for developing thin bones (osteoporosis), making it important to ensure adequate calcium and vitamin D intake throughout life.^[2]

Thyroid problems are common, as are other hormonal issues. Regular monitoring of thyroid function is important.^[2]

Additional health concerns may include high blood pressure (hypertension), obesity, diabetes, an atherogenic lipid profile (unfavorable cholesterol levels), eye problems including strabismus (crossed eyes), and inflammatory bowel disease.^[3]

Most people with Turner’s syndrome have normal intelligence. However, some may experience developmental delays, problems with spatial awareness (such as difficulty with math or map reading), nonverbal learning disabilities, or attention difficulties. The effects on learning and behavior vary among affected individuals.^[4]

Treatment and management

There is currently no cure for Turner’s syndrome, but treatment and support can help manage symptoms and allow individuals to lead healthy, productive lives. Because the condition affects multiple body systems, care typically involves a team of healthcare professionals working together.^[5]

Growth hormone therapy is the standard treatment for short stature in childhood. Treatment typically begins when growth problems are identified and continues until the child reaches a bone age of about 14 years. The ideal age for starting treatment has not been definitively established, but taller adult heights occur with the longest treatment durations before the start of puberty.^[9]

Estrogen replacement therapy is usually required to support pubertal development and maintain bone and reproductive system health. Treatment typically starts around age 12 to 15 years, though it can begin earlier in some cases. Starting with low doses helps ensure proper development while not compromising final adult height. After initial continuous low-dose treatment, estrogen can be cycled, and progestin (another hormone) is added later. Ongoing estrogen therapy is important for maintaining bone health and preventing osteoporosis.^[9]

Regular health monitoring is essential. This includes:^[5]

• Regular blood pressure checks
• Bone density testing
• Thyroid function monitoring
• Cardiovascular evaluations, including periodic echocardiography
• Hearing tests
• Eye examinations
• Kidney function assessment

Specific treatments may be needed for associated health problems. For example, heart defects may require surgery or ongoing monitoring. Hearing problems may need medical treatment or hearing aids. Learning difficulties may require educational support.^[5]

Calcium and vitamin D supplementation should be initiated by age 10 to support bone health.^[12]

Almost all women with Turner’s syndrome are infertile. However, advances in reproductive technology, including egg donation and in vitro fertilization (IVF), can help some women with this condition have children. Women considering pregnancy should have a complete cardiovascular evaluation beforehand, as pregnancy carries increased risks, particularly for those with certain heart abnormalities.^[14]

Psychological support, including talking therapies and counseling, may be helpful for those experiencing depression, low self-esteem, or difficulties related to learning challenges or puberty.^[5]

Living with Turner’s syndrome

With appropriate medical care and support, most people with Turner’s syndrome can lead relatively normal, healthy lives. Turner’s syndrome is a lifelong condition that requires ongoing medical follow-up and management of associated health issues.^[5]

Life expectancy may be slightly reduced compared to the general population, but with regular health checks and early treatment for health problems, many women with Turner’s syndrome live into their senior years. The key to good outcomes is comprehensive, coordinated healthcare throughout life.^[5]

A well-planned transition from pediatric to adult healthcare is important. As children with Turner’s syndrome grow into adults, they need to establish care with adult specialists who understand the condition and can provide appropriate ongoing monitoring and treatment.^[14]

Support from other people affected by Turner’s syndrome can be valuable. Patient organizations and support groups provide information, resources, and connections with others who understand the challenges of living with the condition.^[5]

While Turner’s syndrome presents certain challenges, particularly related to growth, puberty, and fertility, it does not define a person. With proper medical care, educational support when needed, and psychosocial support, individuals with Turner’s syndrome can achieve their full potential in education, careers, relationships, and all aspects of life.^[5]

Tourette’s Disorder

Tourette’s disorder is a neurological condition that causes sudden, repeated movements or sounds called tics that a person cannot control. While the symptoms can range from mild to severe, most people experience significant improvement as they grow older, and many find that tics lessen or disappear by early adulthood.

Table of contents

• What is Tourette’s disorder?
• Symptoms and types of tics
• Causes and risk factors
• How doctors diagnose Tourette’s
• Other conditions that often occur with Tourette’s
• Treatment options
• Living with Tourette’s disorder
• Outlook and prognosis

What is Tourette’s disorder?

Tourette’s disorder, also called Tourette syndrome (TS), is a condition of the nervous system that affects the brain and nerves. It causes people to have tics, which are sudden, repeated movements or sounds that happen involuntarily^[1][2]. Having tics means you cannot stop your body from making these movements or sounds, even though you might not want to. It is a little bit like having hiccups—your body does it anyway^[2].

Tourette’s disorder is part of a larger group of conditions called tic disorders, which affect the developing nervous system^[1]. It is the most severe type of tic disorder^[5].

Symptoms usually begin in early childhood, typically between ages 5 and 10 years, often starting in the head and neck area^[1][2]. The condition affects more boys than girls. Males are about three to four times more likely than females to develop Tourette syndrome^[3][5].

Tourette syndrome affects approximately 1 out of every 160 children in the United States, which means around 300,000 children have the condition^[5]. Most people with TS experience their worst tic symptoms in their early teens, but tics typically lessen and become controlled by the late teens to early 20s^[1]. For many people, tics decrease during adolescence and early adulthood, and sometimes they disappear entirely^[2].

Tourette syndrome is not a condition that continues to get worse over time. People with TS have a normal life expectancy^[1].

Tourette syndrome, TS, Gilles de la Tourette syndrome

Symptoms and types of tics

The main symptoms of Tourette’s disorder are tics. If you have tics, you cannot stop your body from having them, although sometimes people can hold back a tic for a short time. However, tension builds up and the tic eventually comes out^[7].

There are two main types of tics: motor tics, which involve body movements, and vocal tics, which involve sounds made with the voice^[1][2]. Motor tics usually begin before vocal tics develop^[1][5].

Tics are classified as either simple or complex. Simple tics are sudden, brief, and involve only a few muscle groups. They are more common than complex tics and often appear before complex tics develop^[1][2].

Simple motor tics may include:

• Eye blinking and other eye movements
• Facial grimacing
• Shoulder shrugging
• Head or shoulder jerking
• Nose twitching
• Mouth movements

Simple vocal tics may include:

• Repetitive throat clearing
• Sniffing
• Barking
• Grunting
• Coughing
• Humming

Complex tics involve several different parts of the body and usually have a pattern. They are distinct, coordinated movements or sounds involving several muscle groups^[1][2][3].

Complex motor tics might include:

• Facial grimacing combined with a head twist and shoulder shrug
• Sniffing or touching an object
• Hopping, jumping, bending, or twisting
• Stepping in a certain pattern
• Repeating observed movements (echolalia)
• Making obscene gestures

Complex vocal tics may include:

• Repeating one’s own words or phrases
• Repeating others’ words or phrases (echolalia)
• Using vulgar, obscene, or swear words (coprolalia)
• Calling out syllables or words

Although the media often show people with TS involuntarily shouting out swear words (coprolalia) or constantly repeating the words of other people (echolalia), these symptoms are rare and are not required for a diagnosis of TS^[2].

Some tics are preceded by an uncomfortable feeling called a premonitory urge or sensation in the affected muscle group^[1]. People may feel like they have to complete a tic in a certain way or a certain number of times to relieve the urge or decrease the sensation^[1]. These sensations may include a sore throat, itchy joints, muscle tension, or burning in the eyes^[23].

The types of tics and how often a person has tics can change a lot over time. Even though the symptoms might appear, disappear, and reappear, Tourette’s is considered a chronic condition^[2]. Tics can range from mild to severe. Severe symptoms might significantly interfere with communication, daily functioning, and quality of life^[3].

Certain situations can trigger or worsen tics. These include stress, anxiety, fatigue, excitement, or activities requiring high concentration^[15][23]. On the other hand, tics may improve when a person is focused on other tasks or engaged in activities that require concentration, such as playing an instrument or participating in competitive sports^[23].

Causes and risk factors

Scientists do not know the exact cause of Tourette syndrome. Research suggests that it is an inherited condition, meaning it is passed on from parent to child through genes^[2][5]. The condition tends to run in families, and genes play an important role in a person’s risk of developing TS^[2][5].

Issues with how the brain breaks down chemicals called neurotransmitters may also contribute to Tourette syndrome. Neurotransmitters, like dopamine, are chemicals in the brain that regulate behavior and movement^[5]. Some studies suggest alterations in the brain chemical that controls voluntary movements cause tic disorders^[10].

Scientists are also studying other possible causes and environmental factors that might contribute to TS. Some studies have shown that the following factors might be associated with TS, but additional research is needed to better understand these connections^[2][5]:

• Being male—males are 3 to 4 times more likely to develop Tourette syndrome
• Maternal smoking during pregnancy
• Pregnancy complications
• Low birth weight
• First trimester maternal stress and severe nausea or vomiting
• Infection
• Family history of TS, tics, OCD, or ADHD

How doctors diagnose Tourette’s

There is no single test, like a blood test or imaging exam, that can diagnose Tourette syndrome^[2][5]. The diagnosis is based on clinical history and the person’s symptoms^[8].

Health professionals look at the person’s symptoms to diagnose TS. To diagnose Tourette syndrome, a doctor checks when the tics started—they should begin before age 18^[5][8]. The criteria used to diagnose Tourette syndrome include^[8]:

• Both motor tics and vocal tics are present, although not necessarily at the same time
• Tics occur several times a day, nearly every day or intermittently, for more than a year
• Tics begin before age 18
• Tics are not caused by medications, other substances, or another medical condition
• Tics must change over time in location, frequency, type, complexity, or severity

Knowing when tics started and how long symptoms have lasted can help healthcare providers make an accurate diagnosis^[2]. The provider will carefully review the medical history and symptoms^[5].

A diagnosis of Tourette syndrome might be overlooked because the signs can mimic other conditions. For example, eye blinking might initially be associated with vision problems, or sniffling might be attributed to allergies^[8]. The provider may do tests to rule out other conditions that could be causing tics^[5][8].

Other conditions that often occur with Tourette’s

Most people with Tourette’s have other health conditions in addition to tics. It is common for people with TS to have other conditions, and these usually involve mental or behavioral health disorders^[5][9].

The most common conditions that occur alongside Tourette syndrome include^{[2][5][9][10]}:

• Attention-deficit/hyperactivity disorder (ADHD)—affects about 54% of people with TS
• Obsessive-compulsive disorder (OCD)—affects about 50% of people with TS
• Anxiety disorders
• Depression
• Learning disabilities
• Autism spectrum disorder (ASD)
• Oppositional defiant disorder (ODD)

People with additional conditions will require different treatments based on the symptoms. Sometimes treating these other conditions can help reduce tics^[9].

Treatment options

There is no cure for Tourette syndrome^[2][3][9]. However, treatments are available to help manage the tics caused by TS. Many people with TS have tics that do not get in the way of their daily life and do not need any treatment^[3][9]. Mild tics that don’t affect everyday activities might not require treatment^[5].

However, medication and behavioral treatments are available if tics cause pain or injury; interfere with school, work, or social life; or cause stress^[9]. Treatment is aimed at controlling tics that interfere with everyday activities and functioning^[8].

To develop the right treatment plan, people with tics, parents, and healthcare providers can work together and include teachers, child care providers, coaches, therapists, and other family members^[9].

Behavioral therapy

Behavioral therapy is a treatment that teaches people with TS ways to manage their tics^[9]. It is not a cure for tics, but it can help reduce the number of tics, the severity of tics, the impact of tics, or a combination of all of these^[9].

One specific type of behavioral therapy is called Comprehensive Behavioral Intervention for Tics (CBIT) or habit reversal training. This approach helps people gain awareness and control over their tics^[10]. The therapy helps retrain the brain’s habit loop so it doesn’t automatically engage in the tic^[15].

Techniques used in behavioral therapy include:

• Habit reversal—replacing the tic with less disruptive behavior
• Competing response training—teaching people to engage in physically incompatible behaviors with their tics, making it physically challenging to tic

Medications

Medications can be used to reduce severe or disruptive tics that might have led to problems with family, friends, school, or work^[9]. Medications also can be used to reduce symptoms of related conditions, such as ADHD or OCD^[9].

Medications do not eliminate tics completely, but they can help some people with TS in their everyday life^[9]. Common types of medications used include^[8]:

• Medications that block or lessen dopamine (such as haloperidol, risperidone, fluphenazine, and pimozide) can help control tics
• Alpha2-adrenergic agonists (such as clonidine) are recommended for mild to moderate cases
• Muscle relaxants (such as baclofen and clonazepam) can help control tics, especially physical ones

As with all medications, those used to treat tics can have side effects. Side effects can include weight gain, stiff muscles, tiredness, restlessness, and social withdrawal^[9]. The side effects need to be considered carefully when deciding whether or not to use any medication to treat tics. In some cases, the side effects can be worse than the tics^[9].

Medications affect each person differently. One person might do well with one medication but not another. When deciding the best treatment, a doctor might try different medications and doses, and it may take time to find the treatment plan that works best^[9]. There is no one medication that is best for all people^[9].

Living with Tourette’s disorder

Many people with Tourette’s disorder say, “I have Tourette’s, but Tourette’s doesn’t have me.” People can live full lives despite their diagnosis^[19]. What’s important is a strong support system that includes emotional backing coupled with a specially trained medical team^[19].

Several strategies can help people cope with Tourette syndrome in everyday life^[15]:

• Learn about TS and available treatments—it will empower better management of the condition
• Educate family and friends to help them understand TS and provide support
• Join a local support group or online community to connect with others living with Tourette’s
• Work with a doctor to find the medication and dosage that is most effective with the fewest side effects
• Practice stress management—stress and anxiety often make tics worse
• Prioritize sleep and limit caffeine
• Maintain a healthy diet and exercise regimen
• Avoid triggers when possible, such as lack of sleep, stress, flashing lights, and loud noises
• Engage in high-concentration activities, such as playing an instrument or competitive sports

When interacting with someone who has Tourette’s, it helps to understand what makes them feel comfortable. Important tips include^[16]:

• Don’t stare when they have a tic—give it normality and act as if you don’t notice
• While conversing, try to pretend that tics aren’t there—ignoring them is often the best approach
• Be patient if the person has any kind of tic that interrupts their speech
• Ask about their tics only if they seem comfortable discussing them

For parents of children with Tourette’s, education and support are crucial. Training and other educational resources can help parents and schools support children with TS in achieving their full potential^[9]. The first step is to build confidence and understand the condition^[5].

Outlook and prognosis

The outlook for people with Tourette syndrome is often promising. Most people with TS experience their worst tic symptoms in their early teens, but tics typically lessen and become controlled by the late teens to early 20s^[1]. Tics often lessen or become controlled after the teen years^[3].

In most cases, tics decrease during adolescence and early adulthood, and sometimes they disappear entirely^[2]. However, many people with TS experience tics into adulthood, and in some cases, tics can become worse during adulthood^[2]. For some people, TS can be a chronic condition with symptoms that last into adulthood^[1].

Tourette syndrome is not a condition that continues to get worse over time. It is not a degenerative condition, and individuals with TS have a normal life expectancy^[1]. Most of the time, tics become milder and occur less frequently in late adolescence and adulthood^[5].

The severity and presentation of tics in a person may fluctuate over time^[10]. The degree of impairment varies across the population with a diagnosis of Tourette syndrome, and the type and severity of tics experienced by a person may change over time^[10].

Ongoing Clinical Trials for Still’s Disease

There are currently 3 ongoing clinical trials investigating treatments for Still’s disease, also known as Systemic Juvenile Idiopathic Arthritis. These studies are testing medications that aim to reduce inflammation and control symptoms in children and adolescents. The trials are being conducted across multiple European countries, including the Netherlands, Germany, Italy, Spain, and several others, offering opportunities for young patients to access new treatment approaches.

Clinical trial locations

• Austria
  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis
• Belgium
  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis
• Bulgaria
  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis
• Czechia
  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis
  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis
• France
  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis
• Germany
  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis
• Italy
  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis
  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis
• Netherlands
  • Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis
• Poland
  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis
• Romania
  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis
• Spain
  • Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis
  • Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis

Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis

This trial is investigating deucravacitinib, a medication taken as a tablet, for treating Juvenile Psoriatic Arthritis in children and adolescents aged 5 to 18 years. Participants must have a confirmed diagnosis of this condition, which involves both joint inflammation and skin symptoms similar to psoriasis.

Inclusion criteria: Young patients must have been diagnosed with Juvenile Psoriatic Arthritis, meaning they experience both arthritis and skin problems like psoriasis.

Main focus: The study aims to determine whether deucravacitinib is more effective than a placebo in managing symptoms. Researchers will monitor how long it takes for disease flare-ups to occur, measure improvement in symptoms at weeks 16 and 42, and assess how well the medication is tolerated. The trial includes an initial treatment phase, followed by a randomized withdrawal phase where some participants may temporarily stop the medication to compare outcomes. Long-term evaluation will track the number of participants achieving low or no disease activity and measure improvements in skin symptoms.

Investigational drug: Deucravacitinib is a selective tyrosine kinase 2 inhibitor that works by reducing inflammation in the body. It is administered orally and is designed to help control joint pain, swelling, and skin symptoms associated with this type of arthritis.

Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis

This clinical trial is evaluating baricitinib, a medication available as tablets or oral suspension, compared with tocilizumab and placebo for treating Systemic Juvenile Idiopathic Arthritis in children aged 1 to less than 18 years.

Inclusion criteria: Participants must have a diagnosis of Systemic Juvenile Idiopathic Arthritis, with arthritis in at least one joint and a fever lasting at least 2 weeks with daily fever for at least 3 days. They must also have at least one additional symptom such as a temporary red rash, swollen lymph nodes, an enlarged liver or spleen, or inflammation around the heart or lungs. Additionally, participants must have at least 2 joints actively affected by arthritis and be at least 2 years old. Both boys and girls can participate.

Exclusion criteria: The trial excludes patients with other serious health conditions that could interfere with the study, those currently taking medications that might affect results, those with recent infections or illnesses, anyone with a history of allergic reactions to similar medications, and those unable to follow study procedures. Patients who have participated in another recent clinical trial, are pregnant or breastfeeding, have a history of substance abuse, have certain mental health conditions, or have received certain vaccines recently are also excluded.

Main focus: The primary goal is to measure the percentage of participants achieving the Adapted Pediatric American College of Rheumatology 30 response criteria at week 12, which indicates a significant improvement in symptoms. The study will monitor participants throughout the treatment phase with regular assessments including physical examinations and laboratory tests to evaluate both safety and effectiveness.

Investigational drugs: Baricitinib is a Janus kinase inhibitor that works by reducing inflammation in the body. It is administered orally and aims to control arthritis symptoms. Tocilizumab is used as a reference medication in this study and is given as a subcutaneous injection. It blocks a specific protein that causes inflammation.

Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis

This trial is exploring a new treatment strategy using anakinra, an injectable medication, for children with Systemic Juvenile Idiopathic Arthritis. The study is investigating whether a specific blood marker called IL-18 can help guide treatment decisions and potentially reduce the number of injections needed.

Inclusion criteria: Participants must be children and adolescents aged 8 months to 16 years diagnosed with Systemic Juvenile Idiopathic Arthritis. Both male and female patients can participate. Parents or legal guardians must be willing to sign consent forms. For the treatment phase, patients must have been treated with anakinra as their first treatment and shown an initial positive response, meaning no fever by the seventh day of treatment. They must also achieve at least a 90% improvement in symptoms without fever around 90 days after starting treatment.

Exclusion criteria: The trial excludes patients with any other autoimmune disorders, which are conditions where the immune system attacks the body’s own tissues. It also excludes those with any other joint disorders or patients specifically diagnosed with Still’s disease or systemic Juvenile Idiopathic Arthritis as separate conditions.

Main focus: The study aims to determine the average number of injections required to maintain inactive disease within the first year of treatment. It will monitor initial responses to treatment, including the absence of fever by day 7 and significant symptom improvement around 90 days. The trial includes a tapering and stop phase where medication is gradually reduced and eventually stopped, guided by IL-18 biomarkers. Researchers will also track disease flares, the need for alternative treatments, and the number of participants achieving remission without medication after one and two years.

Investigational drug: Anakinra is an interleukin-1 receptor antagonist administered as a subcutaneous injection. It works by blocking the activity of interleukin-1, a protein that contributes to inflammation and joint damage. This helps reduce inflammation and control symptoms of the disease.

Summary

These three clinical trials offer different treatment approaches for children and adolescents with forms of juvenile arthritis related to Still’s disease. The trials are spread across multiple European countries, with the most comprehensive geographic coverage in the baricitinib and tocilizumab study, which spans seven countries. Two trials focus specifically on Systemic Juvenile Idiopathic Arthritis, testing baricitinib and anakinra, while one addresses Juvenile Psoriatic Arthritis with deucravacitinib.

A notable aspect of these studies is the variety of medication mechanisms being explored. Baricitinib and deucravacitinib both work by inhibiting specific enzymes involved in inflammation, though they target different pathways. Anakinra takes a different approach by blocking inflammatory proteins directly. The anakinra trial in the Netherlands is particularly innovative in its use of biomarkers to guide treatment decisions, potentially reducing the treatment burden for young patients.

All three trials emphasize careful monitoring of safety and effectiveness, with regular assessments throughout the treatment period. The studies aim not only to control symptoms but also to achieve disease remission and improve quality of life for children living with these chronic inflammatory conditions.

Still’s disease is a rare inflammatory disorder that can strike unexpectedly, bringing with it a pattern of high fevers, a distinctive rash, and widespread joint pain that challenges both patients and doctors alike.

Prognosis

Understanding what lies ahead with Still’s disease can be challenging, as the condition affects each person differently and its course is difficult to predict at the outset. Healthcare providers have observed that Still’s disease typically follows one of three patterns, and knowing about these patterns can help patients and their families prepare emotionally for the journey ahead.^[1]

Some fortunate individuals experience what doctors call monophasic Still’s disease, where symptoms appear suddenly, last for weeks or months, and then disappear completely within a year. This single episode may resolve as unexpectedly as it began, allowing people to return fully to their previous lives.^[2]

Others encounter a polyphasic or intermittent pattern, where symptoms come and go in episodes separated by weeks, months, or even years. Between these flare-ups, people may feel perfectly well, though they must remain vigilant for signs of recurrence. The good news is that these episodes typically become shorter and less severe over time.^[4]

The third pattern, chronic Still’s disease, involves persistent symptoms or regular flare-ups that continue over extended periods. This form carries the greatest risk of causing progressive damage to joints, similar to what happens in rheumatoid arthritis. Particularly vulnerable are the wrists, which can sustain lasting damage if inflammation isn’t well controlled.^[1]

Each of these three patterns occurs with roughly equal frequency, affecting about one-third of patients each. Research from various populations suggests the condition is very rare overall, with an estimated annual incidence ranging from 0.16 to 0.4 cases per 100,000 adults. The disease appears to affect men and women in approximately equal numbers, though some studies suggest a slight predominance in females.^[3]

For the childhood form of Still’s disease, called systemic juvenile idiopathic arthritis, studies indicate that up to 30% of children still experience symptoms 10 years after their initial diagnosis, and symptoms can persist into adulthood.^[4]

Natural Progression

When Still’s disease goes untreated or undiagnosed, the body’s inflammatory processes continue unchecked, leading to a cascade of worsening problems. The disease typically begins with symptoms that closely mimic common viral illnesses, which is one reason diagnosis can be delayed. People often experience what feels like severe flu that simply refuses to resolve after the expected two or three weeks.^[2]

The initial symptoms usually include dramatic daily fever spikes, often reaching at least 102 degrees Fahrenheit (38.9 degrees Celsius) or higher, sometimes climbing to 41°C. These fevers characteristically spike once or twice daily, commonly in the morning and evening, creating a predictable pattern that becomes exhausting for those experiencing it.^[1]

Accompanying the fever is a distinctive salmon-pink or salmon-colored rash that typically appears when the fever spikes and may fade between episodes. This rash usually begins on the trunk, arms, or legs and can spread to other areas. Many people also develop a sore throat early in the disease course, along with swollen and tender lymph nodes in the neck.^[1]

As the disease progresses without treatment, joint involvement becomes increasingly prominent. What may start as achiness in a few joints gradually expands to affect multiple joints throughout the body. The knees and wrists are most commonly and severely affected, but ankles, elbows, hands, shoulders, and finger joints can all become painful, swollen, and stiff. This joint discomfort typically persists for at least two weeks and often much longer.^[6]

Muscle pain accompanying the fever spikes can become severe enough to disrupt normal daily activities. The combination of fever, joint pain, and muscle aches creates profound fatigue and a general feeling of being unwell, called malaise, that can be debilitating.^[1]

Without proper treatment, inflammation continues to damage joint structures, particularly in the wrists, which are especially vulnerable. Over time, this chronic inflammation can lead to permanent joint deformities and loss of function. The inflammatory process may also begin affecting internal organs, creating more serious complications.^[4]

Possible Complications

Still’s disease can lead to several serious complications, especially when diagnosis is delayed or treatment is inadequate. These complications can affect multiple organ systems and, in some cases, become life-threatening, making early recognition and proper management critically important.^[4]

Joint damage and deformities represent one of the most common long-term complications. When arthritis remains uncontrolled, the persistent inflammation gradually erodes joint structures, leading to permanent changes in joint shape and function. This process can make simple daily tasks like opening jars, writing, or walking progressively more difficult.^[4]

Internal organs can also be affected by the widespread inflammation. Some people develop enlargement of the liver or spleen, which may cause abdominal discomfort or pain. The heart can become involved through pericarditis, an inflammation of the sac surrounding the heart that leads to chest pain and potential cardiac complications. Even more serious is myocarditis, inflammation of the heart muscle itself, which can result in chest pain, irregular heartbeats, and in severe cases, heart failure.^[4]

The lungs may experience pleuritis, inflammation of the lining around the lungs, causing chest pain and difficulty breathing. Rarely, patients may develop more severe lung complications or even adult respiratory distress syndrome, a life-threatening condition affecting the lungs’ ability to function.^[7]

One of the most dangerous complications is macrophage activation syndrome (MAS), a severe and potentially fatal condition. This occurs when certain immune cells become excessively activated, leading to widespread inflammation throughout the body, extremely high fevers, organ dysfunction, and a dangerous drop in blood cell counts. MAS requires immediate medical attention and aggressive treatment.^[4]

Other less common but serious complications include kidney problems ranging from inflammatory conditions to, rarely, deposits of abnormal proteins in various organs (called amyloidosis) that can affect their function. Some patients have experienced neurological complications such as seizures, aseptic meningitis (inflammation of the membranes covering the brain and spinal cord), or cranial nerve problems.^[7]

Blood-related complications can also occur, including rare but serious conditions affecting blood cell production or blood clotting mechanisms. These complications underscore why regular monitoring by healthcare providers is essential for anyone living with Still’s disease.^[5]

Impact on Daily Life

Living with Still’s disease fundamentally changes many aspects of daily existence, creating challenges that extend far beyond physical symptoms. The unpredictable nature of the disease means that people never quite know what each day will bring, making planning and maintaining routines extraordinarily difficult.^[14]

Occupational life often requires significant adjustments. Many people find they can only work limited hours because physical activity or stress can trigger severe flare-ups. The fatigue that accompanies active disease can be so profound that even getting through a shortened workday feels like climbing a mountain. Some individuals must change careers entirely, moving from physically demanding jobs to less strenuous positions, or they may need to reduce their work hours substantially or stop working altogether during active disease periods.^[14]

The disease’s unpredictability creates particular frustration in social life. People frequently must cancel plans at the last minute when symptoms flare unexpectedly. This can strain friendships and family relationships, as others may struggle to understand the invisible nature of the illness. One patient described the challenge: “This disease is so unpredictable. I never know what the day will look like to the next. This can be hard to deal with sometimes. Especially having to cancel plans or appointments due to my disease flaring up.”^[14]

Physical activities and hobbies that were once sources of joy may become impossible or require modification. People who loved team sports, dancing, gardening, or other active pursuits often must find new ways to stay engaged that accommodate their physical limitations. Even during periods of remission, the fear of triggering a flare can make people hesitant to fully participate in physical activities.^[16]

The emotional toll cannot be understated. Living with chronic pain, fatigue, and uncertainty takes a psychological toll. Many people experience periods of grief as they adjust to their changed circumstances and mourn the loss of their former health and capabilities. Some describe going through a “true rollercoaster both physically and emotionally” as they come to terms with their diagnosis.^[16]

Daily self-care becomes more complex. Simple tasks like getting dressed, preparing meals, or cleaning the house may become challenging during flares. People must learn to pace themselves, recognizing when to rest and when they can push forward. This requires patience with oneself that can be difficult to develop, especially for people who were previously very active and independent.^[16]

Managing medications adds another layer of complexity to daily life. Many people must take multiple medications on different schedules, each with its own potential side effects. Some medications may need to be continued even during symptom-free periods to prevent damage to joints and organs. Regular medical appointments for monitoring become a routine part of life.^[8]

One important coping strategy involves learning to adjust expectations. As one person with Still’s disease explained, “I also had to adjust my expectations and what I could reasonably achieve on any given day.” This mindset shift, while difficult, helps reduce frustration and allows people to celebrate small victories rather than focusing on limitations.^[16]

Connecting with others who understand the disease can be healing and empowering. Patient advocacy groups, online support communities, and social media groups dedicated to Still’s disease provide spaces where people can share experiences, exchange practical advice, and simply feel less alone. Many patients report that speaking with others who truly understand their struggles has been invaluable for emotional well-being.^[16]

Despite the challenges, many people with Still’s disease find ways to adapt and maintain quality of life. They develop resilience, learn their body’s signals, and discover new interests and activities that work within their capabilities. Being able to remain active, even in modified ways, is often described as a gift that shouldn’t be taken for granted.^[16]

Support for Family

Family members and loved ones play a crucial role in supporting someone living with Still’s disease, particularly when that person is considering or participating in clinical trials. Understanding the disease and how clinical research works can help families provide better, more informed support during what can be a challenging time.^[16]

Clinical trials for Still’s disease are important because this rare condition needs more research to develop better treatments and ultimately find a cure. Because Still’s disease is so uncommon, with only 0.16 to 0.4 cases per 100,000 adults, gathering enough participants for research studies can be difficult. This rarity also means that many doctors aren’t familiar with the disease, making participation in clinical trials at specialized centers potentially beneficial for patients.^[4]

Family members can help by understanding that clinical trials aren’t necessarily a last resort or a sign that standard treatments have failed. Rather, they represent opportunities to access cutting-edge treatments that might not otherwise be available, while also contributing to medical knowledge that will help future patients. Trials may test new medications, compare different treatment approaches, or investigate better ways to diagnose and monitor the disease.^[9]

When a loved one is considering trial participation, families can assist in several practical ways. They can help research available trials, which are often listed on medical center websites and government registries. Reading through trial information together and preparing questions for the research team can make the process less overwhelming. Family members might accompany the patient to screening visits and help evaluate whether the trial’s requirements fit with the person’s life circumstances.^[16]

Understanding what participation involves is essential. Clinical trials typically require more frequent medical visits than standard care, which may mean arranging transportation, adjusting work schedules, or managing childcare. Patients may need to complete detailed symptom diaries or questionnaires. Blood tests and other monitoring procedures may occur more often than usual. Family members can help with these logistical challenges, providing rides to appointments, helping track symptoms, or simply offering companionship during long clinic visits.^[9]

Emotional support becomes particularly important during trial participation. While many people feel hopeful when starting a new treatment, they may also experience anxiety about unknowns or disappointment if a treatment doesn’t work as hoped. Being a steady, nonjudgmental presence helps patients navigate the emotional ups and downs. Family members should remember that having realistic expectations is important—clinical trials test whether treatments work, meaning there’s uncertainty about outcomes.^[16]

Families should also understand that participants can withdraw from clinical trials at any time if they change their minds or if the trial isn’t working out as expected. This knowledge can provide reassurance that trying a clinical trial doesn’t represent an irreversible commitment, though researchers appreciate advance notice when possible to plan for the patient’s continued care.^[9]

Learning to recognize when the patient needs help versus when they need independence is another important aspect of support. Still’s disease is often described as an “invisible illness”—someone may look fine on the outside while experiencing significant pain and fatigue. Family members can educate themselves about this aspect of the disease and learn to trust when their loved one says they’re struggling, even if symptoms aren’t visible.^[16]

Encouraging connections with Still’s disease patient communities can be incredibly valuable. These groups often share information about clinical trials and can provide insights from others who have participated in research. They also offer peer support that family members, despite their best intentions, simply cannot provide because they haven’t lived with the disease themselves.^[16]

Finally, families should take care of their own well-being. Supporting someone with a chronic illness can be draining, and caregivers need their own support networks, breaks, and activities that replenish their energy. Taking care of yourself isn’t selfish—it’s necessary for being able to provide sustained, effective support over the long term.^[16]

Still’s Disease

Still’s disease is a rare inflammatory condition that causes daily high fevers, a distinctive rash, and joint pain. This disease can appear either in childhood or in adults, often making everyday activities challenging and unpredictable.

Table of contents

• What is Still’s disease?
• Types and patterns of the disease
• Symptoms
• What causes Still’s disease?
• Who gets Still’s disease?
• How is Still’s disease diagnosed?
• Possible complications
• Treatment
• Living with Still’s disease

What is Still’s disease?

Still’s disease is a rare type of inflammatory arthritis, which means it causes swelling and pain in the joints along with problems throughout the entire body^[1]. The condition was first described by English physician Sir George Frederic Still in 1896, when he documented it in children^[7].

The disease exists in two main forms. When it begins in childhood, usually between early childhood and late adolescence, it is called systemic juvenile idiopathic arthritis or SJIA. When it starts after age 16, typically in young adults, it is known as adult-onset Still’s disease or AOSD^[3]. Both forms share similar symptoms, including fatigue, fever, joint pain, and inflammation^[4].

adult-onset Still’s disease, AOSD, systemic juvenile idiopathic arthritis, SJIA, systemic-onset juvenile idiopathic arthritis, SO-JIA

Types and patterns of the disease

Still’s disease affects different people in different ways, and it is hard to predict how it will affect any individual. Healthcare providers have observed that symptoms usually occur in one of three patterns^[2]:

• Monophasic pattern: There is only one episode of symptoms that typically lasts weeks to months, but usually less than a year. This form may occur suddenly and go away just as suddenly.
• Polyphasic (or intermittent) pattern: There are multiple episodes of symptoms that occur periodically, weeks, months, or even years apart. These episodes usually get shorter and less severe over time.
• Chronic pattern: Patients have persistent symptoms or regular flare-ups over time. Chronic Still’s disease is more likely to cause progressive damage to joints, similar to rheumatoid arthritis.

Each of these patterns occurs with about equal frequency. Sometimes what appears to be a single episode or intermittent pattern later develops into chronic disease^[2]. For children with SJIA, up to 30% still experience symptoms 10 years after their first symptoms, and symptoms can persist into adulthood^[4].

Symptoms

Most people with Still’s disease have a combination of several symptoms. The primary symptoms include fever, rash, joint pain, and muscle pain^[1].

Fever is one of the most distinctive features of Still’s disease. When symptoms are active, most people have a daily fever that may spike once or twice a day, typically reaching at least 102 degrees Fahrenheit (38.9 degrees Celsius or higher). One spike usually occurs in the morning and another in the evening. These fever patterns may continue for a week or longer^[2].

A distinctive rash usually appears when the fever is spiking. The rash is typically salmon-pink or pinkish in color and usually affects the chest, arms, or legs first, but may spread to other areas. The rash may come and go with the fever, often disappearing between fever spikes^[1].

Joint pain is another major symptom. The joints may feel achy, and many people also experience swelling and stiffness. The knees and wrists are most commonly affected, but the ankles, elbows, hands, and shoulders can also ache. Joint discomfort usually lasts at least two weeks. In some people, inflammation may affect only a few joints at first, but over time more joints may become involved^[1].

Muscle pain usually comes and goes with the fever. The pain can be severe enough to disrupt daily activities^[1].

Other common symptoms include sore throat, which is often one of the first symptoms to appear. The lymph nodes in the neck might be swollen and tender. People may also experience abdominal pain, fatigue, and a general feeling of being unwell (called malaise)^[1].

At first, Still’s disease might feel a lot like a virus or the flu. Symptoms like fever, body aches, and a sore throat resemble many common illnesses. You and your healthcare provider might become more suspicious when your symptoms still have not gone away after two or three weeks^[2].

What causes Still’s disease?

The cause of Still’s disease remains unknown. Inflammation in the body causes the symptoms. Your immune system usually generates inflammation to fight infections and heal injuries, and this is supposed to be a temporary response. But in Still’s disease, the immune system malfunctions and generates inflammation continuously, even when there is no infection to fight^[2].

The prevailing theory suggests that Still’s disease is a reactive condition, meaning that various infectious agents may act as triggers in people with a genetic predisposition. Both genetic factors and various infectious agents, including viruses and bacteria like Yersinia enterocolitica and Mycoplasma pneumoniae, have been proposed as significant contributors^[3]. However, it is uncertain whether these factors are present in all patients with Still’s disease.

Some studies have shown an association between Still’s disease and specific gene types called human leukocyte antigen (HLA) subtypes^[3]. There have also been rare reports of the disease occurring in twins, which suggests a genetic component^[3].

Who gets Still’s disease?

Still’s disease is a very uncommon condition. For the adult form (AOSD), the estimated annual incidence ranges from 0.1 to 0.4 cases per 100,000 people in Europe. For the childhood form (SJIA), recent studies suggest it affects approximately 3.5 per 100,000 children^[4].

The disease affects men and women approximately equally, though some studies suggest that slightly more females are affected than males^[4].

SJIA starts during childhood years, most commonly in the age range of 0 to 5 years^[4]. AOSD typically occurs in younger adults, most often between the ages of 16 and 35. The age distribution follows a bimodal pattern, with the first peak occurring between 15 and 25 years and the second peak between 36 and 46 years^[3].

How is Still’s disease diagnosed?

Still’s disease can be difficult to diagnose because there is no single test that can definitively identify it. Because it is such a rare disease, many doctors will not be familiar with it^[4]. The disease is considered a diagnosis of exclusion, which means doctors must rule out other conditions that have similar symptoms before confirming Still’s disease^[5].

Diagnosis is based on a review of symptoms, medical history, physical examination, and laboratory tests^[6]. No single test identifies Still’s disease. Instead, blood tests are used to rule out other diseases with similar symptoms. Other tests, such as X-rays, may be done to check for joint inflammation or damage^[6].

Imaging tests can reveal damage caused by the disease. Blood tests can help rule out other conditions that have similar symptoms. A distinguishing feature of Still’s disease is a frequently elevated level of a protein called serum ferritin, which often exceeds 1000 ng/ml^[3].

At least seven sets of diagnostic criteria have been created to help identify Still’s disease. The most commonly used are the Yamaguchi criteria, which have the highest sensitivity. According to these criteria, diagnosis requires at least five features, with at least two of these being major criteria. Major criteria include fever of at least 39 degrees Celsius for at least one week, joint pain or arthritis for at least two weeks, a nonpruritic salmon-colored rash, and increased white blood cell count with a predominance of certain immune cells. Minor criteria include sore throat, swollen lymph nodes or spleen, abnormal liver function tests, and negative tests for certain antibodies^[5].

Symptoms of Still’s disease can differ from person to person and can mimic those of other conditions, including lupus and a type of cancer called lymphoma^[1].

Possible complications

People with Still’s disease can develop complications, especially if the condition is not correctly diagnosed and quickly treated^[4].

Possible complications include:

• Joint damage and deformities: Uncontrolled arthritis can result in lasting damage to the joints, particularly the wrists. SJIA, the form that affects children, can be associated with severe arthritis if not sufficiently controlled^[1].
• Enlargement of the liver or spleen: Several of the body’s organs can be affected by the inflammation^[4].
• Macrophage activation syndrome (MAS): This is a severe and life-threatening complication involving excessive activation of immune cells, leading to widespread inflammation, high fevers, organ dysfunction, and a drop in blood cell counts^[4].
• Heart complications: These include pericarditis (inflammation of the sac surrounding the heart), which can lead to chest pain and potential cardiac complications, and myocarditis (inflammation of the heart muscle), potentially resulting in chest pain, irregular heartbeats, and heart failure^[4].
• Lung complications: Pleuritis, or inflammation of the lining around the lungs, can cause chest pain and difficulty breathing. Other serious lung conditions have also been reported^[4].
• Amyloidosis: Rarely, abnormal proteins can deposit in various organs, which can affect their function^[4].

Treatment

A variety of medicines are used to treat Still’s disease. The type of medicine depends on how severe the symptoms are and possible side effects. Medications can help manage symptoms when they arise^[8].

Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin IB) or naproxen sodium (Aleve) may help with mild joint pain and inflammation. Stronger NSAIDs are available by prescription. Since NSAIDs can damage the liver, regular blood tests may be needed to check liver function^[8].

Steroids (also called corticosteroids) such as prednisone are often needed if the disease is severe or does not respond to prescription NSAIDs. Many people who have Still’s disease require treatment with steroids. These powerful drugs reduce inflammation but may lower the body’s resistance to infections and increase the risk of developing osteoporosis and diabetes^[8].

Methotrexate is often used in combination with prednisone. When combined, the prednisone dose can be reduced. Methotrexate is a type of medicine called a disease-modifying drug (DMARD). DMARDs and biologic medicines are needed in more severe cases or if the arthritis becomes chronic^[6].

Biologic response modifiers (also called biologics) may be recommended if other medicines have not worked. These are medicines that block specific proteins causing inflammation. Anakinra (Kineret), canakinumab (Ilaris), and tocilizumab (Actemra) are biologics used to treat Still’s disease. Medications that block the action of a protein called interleukin-1 (IL-1), such as anakinra, can be particularly effective treatments^[8].

With Still’s disease, medications may need to be taken even after symptoms go away. This is called maintenance therapy. It is important to keep inflammation under control to prevent damage to joints and organs^[6]. It may be necessary to take more than one medication at a time to control symptoms^[6].

Living with Still’s disease

Living with Still’s disease requires patience and adaptation. The disease is unpredictable, and people often never know what each day will look like. This can be hard to deal with, especially when having to cancel plans or appointments due to the disease flaring up^[14].

Caring for the body and mind are key components of managing Still’s disease. Making positive and healthy lifestyle choices and acknowledging the physical and emotional effects of the condition are important. Proper nutrition, activity, rest, and following doctors’ orders are essential for managing the condition and possible medication side effects^[6].

Many people find that seeking out support from others who understand their situation helps. Connecting with Still’s disease social media groups and patient organizations can provide hope for the future and help people live better with their condition^[16]. Just speaking with others who understand can be healing^[16].

For some people, Still’s disease has required making major lifestyle changes, including adjustments to their occupation. Finding the right combination of medications that reduces flare-ups can be one of the biggest challenges. Trying different medications to find what works best is often necessary^[14].

Being able to stay active is considered a gift by many people living with Still’s disease. While the diagnosis can trigger a re-evaluation of how active life can be, many people learn to adjust their expectations and what they can reasonably achieve on any given day^[16].

Ongoing Clinical Trials for Stargardt’s Disease

Currently, there are 3 ongoing clinical trials investigating potential treatments for Stargardt’s disease, a genetic eye disorder that causes progressive vision loss. These trials are taking place across several European countries and are testing different approaches, including gene therapy and oral medications, to slow disease progression and preserve vision in affected patients.

Clinical trial locations

• Belgium
  • Study on Tinlarebant for Treating Stargardt Disease in Adolescents
• France
  • Study on the Long-Term Safety of SAR422459 for Patients with Stargardt’s Disease
  • Study on Tinlarebant for Treating Stargardt Disease in Adolescents
• Germany
  • Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations
  • Study on Tinlarebant for Treating Stargardt Disease in Adolescents
• Netherlands
  • Study on Tinlarebant for Treating Stargardt Disease in Adolescents

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

This Phase 1/2 clinical trial is investigating SB-007, an experimental gene therapy treatment for Stargardt Disease Type 1. The treatment is delivered through a subretinal injection directly under the retina of the eye and contains an adeno-associated virus vector that delivers a corrected version of the ABCA4 gene to retinal cells.

Who can participate: Adults between 18 and 65 years old who have been diagnosed with Stargardt Disease Type 1 and have confirmed mutations in both copies of their ABCA4 gene. Participants must have clear eye tissue and adequate pupil dilation to allow for high-quality retinal imaging. Women of childbearing potential must have negative pregnancy tests and agree to use acceptable birth control for 4 months following treatment. The study eye must show clinical signs consistent with the disease.

Who cannot participate: People with other eye conditions that may affect vision beyond Stargardt Disease, those without confirmed mutations in both ABCA4 genes, anyone who has had eye surgery within 6 months, those with uncontrolled glaucoma, active eye infections or inflammation, or a history of retinal detachment. Pregnant or breastfeeding women, people with a history of cancer in the past 5 years (except certain skin cancers), those with serious medical conditions, and individuals with drug or alcohol abuse history are excluded. People who have participated in another clinical trial within 30 days or who have known allergies to the study medication components also cannot join.

What the study involves: The trial aims to evaluate whether SB-007 is safe, well-tolerated, and potentially effective at slowing disease progression. Participants will be randomly assigned to either receive the treatment in one eye or serve as a control group. Throughout the 96-week (approximately 2-year) follow-up period, researchers will monitor participants using various imaging techniques including fundus autofluorescence and optical coherence tomography to measure changes in lesion size, retinal layer integrity, and retinal sensitivity. Vision will be assessed through multiple tests measuring visual acuity and contrast sensitivity. Regular check-ups will document any changes in vision and disease progression.

This study is being conducted in Germany and is expected to run until September 2028.

Study on the Long-Term Safety of SAR422459 for Patients with Stargardt’s Disease

This is a long-term follow-up study evaluating the safety of SAR422459, a gene therapy treatment delivered through subretinal injection. The treatment uses a lentiviral vector containing the human ABCA4 gene to address the genetic cause of the disease.

Who can participate: This study is open only to patients who previously participated in a related study called protocol TDU13583, received a subretinal injection of SAR422459 in that study, and completed that study through Week 48 or had an early discontinuation visit. Participants must provide signed informed consent and any required local authorization such as HIPAA.

Who cannot participate: Patients with other congenital or hereditary diseases unrelated to Stargardt’s macular degeneration, those with other neonatal diseases not related to the condition, patients outside the specified age range, those not part of the specified trial group, and individuals considered part of a vulnerable population requiring special protection or care.

What the study involves: The primary objective is to evaluate the long-term safety and tolerability of SAR422459. Researchers will monitor the occurrence of adverse events and observe any clinically important changes in eye health. The study also aims to observe whether there is any delay in retinal degeneration. Participants will attend regular monitoring visits where their eye health will be assessed.

This study is taking place in France and is expected to continue until December 2033.

Study on Tinlarebant for Treating Stargardt Disease in Adolescents

This Phase 3 clinical trial is testing Tinlarebant (also known as LBS-008), an oral medication taken in tablet form at a 5 mg dosage. Unlike the gene therapy approaches, this treatment works by inhibiting the formation of toxic byproducts in the retina that contribute to retinal cell degeneration.

Who can participate: Male or female adolescents and young adults between 12 and 20 years old who have a clinical diagnosis of Stargardt Disease (STGD1) with at least one mutation found in the ABCA4 gene. The size of the affected area in the eye must be within 3 disc areas (7.62 mm²) as seen on fundus autofluorescence imaging, and participants must have visual acuity of 20/200 or better in the study eye. Both the participant and their parent or legal guardian must agree to sign the consent form approved by an ethics committee.

Who cannot participate: Patients with any other eye disease that could affect study results, those who have had eye surgery in the last 3 months, anyone currently taking medications that could interfere with the study treatment, people with a history of allergic reactions to similar medications, pregnant or breastfeeding individuals, those who have participated in another clinical trial within the last 30 days, and anyone with a serious health condition that could affect their ability to participate.

What the study involves: This is a double-masked, randomized study, meaning neither participants nor researchers will know who receives the actual medication versus placebo. After initial assessment including genetic testing and eye imaging, participants will be randomly assigned to receive either Tinlarebant or placebo. Regular follow-up visits will include eye examinations and imaging to assess changes in atrophic lesions (damaged areas in the retina). The main goal is to see if Tinlarebant can slow the growth of these areas and preserve retinal thickness and structure.

This study is being conducted across multiple countries including Belgium, Germany, the Netherlands, and France, and is expected to conclude by September 2025.

Summary

The current landscape of clinical trials for Stargardt’s disease reflects two distinct therapeutic approaches. Two of the three trials focus on gene therapy treatments (SB-007 and SAR422459) that aim to address the underlying genetic cause by delivering corrected versions of the ABCA4 gene directly to retinal cells through subretinal injection. The third trial tests an oral medication (Tinlarebant) that takes a different approach by preventing the accumulation of toxic substances in the retina.

Geographically, these trials span several European countries, with France and Germany hosting two trials each, while Belgium and the Netherlands participate in one trial. Notably, the Tinlarebant study is the only trial specifically designed for adolescents and young adults aged 12 to 20, while the SB-007 trial focuses on adults aged 18 to 65. The SAR422459 study represents a unique long-term safety follow-up for patients who previously received treatment, with monitoring extending until 2033.

All three trials share a common emphasis on monitoring disease progression through advanced retinal imaging techniques and assessing both safety and potential benefits for preserving vision in this progressive genetic eye disorder.

Tourette’s disorder is a neurological condition that causes people to make sudden, unwanted movements and sounds called tics. The main goal of treatment is to help those affected manage their symptoms, improve their ability to function in daily life, and reduce the stress that tics can cause. Treatment approaches vary depending on how severe the tics are and how much they interfere with school, work, or social activities. Many people with Tourette’s can live full, productive lives with the right combination of support, education, and when necessary, medical or behavioral interventions.

Understanding Treatment Goals for Tourette’s Disorder

When someone is diagnosed with Tourette’s disorder, it’s important to understand that not everyone needs medical treatment. The decision to start therapy depends on how much the tics affect the person’s everyday life. For some people, especially children, tics may be mild and not cause significant problems at school or with friends. In these cases, education and support may be all that’s needed.^[1][2]

However, when tics become severe enough to interfere with communication, learning, or social relationships, or when they cause physical pain or injury, treatment becomes necessary. The main aims are to reduce the frequency and intensity of tics, help the person cope with the urge to tic, and address any other conditions that often occur alongside Tourette’s, such as attention-deficit/hyperactivity disorder (ADHD) or obsessive-compulsive disorder (OCD). ADHD is a condition that makes it hard to focus and control impulses, while OCD involves unwanted repetitive thoughts and behaviors.^[9][17]

Treatment for Tourette’s is highly individual. What works well for one person may not work for another. Doctors, patients, and families need to work together to find the best approach. This often involves trying different strategies and being patient, as it can take time to see what combination of treatments brings the most relief with the fewest side effects.^[8]

There are standard treatments that have been used for many years and are recommended by medical societies around the world. These include medications that affect brain chemicals and behavioral therapy techniques. At the same time, researchers continue to study new therapies and refine existing ones through clinical trials. These studies help doctors understand which treatments are safest and most effective, and they may lead to better options for people living with Tourette’s in the future.^[10][13]

Standard Medical Treatment for Tourette’s Disorder

The most commonly used medications for Tourette’s disorder work by affecting the levels of certain chemicals in the brain, particularly a substance called dopamine. Dopamine is a chemical messenger that helps control movement and behavior. When there’s too much activity in dopamine pathways, it can lead to increased tics.^[5][12]

One group of medications used to treat tics are called dopamine antagonists or neuroleptics. These drugs block dopamine receptors in the brain, which helps reduce the intensity and frequency of tics. Common medicines in this category include haloperidol, pimozide, risperidone, and fluphenazine. Haloperidol was one of the first medications shown to help with tics and has been used for decades. Risperidone and other newer medications in this group tend to have fewer side effects than the older ones, though they still require careful monitoring.^[8][10]

Another medication sometimes prescribed is tetrabenazine. This drug works differently by reducing the amount of dopamine that nerve cells can release. It can be helpful for people who don’t respond well to other medications, though it may cause mood changes or depression in some individuals.^[8]

For people with milder tics, doctors may recommend medications called alpha2-adrenergic agonists, such as clonidine or guanfacine. These drugs were originally developed to treat high blood pressure, but they’ve been found to help with tics as well. They work by affecting a different brain chemical called norepinephrine. While they may not be as powerful as dopamine-blocking drugs, they often have fewer side effects and can be particularly helpful when ADHD is also present.^[10][13]

Treatment with medication is usually long-term, often continuing for months or years. Doctors typically start with a low dose and gradually increase it until they find the amount that provides the best control of tics with the least side effects. Regular follow-up appointments are essential to monitor how well the medication is working and to check for any problems. Many people find that they need less medication as they get older, particularly during late adolescence and early adulthood when tics often naturally decrease.^[1][9]

Most medications prescribed for Tourette’s have not been specifically approved by the U.S. Food and Drug Administration for treating tics, even though they are widely used and recommended by medical experts. This means doctors are using them “off-label,” which is a common and accepted practice when there’s good evidence that a medication helps.^[9][17]

Behavioral Therapy as a Standard Treatment

In addition to medication, behavioral therapy has become a key part of treatment for Tourette’s disorder. The most studied and effective type is called Comprehensive Behavioral Intervention for Tics (CBIT). This therapy doesn’t cure tics, but it can help people gain better control over them and reduce how much they interfere with daily life.^[9][17]

CBIT includes several components. One important technique is called habit reversal training. This involves becoming more aware of when a tic is about to happen—many people feel a warning sensation called a premonitory urge right before a tic occurs. The person then learns to do a different, less noticeable movement instead of the tic. For example, if someone has a tic of jerking their neck, they might learn to gently tighten their neck muscles in a way that’s not visible to others until the urge passes.^[10][13]

Another part of CBIT focuses on managing situations that make tics worse. Stress, anxiety, excitement, and fatigue can all trigger more frequent or intense tics. Therapists work with patients to identify their specific triggers and develop strategies to handle them. This might include relaxation techniques, changing routines, or finding ways to take breaks when feeling overwhelmed.^[9][11]

Behavioral therapy is typically conducted by a psychologist or specially trained therapist over several weeks or months. It requires active participation and practice at home. While it can be challenging at first, many people find that learning these techniques gives them a sense of control over their tics that medication alone doesn’t provide. Some people use behavioral therapy alone, while others combine it with medication for the best results.^[11]

Treatment Options Being Studied in Clinical Trials

Researchers continue to search for new and better ways to treat Tourette’s disorder. Clinical trials are research studies that test whether new treatments are safe and effective before they become widely available. These studies are essential for advancing medical care and may offer options for people who haven’t found relief with standard treatments.^[10][13]

Clinical trials typically happen in phases. Phase I trials test whether a new treatment is safe and identify what dose should be used. These usually involve a small number of participants. Phase II trials look at whether the treatment actually works to reduce symptoms and continues to gather safety information with more people. Phase III trials compare the new treatment to standard therapies or placebo (inactive treatment) in large groups of patients to confirm effectiveness and monitor side effects. Only treatments that successfully complete all these phases are considered for approval by regulatory agencies.^[10]

One area of active research involves finding medications that work on different brain pathways than the current standard drugs. Scientists are studying compounds that affect other neurotransmitters—the chemical messengers in the brain—beyond dopamine. Some research is looking at medications that work on serotonin, another brain chemical involved in mood and behavior. While early studies have shown mixed results, this remains a promising direction because different people may respond to different types of medications.^[10]

Researchers are also investigating whether cannabis-based medicines might help with tics. Some small studies have suggested that compounds from the cannabis plant could reduce tic frequency in some people. However, these studies have been limited in size and design, so more rigorous clinical trials are needed before doctors can know whether these treatments are truly effective and safe, especially for children and teenagers.^[13]

For people with very severe tics that don’t respond to any other treatment, a procedure called deep brain stimulation (DBS) is being studied. This involves surgically implanting small electrodes in specific areas of the brain. These electrodes deliver tiny electrical pulses that can help regulate the brain circuits involved in tics. While DBS is still considered experimental for Tourette’s, some clinical trials have shown promising results in reducing tic severity for carefully selected patients. The procedure carries risks associated with brain surgery and is only considered when all other options have been exhausted.^[10][13]

Another innovative approach being tested is transcranial magnetic stimulation (TMS). This is a non-invasive procedure that uses magnetic fields to stimulate specific areas of the brain from outside the skull. Unlike DBS, TMS doesn’t require surgery. Early research suggests it might help reduce tics in some people, though more studies are needed to determine the best way to use this technology and which patients are most likely to benefit.^[13]

Some clinical trials are also exploring whether improving behavioral therapy techniques can make them more effective. Researchers are testing different variations of CBIT, including versions that can be delivered through telemedicine or smartphone apps, which could make this treatment more accessible to people who don’t live near specialized clinics.^[11]

Participation in clinical trials is voluntary and involves careful consideration of the potential benefits and risks. People interested in joining a trial usually need to meet specific criteria, such as age range, severity of tics, or previous treatments tried. Trials may be conducted at medical centers in various locations, including in the United States and other countries. Information about ongoing trials can often be found through organizations that focus on Tourette’s disorder or through healthcare providers who specialize in movement disorders.^[10]

Managing Related Conditions

Most people with Tourette’s disorder have other conditions alongside their tics, and treating these can be just as important as treating the tics themselves. In fact, these other conditions sometimes cause more difficulty in daily life than the tics do. About half of people with Tourette’s also have ADHD or OCD, and many experience anxiety or depression.^[2][5]

When ADHD is present, stimulant medications like methylphenidate or amphetamine are often prescribed. In the past, doctors worried that these medications might make tics worse, but research has shown they’re usually safe and can significantly help with attention and impulse control. Sometimes treating ADHD can even reduce stress and indirectly help with tics.^[9][10]

For OCD symptoms, medications called selective serotonin reuptake inhibitors (SSRIs) are commonly used. These include drugs like fluoxetine and sertraline. A specific type of behavioral therapy called exposure and response prevention is also very effective for OCD. This therapy helps people face their fears or obsessive thoughts without performing the compulsive behaviors they feel driven to do.^[10][13]

Anxiety and depression can be addressed through counseling, therapy, or medication. Sometimes the same medications used for OCD can help with these conditions. Support groups and education about Tourette’s can also reduce anxiety by helping people feel less alone and more understood.^[11]

The Role of Education and Support

Medical treatments and therapy are only part of managing Tourette’s disorder. Education and support play crucial roles in helping people live well with this condition. When children with Tourette’s, their families, teachers, and classmates understand what tics are and that they’re involuntary, it reduces embarrassment and prevents bullying.^[2][11]

Schools can make accommodations that help students with Tourette’s succeed. This might include allowing breaks when tics are bothersome, providing a quiet place where a student can release tics without distraction, or giving extra time on tests if tics interfere with concentration. These adjustments are often formalized in documents called 504 Plans or Individualized Education Programs.^[11]

Many families and individuals benefit from connecting with others who have Tourette’s. Support groups, both in-person and online, provide a place to share experiences, learn coping strategies, and feel understood. Organizations dedicated to Tourette’s disorder offer educational resources, connect people with specialists, and advocate for awareness and research funding.^[11]

Most common treatment methods

• Behavioral therapy
  • Comprehensive Behavioral Intervention for Tics (CBIT) which teaches awareness of tics and strategies to manage them
  • Habit reversal training that helps replace tics with less noticeable movements
  • Identifying and managing situations that trigger tics, such as stress or fatigue
  • Relaxation techniques to reduce the frequency of tics
• Dopamine-blocking medications
  • Haloperidol, one of the oldest medications proven to reduce tics
  • Risperidone, which tends to have fewer side effects than older medications
  • Pimozide and fluphenazine, other options in this category
  • These medications work by blocking dopamine receptors in the brain
• Alpha2-adrenergic agonists
  • Clonidine and guanfacine for milder cases of tics
  • Originally developed for high blood pressure but found helpful for tics
  • Particularly useful when ADHD is also present
  • Generally have fewer side effects than dopamine blockers
• Other medications
  • Tetrabenazine, which reduces dopamine release by nerve cells
  • SSRIs for treating co-occurring OCD symptoms
  • Stimulant medications for managing ADHD symptoms alongside Tourette’s
• Experimental treatments in clinical trials
  • Deep brain stimulation for severe, treatment-resistant cases
  • Transcranial magnetic stimulation as a non-invasive option
  • Cannabis-based medicines being studied in small trials
  • Novel medications targeting different brain pathways
• Education and support
  • School accommodations through 504 Plans or Individualized Education Programs
  • Support groups for individuals and families
  • Education programs to reduce stigma and increase understanding
  • Connection with organizations dedicated to Tourette’s disorder

Still’s disease is a rare inflammatory condition that causes daily fevers, a distinctive rash, and joint pain, typically affecting young adults between ages 16 and 35. The path to controlling symptoms often involves a combination of medicines—from common pain relievers to cutting-edge biological therapies—and finding the right treatment can be a process of trial and adjustment.

Understanding the Goals of Still’s Disease Treatment

When someone receives a diagnosis of Still’s disease, the immediate focus shifts to managing the inflammation that drives this condition. Treatment aims to reduce pain, control fever, prevent joint damage, and improve the overall quality of life. Because Still’s disease can follow different patterns in different people—sometimes appearing once and disappearing, sometimes returning in episodes, or sometimes persisting chronically—doctors must tailor treatment to each individual’s disease course and symptom severity.^[1][2]

The medical approach to Still’s disease recognizes that this is not simply about making symptoms bearable. Without proper treatment, the condition can cause serious complications including permanent joint damage (particularly to the wrists), liver problems, heart inflammation, and lung issues. In rare cases, a life-threatening complication called macrophage activation syndrome (a severe overactivation of immune cells) can occur.^[4][12] This makes timely and effective treatment essential, even during periods when symptoms seem to have calmed down.

Current medical guidelines recognize several approved treatment options that have proven effective for many patients. At the same time, researchers continue to explore new therapies in clinical trials, testing innovative approaches that may offer better outcomes for people who don’t respond well to standard treatments or who experience difficult side effects.^[8][9]

Standard Medical Treatment for Still’s Disease

The foundation of Still’s disease treatment typically begins with medicines designed to reduce inflammation and control pain. The choice of medication depends on how severe the symptoms are, how the disease is behaving, and how well a patient tolerates different drugs.

Nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, are often the first medicines tried for people with milder symptoms. These include medications like ibuprofen (sold as Advil or Motrin) and naproxen sodium (sold as Aleve). Stronger prescription NSAIDs are also available. These drugs work by blocking enzymes in the body that create inflammation. While NSAIDs can be effective for joint pain and mild inflammation, they carry a risk of liver damage, especially with long-term use. Because of this, patients taking NSAIDs regularly need periodic blood tests to monitor their liver function.^[8][11]

When NSAIDs alone aren’t sufficient—which is often the case with Still’s disease—doctors turn to corticosteroids, with prednisone being the most commonly used. These powerful anti-inflammatory medicines work by suppressing the immune system’s overactive response. Many people with Still’s disease require corticosteroid treatment to bring their symptoms under control. Prednisone can be remarkably effective at reducing fever, rash, and joint inflammation, often providing relief within days.^[8][13]

For patients who need ongoing treatment or who experience disease recurrence, doctors often add a disease-modifying antirheumatic drug (DMARD) to the treatment plan. Methotrexate (sold as Trexall) is the most commonly used DMARD for Still’s disease. It works by interfering with the body’s production of inflammatory substances. Methotrexate is frequently combined with prednisone, which allows doctors to reduce the prednisone dose while maintaining disease control. This combination approach can minimize the side effects associated with long-term steroid use.^[8][11]

When standard treatments with NSAIDs, corticosteroids, and methotrexate don’t provide adequate relief, or when patients develop severe or chronic forms of the disease, physicians turn to biologic therapies. These are a newer class of medicines called biologic response modifiers, or simply biologics, which target specific proteins in the immune system that drive inflammation.^[8]

Three biologic medicines have proven particularly useful for treating Still’s disease. Anakinra (sold as Kineret) blocks a protein called interleukin-1 (IL-1), which plays a central role in the inflammation seen in Still’s disease. Canakinumab (sold as Ilaris) also targets IL-1 but works in a slightly different way than anakinra. Tocilizumab (sold as Actemra) blocks a different inflammatory protein called interleukin-6 (IL-6). These medicines are given by injection or intravenous infusion and have helped many patients who didn’t respond to other treatments.^[8][13]

An important aspect of Still’s disease treatment is something called maintenance therapy. Even after symptoms disappear, doctors often recommend continuing medication for some time. This approach helps prevent flare-ups and protects joints and organs from damage. The duration of treatment varies considerably—some people may need medication for months, while others require years of treatment. Regular monitoring through blood tests and medical examinations helps doctors adjust treatment as needed.^[11][17]

Treatment Approaches Being Studied in Clinical Trials

While standard treatments help many people with Still’s disease, researchers continue to investigate new therapies that might work better, cause fewer side effects, or help patients who don’t respond to currently available medicines. Clinical trials are research studies that carefully test new treatments in volunteer patients to see if they are safe and effective.

Much of the clinical research in Still’s disease focuses on better understanding which inflammatory molecules drive the disease. Scientists have learned that substances called cytokines—chemical messengers that immune cells use to communicate—are overproduced in Still’s disease. Specifically, interleukin-1 (IL-1) and interleukin-18 (IL-18) appear to be key players. This understanding has led researchers to develop and test medicines that specifically block these inflammatory signals.^[3][5]

Clinical trials examining Still’s disease treatments typically follow a structured progression through different phases. Phase I trials are the first step, primarily focused on determining whether a new medicine is safe and identifying the appropriate dose. These studies usually involve small numbers of participants. Phase II trials expand to more patients and begin examining whether the treatment actually helps reduce symptoms or alter the disease course. Phase III trials are large studies that compare the new treatment against standard treatments or placebo to definitively determine effectiveness.

Current research is exploring several promising directions. Some studies are investigating new ways to block interleukin-1, building on the success of anakinra and canakinumab. Other research examines medicines that target different inflammatory pathways, potentially offering options for patients who don’t respond to IL-1 blocking drugs. Researchers are also studying combination approaches—using two or more medicines together that target different aspects of the inflammatory process.

One area of active investigation involves identifying biomarkers—measurable indicators in the blood or other body fluids—that can predict which patients will respond best to which treatments. Currently, doctors often must try different medicines sequentially to find what works for each individual patient. Biomarkers could potentially allow for more personalized treatment selection from the start. Studies have noted that extremely elevated levels of a protein called ferritin (often exceeding 1000 nanograms per milliliter) are characteristic of Still’s disease, and researchers are exploring whether ferritin levels or other markers can guide treatment decisions.^[3][5]

Clinical trials for Still’s disease take place in medical centers around the world, including locations in the United States, Europe, and other regions. Eligibility for these trials depends on factors such as the patient’s age, disease duration, current treatments, and overall health. Some trials specifically seek patients who haven’t responded well to standard therapies, while others may accept patients earlier in their disease course. Interested patients can discuss clinical trial options with their rheumatologist, who can help identify appropriate studies and explain what participation would involve.

Preliminary results from some clinical trials have shown encouraging signs. Studies of IL-1 blocking drugs in particular have demonstrated improvements in fever frequency, rash, joint pain, and blood test results indicating reduced inflammation. Some patients who had persistent disease despite other treatments achieved remission with these targeted therapies. Safety profiles have generally been acceptable, though as with all immunosuppressive treatments, increased infection risk is a concern that requires monitoring.^[9]

Most Common Treatment Methods

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Over-the-counter options like ibuprofen (Advil, Motrin) and naproxen sodium (Aleve) for mild pain and inflammation
  • Stronger prescription NSAIDs available for more significant symptoms
  • Regular liver function monitoring required during long-term use
• Corticosteroids
  • Prednisone is the most commonly used steroid medication
  • Powerful anti-inflammatory effects often provide rapid symptom relief
  • Used when NSAIDs alone are insufficient to control disease
  • Long-term use carries risks including infection susceptibility, osteoporosis, and diabetes
• Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Methotrexate (Trexall) is the primary DMARD used for Still’s disease
  • Often combined with prednisone to allow lower steroid doses
  • Helps control chronic or recurrent disease patterns
• Biologic Therapies
  • Anakinra (Kineret) – blocks interleukin-1 protein, given by injection
  • Canakinumab (Ilaris) – also targets interleukin-1 with different mechanism
  • Tocilizumab (Actemra) – blocks interleukin-6, given by injection or infusion
  • Reserved for cases not responding to standard treatments or severe disease
• Maintenance Therapy
  • Continued medication use even after symptoms resolve
  • Helps prevent disease flares and protects against organ and joint damage
  • Duration varies from months to years depending on individual disease pattern

Diagnosing Sjögren’s syndrome involves multiple tests and careful evaluation, as symptoms can mimic many other conditions and vary greatly from person to person.

Introduction: Who Should Seek Diagnostics

If you are experiencing persistent dryness in your eyes or mouth that does not improve with regular measures, it may be time to consult a healthcare provider. Sjögren’s syndrome is particularly worth investigating when dryness is accompanied by other symptoms such as joint pain, chronic fatigue, or swelling of the glands around your jaw and neck^[1]. The condition most commonly affects women, with about nine out of ten diagnosed patients being female, though men and children can also develop it^[2].

It is especially important to seek medical evaluation if you already have another autoimmune disease—a condition where the immune system attacks the body—such as rheumatoid arthritis or lupus. About half of all people with Sjögren’s syndrome have it alongside another autoimmune condition^[2]. Even if your symptoms seem mild at first, early diagnosis matters because proper treatment can prevent serious complications such as tooth decay, vision problems, or damage to internal organs^[2].

Most people are diagnosed between the ages of 45 and 55, though the disease can develop at any age^[1]. If your eyes feel gritty, as though sand is in them, or your mouth feels like it is full of cotton, these are strong signals to contact your doctor^[1][3].

Diagnostic Methods

Diagnosing Sjögren’s syndrome requires a combination of different tests because no single test can confirm the condition on its own. Your healthcare provider will begin with a detailed medical history and a physical examination, looking for signs such as dry mouth, dry eyes, or swollen salivary glands^[7]. The doctor will also check for signs of other diseases that commonly occur with Sjögren’s syndrome, such as rheumatoid arthritis or lupus^[7].

Blood Tests

Blood tests are a fundamental part of diagnosing Sjögren’s syndrome. Your doctor will order tests to look for specific antibodies—proteins made by the immune system—that are commonly found in people with this condition^[8]. The most common antibodies tested are anti-SSA (also called Ro) and anti-SSB (also called La)^[4][13]. A positive test for these antibodies strongly suggests Sjögren’s syndrome, though some patients test negative even when they have the disease^[4].

Other blood tests may include checking for a positive anti-nuclear antibody (ANA), which indicates autoimmune activity, and rheumatoid factor (RF), another marker of immune system dysfunction^[4][13]. Blood tests can also measure levels of different types of blood cells, check for signs of inflammation, and evaluate whether your liver or kidneys are functioning properly^[8].

Eye Tests

Because dry eyes are one of the hallmark symptoms of Sjögren’s syndrome, eye examinations play an important role in diagnosis. One common test is the Schirmer tear test, where a small piece of filter paper is placed under your lower eyelid for about five minutes to measure how much moisture your eyes produce^[8][18]. If your eyes produce very little moisture, this can indicate Sjögren’s syndrome.

An eye specialist, called an ophthalmologist, may also perform a slit lamp examination. During this test, special eye drops containing dye are placed in your eyes, and the doctor uses a magnifying device to examine the surface of your eyes for damage or dryness^[8][18]. This helps determine how severely your eyes are affected and whether there is any damage to the cornea, the clear front part of your eye.

Saliva Tests

Tests that measure saliva production help doctors understand how well your salivary glands are working. One simple test involves spitting or allowing saliva to dribble into a container for five minutes to measure the total amount produced^[6][14]. If you produce very little saliva, it may suggest that Sjögren’s syndrome is affecting your salivary glands.

Imaging Tests

Certain imaging tests can help evaluate the function and structure of your salivary glands. A sialogram is a special X-ray where dye is injected into the salivary glands in front of your ears, allowing doctors to see how much saliva flows into your mouth and whether the glands are blocked^[8][18].

Another test called salivary scintigraphy is a nuclear medicine procedure where a small amount of radioactive material is injected into a vein. A special camera then tracks how quickly this substance reaches all of your salivary glands, providing information about their function^[8][18].

In some cases, an ultrasound scan of the salivary glands may be performed. Ultrasound uses sound waves to create images and can show abnormalities in the gland structure that may suggest Sjögren’s syndrome^[6][14].

Salivary Gland Biopsy

A lip biopsy is often considered one of the most definitive tests for Sjögren’s syndrome. During this procedure, a small sliver of tissue containing minor salivary glands is removed from the inside of your lower lip and examined under a microscope^[8][18]. Doctors look for clusters of inflammatory cells, which indicate that the immune system is attacking the glands. This biopsy is particularly important when blood tests for antibodies are negative but symptoms strongly suggest Sjögren’s syndrome^[4][13].

The biopsy is usually done under local anesthesia in an outpatient setting, meaning you can go home the same day. While it may sound intimidating, it is generally a safe and straightforward procedure.

Other Tests

Your doctor may also order a urine test to check kidney function or look for signs that Sjögren’s syndrome is affecting other organs^[6][14]. Depending on your symptoms, additional specialized tests may be recommended to evaluate whether the disease has spread to your lungs, kidneys, nervous system, or other parts of your body.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or medications for Sjögren’s syndrome. To participate in a clinical trial, patients usually need to meet specific criteria that are established through standardized diagnostic tests. These criteria help researchers ensure that all participants have similar disease characteristics, which makes the study results more reliable.

For enrollment in clinical trials, doctors typically require confirmation of Sjögren’s syndrome according to established classification criteria. The most widely used are the 2016 criteria, which require evidence of an immune process demonstrated either by positive antibodies to SS-A (Ro) or a positive salivary gland biopsy^[10]. Some newer studies are also considering positive ultrasound findings as part of the diagnostic process^[10].

Blood tests for specific antibodies are often mandatory for trial participation. The presence of anti-SSA (Ro) antibodies in the blood is one of the most important markers^[10]. In patients who do not have these antibodies, a positive lip biopsy showing inflammatory cells in the salivary glands may be required instead^[4][13].

Clinical trials may also use standardized questionnaires and scoring systems to measure the severity and impact of symptoms. These tools help researchers track whether the treatment being tested is effective. Common measures include assessments of dryness severity, pain levels, fatigue, and how much the disease affects daily activities^[10].

In addition to confirming the diagnosis, clinical trials often perform additional tests to evaluate organ involvement or disease activity. These can include imaging studies, blood tests to measure inflammation, and tests of kidney or lung function, depending on the focus of the study. Some trials are specifically designed for patients with certain disease subtypes or those with involvement of particular organs^[10].

If you are interested in participating in a clinical trial, your healthcare provider can help determine whether you meet the necessary diagnostic criteria. Clinical trials offer the opportunity to access new therapies that are not yet widely available, and they contribute to advancing knowledge about Sjögren’s syndrome for future patients^[17].

Sjogren’s Syndrome

Sjogren’s syndrome is a long-term autoimmune disease where the body’s immune system attacks the glands that produce moisture, leading to widespread dryness throughout the body, especially in the eyes and mouth.

Table of contents

• What is Sjogren’s syndrome?
• What causes this condition?
• Signs and symptoms
• Who is most affected?
• How is it diagnosed?
• Treatment options
• Living with Sjogren’s syndrome
• Outlook and life expectancy

What is Sjogren’s syndrome?

Sjogren’s syndrome is a disease where your immune system (the body’s defense against germs and illness) makes a mistake and attacks your own healthy tissues instead of protecting them. This type of disease is called an autoimmune disease^[1].

In Sjogren’s syndrome, the immune system specifically targets the glands that produce moisture in your body. These include the glands that make tears for your eyes and saliva (spit) for your mouth. When these glands are damaged, they cannot produce enough moisture, which leads to dryness^[3].

The condition can affect the entire body beyond just the eyes and mouth. It may also cause problems in other organs such as the lungs, kidneys, joints, skin, and nervous system^[2].

Doctors classify Sjogren’s syndrome into two types. Primary Sjogren’s syndrome develops on its own without any other health condition causing it. Secondary Sjogren’s syndrome happens when another disease, especially another autoimmune condition, triggers it^[3].

Sjogren’s syndrome is more common than many people realize. An estimated four million Americans live with this disease, making it one of the most common autoimmune diseases^[2].

What causes this condition?

Scientists do not fully understand what causes Sjogren’s syndrome. They believe it happens due to a combination of genetic factors (traits passed down in families) and environmental triggers^[7].

Several genes appear to be involved in the development of Sjogren’s syndrome. Some researchers think that a previous infection with a virus or bacteria might trigger the condition in people who are genetically prone to developing it^[7].

For secondary Sjogren’s syndrome, other health conditions can trigger the disease. These triggers include other autoimmune diseases and some viral infections^[3].

Viral infections that have been linked to secondary Sjogren’s syndrome include hepatitis C, cytomegalovirus (a common virus in the herpes family), Epstein-Barr virus, human T-lymphotropic virus 1, and COVID-19^[3].

Autoimmune diseases that are commonly associated with Sjogren’s syndrome include rheumatoid arthritis, psoriatic arthritis, and lupus. About half of people with Sjogren’s syndrome also have another autoimmune disease^[3][4].

Signs and symptoms

The two main symptoms of Sjogren’s syndrome are dry eyes and dry mouth. However, the condition can cause many other problems throughout the body^[1].

People with dry eyes may feel like their eyes burn, itch, or feel gritty, as if there is sand in them. The eyes might turn red or be sensitive to light^[1][4].

Dry mouth can make it feel like your mouth is full of cotton. This makes it difficult to swallow or speak, especially when eating dry foods. Without enough saliva, you may have trouble tasting food properly. Dry mouth also increases the risk of tooth decay, gum disease, and infections in the mouth^[1][4].

The salivary glands (the glands that produce saliva) may become swollen, particularly the ones located behind your jaw and in front of your ears^[1][4].

Many people with Sjogren’s syndrome experience additional symptoms. These include joint pain and swelling, muscle pain or weakness, and swollen lymph nodes (small organs that are part of the immune system)^[3].

Severe tiredness, called fatigue, is very common. This is not ordinary tiredness but an overwhelming feeling of exhaustion that does not improve with rest^[2][4].

Other areas of the body can also be affected. Dryness may occur in the skin, nose, throat, and vagina. Some people develop skin rashes. You may experience a persistent dry cough, a hoarse or quiet voice, or frequent nosebleeds. Heartburn and other digestive problems can occur. Some people have difficulty thinking clearly, which is sometimes called brain fog^[3][6].

The condition affects people differently. Some individuals have mild symptoms that barely affect their daily life. Others have more severe symptoms that make everyday activities challenging^[6].

Symptoms may come and go in cycles. There may be times when symptoms get worse (called flare-ups) and times when they improve (called remission). It is not always clear why symptoms change, but things like not getting enough rest or doing too much may trigger flare-ups^[6].

Who is most affected?

Sjogren’s syndrome can affect anyone, regardless of age, race, or background. However, certain groups of people are more likely to develop this condition^[7].

Women are much more likely to have Sjogren’s syndrome than men. More than 90% of people with this condition are women. The disease is about ten times more common in women than in men^[3][4].

Most people are diagnosed between the ages of 45 and 55, though the condition can develop at any age. While children can be affected, this is less common^[3][4].

People who already have another autoimmune disease are at higher risk. Around half of people with Sjogren’s syndrome have at least one other autoimmune condition^[3].

How is it diagnosed?

Diagnosing Sjogren’s syndrome can be challenging. The symptoms are similar to those caused by other diseases, and side effects from certain medications can mimic the signs of Sjogren’s syndrome. Because of this, it may take several years to reach a proper diagnosis^[8].

A doctor will start by taking your medical history and performing a physical examination. During the exam, the doctor checks for physical signs of Sjogren’s syndrome, such as a dry mouth, and looks for signs of other related diseases^[7][8].

Several tests can help confirm the diagnosis. Blood tests check for different things, including levels of various types of blood cells, the presence of antibodies (proteins made by the immune system) that are common in Sjogren’s syndrome, evidence of inflammation, and signs of problems with your liver and kidneys^[8].

The most common antibodies found in people with Sjogren’s syndrome are called anti-SSA (also known as Ro) and anti-SSB (also known as La). Tests may also look for a positive antinuclear antibody (ANA) and rheumatoid factor^[4].

Eye tests can measure how dry your eyes are. One common test is called a Schirmer tear test, where a small piece of filter paper is placed under your lower eyelid to measure how much tears you produce. An eye doctor may also examine the surface of your eyes with a special magnifying device called a slit lamp^[8].

Tests to check your salivary glands may include measuring how much saliva you produce. For this test, you might be asked to spit or drip saliva into a container for five minutes^[6].

Special imaging tests can check how well your salivary glands are working. These might include X-rays or nuclear medicine tests that track how quickly a special substance reaches your salivary glands^[8].

Sometimes a lip biopsy is needed to confirm the diagnosis. During this procedure, a small piece of tissue containing salivary glands is removed from your lip and examined under a microscope to look for clusters of inflammatory cells^[8].

Treatment options

There is currently no cure for Sjogren’s syndrome. However, many treatments are available to help relieve symptoms and prevent complications. Treatment focuses on managing the dryness and other symptoms to improve quality of life^[1][6].

Your treatment plan should be personalized based on your specific symptoms and how they affect you. Most people will need a combination of different treatments^[9].

For dry eyes, you can use artificial tears (eye drops) throughout the day. These are available without a prescription. Some people need prescription eye drops that help increase tear production, such as cyclosporine or lifitegrast^[4][6].

For severe dry eyes, a doctor may recommend a procedure to seal the tear ducts in your eyes. This helps keep more moisture on the surface of the eye^[3].

For dry mouth, drinking water frequently throughout the day helps keep your mouth moist. Chewing sugar-free gum can help stimulate saliva production. Some people need prescription medications such as pilocarpine or cevimeline to increase saliva production^[4][6].

Good dental care is very important. You should brush your teeth two or three times a day with fluoride toothpaste, floss daily, and see your dentist every six months for check-ups^[6].

For joint and muscle pain, your doctor may recommend pain relievers such as paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are medications that reduce inflammation and pain^[6][9].

For more severe symptoms or when the disease affects internal organs, stronger medications may be needed. These might include hydroxychloroquine, corticosteroids (medications that reduce inflammation), or other drugs that suppress the immune system such as methotrexate, azathioprine, or mycophenolate^[4][6].

For life-threatening cases or severe complications, doctors may use a medication called rituximab or intravenous immunoglobulin therapy (IVIG), which involves giving antibodies through a vein^[4].

New treatments are being studied in clinical trials. These include drugs called dazodalibep, ianalumab, and nipocalimab^[4].

Living with Sjogren’s syndrome

While Sjogren’s syndrome is a chronic condition, there are many things you can do to manage your symptoms and improve your quality of life.

Staying hydrated is very important. Drink plenty of water throughout the day by taking small sips. Carry a water bottle with you so you always have water available^[6].

Using a humidifier in your home can add moisture to the air, which helps with dryness in your eyes, mouth, nose, and skin^[6].

Wearing sunglasses when you go outside can protect your eyes from wind, dust, and sun, which can make dry eyes worse. Choose sunglasses with sides that cover the area around your eyes^[6].

Eating a healthy, balanced diet is important. Include foods rich in omega-3 fatty acids, such as oily fish and walnuts. Avoid spicy, acidic, and salty foods that can irritate your dry mouth. Also avoid sugary foods and drinks, which can increase the risk of tooth decay^[6].

If you smoke, quitting is strongly recommended. Smoking can irritate your eyes and mouth and makes saliva dry up faster^[6].

Try to avoid spending long periods in smoky, dry, dusty, or windy places, or in air-conditioned or heated rooms. These environments can make dryness worse^[6].

Getting adequate rest is crucial. Listen to your body and take breaks when you need them. Try to get enough sleep each night. Dividing your day into parts and resting during one of those parts can help manage fatigue^[16].

Regular gentle exercise can help with mobility, joint problems, and overall wellbeing. However, avoid overdoing it, as too much activity can trigger symptoms^[16].

Managing stress is important. Consider techniques such as meditation or mindfulness. Talking with a mental health professional can also help^[16].

It can be helpful to connect with other people who have Sjogren’s syndrome. Consider joining a support group where you can share experiences and learn from others^[16].

Regular check-ups with your healthcare providers are essential. This includes visits to your doctor who manages your Sjogren’s syndrome (often a specialist called a rheumatologist), regular dental check-ups, and regular eye examinations^[4].

Outlook and life expectancy

Sjogren’s syndrome is a lifelong condition, but with proper treatment and self-care, most people can manage their symptoms and continue with their normal activities^[4].

The condition affects everyone differently. Some people are able to work and do their usual activities with minimal disruption. Others may find that symptoms affect their daily life more significantly. For example, severe dry mouth can make eating difficult, and dry eyes may cause vision problems. Fatigue and pain can also impact what you are able to do^[6].

Early diagnosis and proper treatment are important. They can prevent serious complications and greatly improve a person’s quality of life^[2].

Most people with Sjogren’s syndrome live into old age and have the same life expectancy as the general population. Rarely, the condition can cause serious complications, including an increased risk of a type of cancer called lymphoma^[4][6].

Regular monitoring by your healthcare team helps ensure that any complications are caught early and treated appropriately.

Living with Sjögren’s syndrome means learning how to manage persistent dryness throughout your body, but with the right combination of treatments and daily care strategies, many people continue to lead active, fulfilling lives despite this challenging autoimmune condition.

Finding Relief Through Modern Treatment Options

When someone receives a diagnosis of Sjögren’s syndrome, the first question that often comes to mind is: what can be done to feel better? The treatment journey for this condition is deeply personal, as each patient experiences different symptoms with varying levels of severity. The main goal of treatment is not to cure the disease—because currently no cure exists—but rather to help manage symptoms, prevent complications, and improve quality of life. This means working closely with healthcare providers to find a tailored plan that addresses your specific challenges, whether that’s extreme dryness, fatigue, joint pain, or organ involvement.^[1]

Treatment approaches for Sjögren’s syndrome depend heavily on which parts of your body are affected and how severe your symptoms are. Some people experience only mild discomfort and can manage with over-the-counter products and lifestyle adjustments. Others face debilitating symptoms that greatly impair their daily functioning and require prescription medications or more intensive interventions. Because Sjögren’s is a systemic disease that can affect the entire body, your healthcare team may include several specialists—a rheumatologist to coordinate overall care, an ophthalmologist for eye concerns, a dentist for oral health, and possibly others depending on which organs are involved.^[2]

The good news is that medical societies have developed standard treatment recommendations based on years of research, and at the same time, scientists continue to explore new therapies through clinical trials. This means that patients today have access to proven treatments while researchers work on developing even better options for the future.^[4]

Standard Approaches to Managing Sjögren’s Symptoms

The foundation of treating Sjögren’s syndrome starts with addressing the most common and bothersome symptom: dryness. For dry eyes, many patients begin with artificial tears—lubricating eye drops that can be purchased without a prescription. These drops temporarily replace natural tears and should be used throughout the day to prevent discomfort and protect the surface of the eye. It’s important to choose preservative-free formulations, especially if you need to use drops frequently, because preservatives can irritate already sensitive eyes.^[6]

When over-the-counter artificial tears aren’t enough, doctors may prescribe special eye drops that do more than just add moisture—they actually help your eyes produce more natural tears. Two medications commonly prescribed for this purpose are cyclosporine (brand name Restasis) and lifitegrast (brand name Xiidra). These prescription eye drops work by reducing inflammation on the surface of the eye, which allows the tear glands to function better. Patients typically need to use these drops twice daily, and it may take several weeks before you notice improvement. Some people experience a burning sensation when first using cyclosporine drops, but this side effect often lessens over time.^[4]

For dry mouth, the treatment strategy is similar—starting simple and advancing to prescription medications if needed. Sipping water throughout the day, chewing sugar-free gum, and sucking on sugar-free hard candies can all help stimulate saliva production. However, when these measures aren’t sufficient, doctors may prescribe medications that directly stimulate the salivary glands. The two main drugs used for this purpose are pilocarpine (brand name Salagen) and cevimeline (brand name Evoxac). These medications cause the salivary glands to produce more saliva by acting on certain receptors in the glands. Common side effects can include sweating, flushing, and increased need to urinate, because these drugs affect similar receptors throughout the body.^[9]

Joint pain and muscle aches are common in Sjögren’s syndrome, affecting many patients beyond the signature dryness symptoms. For these concerns, doctors often recommend nonsteroidal anti-inflammatory drugs or NSAIDs. These medications reduce inflammation and pain by blocking the production of prostaglandins—chemicals in the body that promote inflammation and cause pain. Common over-the-counter NSAIDs include aspirin, ibuprofen (Advil, Motrin), and naproxen (Aleve). Many prescription-strength NSAIDs are also available. The most common side effect is stomach upset, and in rare cases, NSAIDs can cause stomach bleeding. Taking these medications with food or milk can help reduce stomach irritation.^[9]

When Sjögren’s syndrome causes more serious systemic problems—affecting internal organs like the lungs, kidneys, or nervous system, or when joint pain and fatigue become severe—stronger medications may be necessary. Hydroxychloroquine is a medication originally developed to treat malaria but now commonly used for autoimmune conditions. It helps reduce inflammation throughout the body and may help with fatigue and joint pain. This medication must be taken daily for several months before its full benefits are seen.^[4]

For more severe cases, doctors may prescribe medications that more powerfully suppress the immune system. These include corticosteroids (such as prednisone), which quickly reduce inflammation but can have significant side effects if used long-term, including weight gain, increased blood sugar, bone thinning, and increased infection risk. Other immune-suppressing medications used in Sjögren’s include methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate (Cellcept). These medications are typically reserved for patients with serious organ involvement or symptoms that haven’t responded to other treatments.^[4]

In life-threatening cases or when major organs are severely affected, a medication called rituximab (Rituxan) may be used. This drug works by targeting and temporarily depleting certain white blood cells called B-lymphocytes, which play a role in the autoimmune attack. Rituximab is given as an intravenous infusion, meaning it’s delivered directly into a vein over several hours in a medical facility. For patients with nervous system involvement, intravenous immunoglobulin therapy (IVIG) might provide benefits. This treatment involves infusing antibodies collected from donated blood plasma to help modulate the immune system.^[4]

Patients who experience acid reflux—a common problem when you have dry mouth and reduced saliva—may benefit from medications called proton-pump inhibitors or H2 blockers. These medications reduce the amount of acid your stomach produces, helping prevent damage to the esophagus and reducing that unpleasant burning sensation.^[4]

Standard treatment typically continues for years, often for a patient’s entire life. The duration and intensity of treatment depend on how active the disease is and which symptoms are most troublesome. Regular monitoring by healthcare providers is essential to assess whether treatments are working, to watch for side effects, and to adjust the treatment plan as needed over time.^[2]

Promising New Therapies Being Tested in Clinical Trials

While standard treatments help many people with Sjögren’s syndrome manage their symptoms, researchers recognize that current options don’t work for everyone and that better therapies are needed. This has led to growing interest from pharmaceutical companies and research institutions in developing new treatments specifically for this condition. Clinical trials are research studies that test new drugs or therapies to determine whether they are safe and effective. These trials represent hope for patients who haven’t found adequate relief with existing treatments.^[10]

Clinical trials typically progress through several phases. Phase I trials focus primarily on safety—researchers want to know if the new treatment causes harmful side effects and what dose is appropriate. These studies usually involve small numbers of participants. Phase II trials expand to larger groups and focus on whether the treatment actually works—does it improve symptoms or slow disease progression? Phase III trials compare the new treatment directly against current standard treatments to see if the new option is better, equally effective, or perhaps causes fewer side effects. Only after successfully completing these phases can a new drug be approved by regulatory agencies like the FDA in the United States or similar bodies in other countries.^[10]

Several innovative therapies are currently being evaluated in Phase II and Phase III clinical trials for Sjögren’s syndrome. One promising drug is called dazodalibep. This medication works by targeting a specific molecular pathway that drives inflammation in autoimmune diseases. Dazodalibep blocks the interaction between two proteins—CD40 and CD40 ligand—that normally work together to activate immune cells. By interrupting this communication, the drug aims to reduce the immune system’s attack on moisture-producing glands. Early trial results have shown that patients taking dazodalibep experienced improvements in clinical parameters measuring disease activity, with a favorable safety profile reported in preliminary findings.^[4]

Another drug being tested is ianalumab, which represents a different approach to calming the overactive immune system. This medication is a type of monoclonal antibody—a laboratory-made protein designed to attach to specific targets on immune cells. Ianalumab targets a receptor called B-cell activating factor receptor (BAFF-R) found on B-cells, a type of white blood cell that produces antibodies. In Sjögren’s syndrome, B-cells play a significant role in the autoimmune attack. By blocking BAFF-R, ianalumab depletes these problematic B-cells, potentially reducing inflammation and symptoms. This drug is administered as an injection and has shown encouraging results in clinical studies.^[4]

A third experimental treatment is nipocalimab, another monoclonal antibody that works through yet another mechanism. This drug targets the neonatal Fc receptor (FcRn), which is involved in prolonging the life of antibodies in the bloodstream. By blocking this receptor, nipocalimab helps clear harmful autoantibodies—the antibodies that mistakenly attack the body’s own tissues—from the circulation more quickly. This approach could potentially reduce the autoimmune damage that causes Sjögren’s symptoms. Clinical trials are evaluating whether this mechanism translates into real benefits for patients.^[4]

These clinical trials are being conducted at medical centers throughout the United States, Europe, and other regions around the world. Eligibility to participate varies depending on the specific study but generally includes adults with a confirmed diagnosis of Sjögren’s syndrome who meet certain criteria regarding disease severity and symptoms. Some trials specifically seek patients who haven’t responded well to standard treatments, while others may be open to people with different levels of disease activity. Participation in a clinical trial is voluntary and involves careful monitoring by the research team. Patients receive the investigational treatment at no cost and often receive compensation for their time and travel.^[10]

Beyond these specific drugs, researchers are also exploring other innovative approaches. Some studies are investigating whether targeting different inflammatory pathways or using combination therapies might be more effective than single-drug treatments. The heterogeneity of Sjögren’s syndrome—meaning that patients have very different patterns of symptoms and disease involvement—has led scientists to consider whether clustering patients into biologically similar subgroups could improve treatment outcomes. This personalized medicine approach might allow doctors to predict which patients will respond best to which treatments.^[10]

While these new therapies are promising, it’s important to maintain realistic expectations. Not every drug that enters clinical trials proves to be effective, and even successful drugs may only work for a subset of patients. The clinical trial process typically takes many years from initial testing to final approval, so these investigational treatments may not be widely available for some time. However, the fact that multiple pharmaceutical companies are now investing in Sjögren’s syndrome research represents a significant shift—this disease, which has historically received less attention than some other autoimmune conditions, is finally getting the research focus it deserves.^[10]

Most common treatment methods

• Moisture replacement therapies
  • Preservative-free artificial tears for dry eyes used throughout the day
  • Eye gels and ointments for nighttime use
  • Saliva substitutes in spray, gel, or lozenge form for dry mouth
  • Oral moisturizers and specialized mouthwashes
  • Vaginal moisturizers for dryness
• Prescription medications to stimulate gland function
  • Cyclosporine (Restasis) eye drops to increase tear production by reducing eye inflammation
  • Lifitegrast (Xiidra) eye drops to increase tear production
  • Pilocarpine (Salagen) to stimulate saliva and tear production
  • Cevimeline (Evoxac) to increase saliva production
• Anti-inflammatory medications
  • Over-the-counter NSAIDs like ibuprofen (Advil, Motrin) and naproxen (Aleve) for joint pain
  • Prescription-strength NSAIDs for more severe inflammation
  • Hydroxychloroquine for systemic inflammation and joint symptoms
• Immune-suppressing medications
  • Short-term corticosteroids (prednisone) for severe joint pain or flares
  • Methotrexate (Rheumatrex) for patients with significant systemic involvement
  • Azathioprine (Imuran) to suppress immune system activity
  • Mycophenolate (Cellcept) for organ involvement
  • Rituximab (Rituxan) for life-threatening cases with major organ damage
• Supportive therapies
  • Proton-pump inhibitors or H2 blockers for acid reflux and heartburn
  • Intravenous immunoglobulin therapy (IVIG) for nervous system involvement
  • Moisturizing skin creams and emollients for dry skin
• Investigational treatments in clinical trials
  • Dazodalibep targeting CD40-CD40 ligand pathway to reduce immune activation
  • Ianalumab depleting B-cells by targeting BAFF-R receptor
  • Nipocalimab clearing harmful autoantibodies by blocking FcRn receptor

Sjogren’s syndrome is a long-term autoimmune condition that primarily causes dryness throughout the body, especially in the eyes and mouth, but can affect many other parts of your life in ways you might not expect.

Understanding the Long-Term Outlook

When you receive a diagnosis of Sjogren’s syndrome, one of the first questions that may come to mind is what the future holds. The prognosis for people living with Sjogren’s syndrome varies greatly from person to person, which can make it challenging to predict exactly how the condition will affect you over time^[2]. This uncertainty is a normal part of living with an autoimmune disease, and understanding what might lie ahead can help you prepare emotionally and practically.

Most people with Sjogren’s syndrome live into old age and have the same life expectancy as the general population^[6][14]. This is reassuring news that highlights how, with proper management, Sjogren’s syndrome does not necessarily shorten your lifespan. However, the quality of life and daily functioning can vary significantly. Some people experience only mild discomfort with dry eyes and mouth, while others face more debilitating symptoms that greatly impair their ability to function in everyday activities^[2].

The disease does not follow a single, predictable pattern. There is no one standard progression that applies to everyone^[2]. Symptoms may remain relatively steady over the years, or they may worsen over time. Some people experience periods when symptoms flare up and become more severe, followed by times of remission when symptoms improve or become less bothersome^[6][14]. It is thought that certain triggers, such as overdoing activities and not getting enough rest, may provoke these flare-ups, though the exact reasons are not fully understood^[6][14].

Early diagnosis and appropriate treatment are important factors that can help prevent serious complications and greatly improve your quality of life^[2]. Working closely with your healthcare team, particularly a rheumatologist (a doctor who specializes in autoimmune and joint diseases), gives you the best chance of managing symptoms effectively and monitoring for any changes that might require adjustments in your care.

How the Disease Develops Without Treatment

If Sjogren’s syndrome is left untreated, the natural course of the disease involves ongoing inflammation and damage to the glands that produce moisture. The immune system continues to mistakenly attack the tear glands in your eyes and the salivary glands (glands that produce saliva) in your mouth^[1][7]. Over time, this immune attack causes scarring in these glands, which leads to a marked reduction in tear and saliva production^[5].

Without adequate tears, your eyes may become increasingly uncomfortable and vulnerable to damage. The lack of moisture makes the surface of the eye, especially the cornea (the clear front part of the eye), more prone to injury and infection^[7]. Similarly, without enough saliva to wash away bacteria and food particles, your mouth becomes a breeding ground for dental problems. The chronic dryness in your mouth can lead to rapid tooth decay, cavities, gum disease, mouth infections including fungal infections like thrush (a yeast infection in the mouth), and even tooth loss^[7][4].

Saliva plays a vital role in helping you chew and swallow food. When saliva production decreases significantly, you may find it increasingly difficult to eat, especially dry foods, and swallowing can become painful or challenging^[1][7]. This can affect your nutrition and overall wellbeing. Your sense of taste may also be altered, making meals less enjoyable^[3].

Beyond the eyes and mouth, Sjogren’s syndrome is a systemic disease, meaning it can affect the entire body^[2][5]. If the condition progresses without intervention, up to half of affected individuals may develop what is called extraglandular involvement, which means the disease begins to affect organs and tissues beyond the moisture-producing glands^[2][5]. This can include the joints, skin, lungs, kidneys, blood vessels, liver, pancreas, and the nervous system^[1][2][3].

The chronic inflammation that characterizes Sjogren’s syndrome can lead to persistent fatigue, widespread pain, and other systemic symptoms that worsen over time if not addressed^[2]. Without treatment, these progressive changes can significantly diminish your ability to carry out daily activities and enjoy life.

Possible Complications

While many people with Sjogren’s syndrome experience manageable symptoms, there are a number of potential complications that can arise, some of which can be serious. Understanding these risks helps you and your healthcare providers stay vigilant and address problems early.

One of the most concerning complications is damage to your eyes. Because of the chronic dryness and lack of protective tears, the cornea can become damaged over time. This damage may lead to vision problems or, in severe cases, vision loss^[7]. Eye infections are also more common when the eyes do not produce enough tears to wash away bacteria and other irritants^[4].

Your mouth is also at risk for several complications. The lack of saliva increases the likelihood of severe tooth decay, gum disease, poorly fitting dentures, and the formation of salivary gland stones (hard deposits that can block the ducts where saliva flows)^[7]. Infections of the salivary glands can occur, leading to pain and swelling in your cheeks, neck, or under your jaw^[4]. Oral fungal infections like thrush become more common, and mouth sores may develop^[7].

Difficulty swallowing and eating can lead to weight loss and malnutrition if not properly managed^[7]. This is particularly important to watch for, as good nutrition is essential for maintaining energy and overall health.

Sjogren’s syndrome can affect internal organs in ways that are less visible but equally significant. The lungs may become inflamed, leading to conditions such as interstitial lung disease (scarring and inflammation of the lung tissue), which can cause shortness of breath and chronic cough^[3][4]. The kidneys may also be affected, potentially impacting their ability to filter waste from your blood^[3][5].

The nervous system can be involved as well, leading to neuropathy (nerve damage that causes numbness, tingling, or pain, often in the hands and feet)^[2][3][4]. Some people experience problems with the gastrointestinal tract, blood vessels, liver, or pancreas^[3][4][5].

Vaginal dryness is another complication that can affect women with Sjogren’s syndrome. This can lead to discomfort, pain during sexual activity, and an increased risk of vaginal yeast infections^[1][4].

Because Sjogren’s syndrome often occurs alongside other autoimmune diseases such as rheumatoid arthritis (a condition that causes joint inflammation and pain) or lupus (a disease where the immune system attacks many parts of the body), complications from these overlapping conditions can add further challenges^[1][3][5].

Impact on Daily Life

Living with Sjogren’s syndrome affects more than just your physical health. The condition can have a profound impact on nearly every aspect of your daily life, from the moment you wake up to the time you go to bed.

Physically, the constant dryness in your eyes and mouth can be uncomfortable and distracting. Your eyes may burn, itch, or feel as if there is sand in them, making it difficult to read, watch television, or use a computer for long periods^[1][6][14]. The dryness may worsen in certain environments, such as air-conditioned rooms, heated spaces, or places with a lot of wind or dust^[6][14]. This can limit where you feel comfortable spending time and may require you to make adjustments, such as using a humidifier at home or wearing wraparound sunglasses when outdoors.

Dry mouth can make speaking, chewing, and swallowing challenging^[1][4]. Your mouth might feel like it is full of cotton, which can be frustrating during meals or conversations^[1]. You may need to carry a water bottle with you at all times and take frequent sips to keep your mouth moist^[16][21]. Eating dry foods, such as crackers or bread, may become difficult, and you might find yourself needing to choose softer, moister foods^[6][14][20].

Joint and muscle pain, along with profound fatigue, are common symptoms that can be particularly limiting^{[1][2][4][6][14]}. Many people with Sjogren’s syndrome describe feeling tired all the time, no matter how much rest they get. This chronic fatigue can make it hard to keep up with work, household responsibilities, and social activities. You may need to adjust your daily routine, taking more breaks and pacing yourself throughout the day to conserve energy^[21].

Emotionally, living with a chronic illness like Sjogren’s syndrome can be draining. The unpredictability of symptoms and the challenges of managing a condition that others may not understand can lead to feelings of frustration, anxiety, or sadness. Some people experience periods of low mood or depression as they cope with the limitations the disease imposes.

Socially, the symptoms of Sjogren’s syndrome can affect your interactions with others. Dry mouth and difficulty speaking may make you self-conscious in conversations. Fatigue and pain might lead you to decline invitations to social events or gatherings, which can result in feelings of isolation. You may also find that friends or family members do not fully grasp the impact of your symptoms, since dryness and fatigue are “invisible” problems that are not always obvious to others.

In the workplace, Sjogren’s syndrome can present unique challenges. Depending on the severity of your symptoms, you may need accommodations such as flexible working hours, additional breaks to rest or use eye drops, or adjustments to your work environment to reduce exposure to dry or dusty conditions^[16]. Some people find that their ability to concentrate is affected by brain fog, which can make tasks that require focus more difficult^[3].

Hobbies and leisure activities may also be impacted. Activities that require prolonged visual attention, such as reading or crafting, can be harder to enjoy when your eyes are dry and uncomfortable. Physical hobbies may be limited by joint pain and fatigue. However, with proper symptom management and adjustments, many people are able to continue doing the things they love.

There are coping strategies that can help you manage the limitations Sjogren’s syndrome imposes. Maintaining a daily routine is more important than ever, as the condition requires a great deal of self-care throughout the day^[21]. Prioritizing rest, eating a healthy and balanced diet, managing stress, and engaging in regular gentle exercise are all important pillars of living well with this disease^[6][14][21]. Some people find that meditation, mindfulness, or other relaxation techniques help reduce anxiety and improve their overall sense of wellbeing^[21].

Connecting with other people who have Sjogren’s syndrome can be incredibly healing. Joining a support group, either in person or online, allows you to share experiences, learn from others, and feel less alone^[16][21]. Hearing how others cope with similar challenges can provide both practical tips and emotional support.

Support for Family and Friends

If someone you love has Sjogren’s syndrome, you may be wondering how you can best support them, especially when it comes to navigating clinical trials and finding the right treatments.

Clinical trials are research studies that test new treatments or therapies to see if they are safe and effective. For people with Sjogren’s syndrome, participating in a clinical trial can provide access to cutting-edge treatments that are not yet available to the general public. However, understanding clinical trials and deciding whether to participate can be overwhelming for patients. This is where family members can play a vital role.

First, it is important for family members to educate themselves about Sjogren’s syndrome. Learning about the symptoms, progression, and treatment options helps you understand what your loved one is going through and why clinical trials might be an option worth considering. The Sjogren’s Foundation and other reputable organizations provide resources specifically designed for family and friends^[16][17].

When it comes to clinical trials, you can help by assisting your loved one in researching available studies. Many trials are listed on websites dedicated to clinical research, and some are specific to Sjogren’s syndrome. Reading through the eligibility criteria, understanding what the trial involves, and discussing the potential benefits and risks together can make the decision-making process less daunting.

Encourage your loved one to discuss any clinical trial they are considering with their rheumatologist or healthcare team. Doctors can provide valuable insight into whether a particular trial is appropriate and how it fits into the overall treatment plan. Family members can attend these appointments, take notes, and help ask important questions that the patient might not think of in the moment.

If your loved one decides to participate in a clinical trial, your support becomes even more important. Clinical trials often require multiple visits, tests, and close monitoring. Offering to drive them to appointments, keeping track of schedules, and providing emotional encouragement can make a significant difference. Some trials may involve new medications or treatments with unknown side effects, so being present and attentive to any changes in symptoms or wellbeing is crucial.

It is also important to respect your loved one’s autonomy and decisions. While you can offer support and information, ultimately, the decision to participate in a clinical trial is theirs to make. Being understanding and supportive, regardless of their choice, is what matters most.

Beyond clinical trials, family members can assist in other practical ways. Help with daily tasks that may be more difficult due to fatigue or pain, such as grocery shopping, meal preparation, or household chores. Encourage your loved one to follow their treatment plan, take medications as prescribed, and attend regular medical appointments. Sometimes, simply listening and validating their feelings can be the most powerful form of support.

Family members should also be aware that Sjogren’s syndrome is often an “invisible” illness. Your loved one may look fine on the outside, but they may be struggling with significant discomfort, fatigue, or pain. Be patient and understanding, even on days when they seem unable to do things they could do before. Avoid making judgments or comparisons, and recognize that chronic illness requires ongoing adjustment and resilience.

Finally, encourage your loved one to connect with support groups and patient communities. Knowing they are not alone and that others understand their experience can be incredibly comforting. You can help by researching local or online support groups and accompanying them if they feel nervous about attending for the first time^[16][17].

Ongoing Clinical Trials for Sjögren’s Syndrome

Sjögren’s syndrome is an autoimmune condition where the body’s immune system attacks moisture-producing glands, leading to symptoms like dry eyes and dry mouth. Currently, there are 19 ongoing clinical trials testing new treatments to help manage this condition and improve quality of life for patients. (Also known as: Sjögren’s Disease, Primary Sjögren’s Syndrome, Sjogren’s Syndrome)

Clinical trial locations

• Austria
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Belgium
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Safety Study of Efgartigimod in Adults with Primary Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Bulgaria
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Czechia
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease
  • Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Denmark
  • Study on the Effectiveness of CL-AD-MSC-002 Injections for Dry Mouth in Patients with Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
• Estonia
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
• Finland
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
• France
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome
  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
  • See more trials
• Germany
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections
  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • See more trials
• Greece
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections
  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Hungary
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Safety Study of Efgartigimod in Adults with Primary Sjögren’s Syndrome
  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Ireland
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
• Italy
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Lithuania
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Netherlands
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on Anifrolumab for Patients with Primary Sjogren’s Syndrome
  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome
  • Study on Leflunomide and Hydroxychloroquine for Patients with Primary Sjögren’s Syndrome
  • Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease
• Norway
  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome
• Poland
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections
  • Safety Study of Efgartigimod in Adults with Primary Sjögren’s Syndrome
  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • See more trials
• Portugal
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Romania
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Slovakia
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome
• Spain
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease
  • Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren’s Disease
  • Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease
  • Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections
  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome
  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease
  • See more trials
• Sweden
  • Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome
  • Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome
  • Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome
  • Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome
  • Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren’s Syndrome

This trial is testing a medication called deucravacitinib in adults who have active symptoms of the condition. Deucravacitinib is a pill that works by blocking specific pathways in the immune system that cause inflammation.

Who can participate: Adults aged 18 or older who have been diagnosed according to 2016 medical criteria, with moderate to severe disease activity measured by a score called ESSDAI of 5 or higher. Participants must test positive for anti-SSA/Ro antibody and have had symptoms for 10 years or less. They also need to have a minimum level of saliva production.

Who cannot participate: People with other serious health conditions that could interfere with the study, those who are pregnant or breastfeeding, individuals with recent infections requiring antibiotics, those who received live vaccines recently, people with a history of cancer in the past five years (except certain skin cancers), and those with substance abuse issues.

What the trial involves: Participants will be randomly assigned to receive either deucravacitinib at doses of 3 mg or 6 mg, or a placebo. The trial lasts about one year, with regular check-ups to monitor health and symptom changes. The main goal is to see if there is improvement in disease activity after 52 weeks of treatment.

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren’s Syndrome

This study examines efgartigimod, a medication given as an injection under the skin. The trial compares efgartigimod with a placebo to see how it affects disease activity and symptoms.

Who can participate: Adults aged 18 or older with a diagnosis meeting 2016 ACR/EULAR criteria, a disease activity score (clinESSDAI) of 6 or higher, positive anti-Ro/SS-A antibodies, and a minimum saliva production level of at least 0.01 mL/min.

Who cannot participate: People with other autoimmune diseases besides primary Sjögren’s, those with recent or current infections, individuals who received investigational drugs recently, people with severe allergies to medications, pregnant or breastfeeding women, those with cancer history in the past 5 years (except certain skin cancers), people with drug or alcohol abuse history, and those who cannot follow study procedures.

What the trial involves: Participants receive either efgartigimod or placebo through subcutaneous injections over 48 weeks. Regular visits monitor disease activity and any side effects. The study includes an open-label extension phase where all participants may receive the active medication.

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren’s Disease

This trial investigates nipocalimab, a medication given as an injection under the skin, compared to a placebo. Nipocalimab targets specific proteins in the immune system that contribute to inflammation.

Who can participate: Adults who are medically stable based on physical exam and lab tests, with a diagnosis according to 2016 criteria, positive for Ro/SSA antibodies, and a disease activity score (Total ClinESSDAI) of 5 or higher. Women of childbearing potential must have negative pregnancy tests.

Who cannot participate: People with other serious health conditions that could interfere, those participating in another clinical trial, individuals with recent infections requiring treatment, people with severe allergic reactions history, pregnant or breastfeeding women, those with drug or alcohol abuse history, people who received investigational drugs recently, those with cancer history in the past 5 years (except certain skin cancers), individuals with uncontrolled medical conditions, and those with certain other autoimmune diseases.

What the trial involves: Participants receive either nipocalimab or placebo subcutaneously over 48 weeks. Regular monitoring assesses disease activity changes, with the primary goal of observing improvement in the ClinESSDAI score from baseline to week 48.

Study on the Effectiveness of CL-AD-MSC-002 Injections for Dry Mouth in Patients with Sjögren’s Syndrome

This trial in Denmark tests a special cell therapy using adipose-derived mesenchymal stem cells. These cells are injected directly into the salivary glands to see if they can help improve saliva production and reduce dry mouth symptoms.

Who can participate: Adults over 18 years old diagnosed with primary Sjögren’s Syndrome according to 2016 ACR-EULAR criteria, who have dry mouth and a saliva flow rate between 0.05 ml/min and 3.0 ml/min, and can provide informed consent.

Who cannot participate: People without a confirmed diagnosis, those outside the specified age range, individuals in certain clinical trial groups not included in this study, and vulnerable populations.

What the trial involves: Participants receive an injection in the submandibular glands containing either stem cells or a placebo (sterile saline). The study monitors saliva flow rate over four months to determine treatment effectiveness.

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren’s Disease

This trial studies a new cell therapy called rapcabtagene autoleucel (YTB323) for people with severe, hard-to-treat disease. The treatment uses specially modified immune cells to target the disease, combined with other medications.

Who can participate: Adults aged 18-65 who provide informed consent. For those with severe, refractory disease with organ involvement, they must have a diagnosis according to specific criteria and show moderate to high disease activity despite previous treatments.

Who cannot participate: Those with severe organ-involving disease that is refractory to treatment, as this particular group cannot participate in this study phase.

What the trial involves: Participants receive preparatory medications (fludarabine and cyclophosphamide) followed by the cell therapy rapcabtagene autoleucel and other medications including tocilizumab. The study monitors safety and cellular behavior throughout the treatment period.

Title: Study of Sibeprenlimab Treatment for Adults with Sjögren’s Disease Using Subcutaneous Injections

This study evaluates sibeprenlimab (VIS649) given as injections under the skin, compared to placebo, in addition to patients’ regular treatments. The goal is to reduce disease activity after 28 weeks.

Who can participate: Adults aged 18-75 who meet 2016 ACR/EULAR criteria, test positive for anti-Ro antibodies, have an ESSDAI score of 5 or more, salivary flow rate of at least 0.05 mL per minute, and blood IgG levels above 900 mg/dL. Patients may continue stable doses of certain background medications like hydroxychloroquine, methotrexate, leflunomide, or azathioprine.

Who cannot participate: People under 18, those with active tuberculosis, history of lymphoma or other cancers in the past 5 years, severe or uncontrolled infections, pregnant or breastfeeding women, those with significant heart/liver/kidney disease, recent live vaccinations, treatment with experimental medications within 3 months, known allergies to similar medications, uncontrolled diabetes, active hepatitis B or C, HIV infection, severe mental health conditions, or drug/alcohol abuse within the past year.

What the trial involves: Participants receive subcutaneous injections of sibeprenlimab or placebo for 28 weeks, with regular monitoring of disease activity, tear and saliva production, fatigue levels, and overall symptoms. Maximum single dose is 400 mg.

Study of AlloNK and rituximab with cyclophosphamide and fludarabine in adults with relapsing rheumatoid arthritis, inflammatory myopathies, systemic sclerosis, or Sjögren’s disease

This trial tests a combination of AlloNK (natural killer cells from cord blood) with rituximab in patients whose conditions have not responded well to standard treatments. Before the main treatment, patients receive cyclophosphamide and fludarabine to prepare the immune system.

Who can participate: Adults 18 or older with adequate lung function (DLCO ≥60%, FVC ≥70%), heart function (LVEF ≥45%), acceptable blood counts and organ function. For those with this condition specifically, they must meet diagnostic criteria, have active disease symptoms, and adequate saliva production. Must use effective contraception during the trial and for 1 year after treatment.

Who cannot participate: Those with allergic reactions to rituximab, active or chronic infections (hepatitis B, hepatitis C, HIV, tuberculosis), severe heart conditions or uncontrolled high blood pressure, active cancer or history in past 5 years (except certain skin cancers), pregnant or breastfeeding women, severe kidney or liver problems, mental health conditions affecting informed consent, participation in other trials within 30 days, live vaccines within 4 weeks, substance abuse or alcohol dependency within the past year, certain blood disorders, or major surgery recently.

What the trial involves: Treatment begins with lymphodepletion using fludarabine and cyclophosphamide, followed by AlloNK cells and rituximab through intravenous infusion. Regular monitoring up to 52 weeks includes disease activity measurements specific to each condition, safety assessments, physical examinations, blood tests, heart monitoring, and tracking of side effects.

Safety Study of Efgartigimod in Adults with Primary Sjögren’s Syndrome

This long-term safety study is for patients who have completed previous studies with efgartigimod. It evaluates the medication’s safety over 48 weeks of continued treatment.

Who can participate: Adults at least 18 years old (or legal age of consent) with a diagnosis according to 2016 criteria who have completed qualifying studies with efgartigimod and can provide informed consent. Women of childbearing potential must have negative pregnancy tests.

Who cannot participate: Those with other serious health conditions that could interfere, people currently in another clinical trial, individuals with recent infections requiring antibiotics, those with severe allergic reaction history, pregnant or breastfeeding women, people with drug or alcohol abuse history, those who received certain medications affecting study results, individuals with cancer history in the past 5 years (except certain skin cancers), people with heart problems, and those who had major surgery within 3 months.

What the trial involves: Participants receive efgartigimod through intravenous infusion over 48 weeks. Regular assessments monitor for adverse events, changes in laboratory results, vital signs, and ECG results. The study evaluates improvements in disease activity scores (ESSDAI and clinESSDAI) at weeks 24 and 48.

Study on Anifrolumab for Patients with Primary Sjogren’s Syndrome

This trial in the Netherlands tests anifrolumab (MEDI-546) given as an intravenous infusion compared to placebo over 24 weeks. The medication works by blocking specific proteins in the immune system involved in inflammation.

Who can participate: Adults aged 18 or older with disease duration of 10 years or less (15 years if started in childhood with remaining gland function), meeting 2016 ACR-EULAR criteria, with anti-SSA antibodies, ESSDAI score of 5 or more and/or ESSPRI score of 5 or more. At least half of participants need ESSDAI score of 5 or more. Must be willing to have parotid gland biopsies and use reliable contraception. Need COVID-19 vaccination (at least two doses) or recovery from confirmed infection with vaccination or positive antibodies.

Who cannot participate: Those with a different condition, outside the specified age range, unable to follow study procedures, with other serious health issues that might interfere, pregnant or breastfeeding women, currently in another clinical trial, those who had recent major surgery or planning one during the study, individuals with substance abuse or alcohol dependency history, and those who received certain medications or treatments affecting study results.

What the trial involves: Participants receive anifrolumab or placebo through intravenous infusion over 24 weeks, with visits at weeks 0, 4, 8, 12, 16, 20, and 24. The study includes parotid gland biopsies at baseline and week 24, measuring various outcomes including the Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS) as the primary outcome at week 24.

Study on Hydroxychloroquine, Leflunomide, and Mycophenolate Mofetil for Patients with Primary Sjogren’s Syndrome

This 24-week study tests combinations of commonly used medications: hydroxychloroquine with leflunomide, or hydroxychloroquine with mycophenolate mofetil, compared to placebo. These medications are taken as oral tablets.

Who can participate: Adults over 18 years old with a diagnosis according to ACR/EULAR 2016 or AECG 2002 criteria who can provide written informed consent and use highly reliable contraception. Women must have negative pregnancy tests. For Cohort 1: ESSPRI score of 5 or more with low systemic disease activity. For Cohort 2: ESSDAI score of 5 or more with moderate to high systemic disease activity.

Who cannot participate: Pregnant or breastfeeding women, those with severe allergic reactions to study medications, people with other autoimmune diseases, individuals with recent infections requiring antibiotics or antivirals, those with significant liver or kidney problems, people currently using medications interfering with study drugs, individuals with cancer history within five years (except certain skin cancers), those with uncontrolled high blood pressure, people who had recent heart attack or stroke, and those with drug or alcohol abuse history within the past year.

What the trial involves: After providing informed consent and confirming eligibility, participants are randomly assigned to receive hydroxychloroquine combined with either mycophenolate mofetil or leflunomide, taken as film-coated tablets. Regular monitoring assesses treatment response, with the goal of determining improvement proportion by week 24.

Summary

The 19 ongoing clinical trials for Sjögren’s syndrome span across Europe, with notable concentrations in countries like France, Germany, Poland, and Spain. These trials reflect a strong international effort to find better treatments for this challenging autoimmune condition.

Several medications appear in multiple trials, indicating they are considered promising candidates. Ianalumab is being tested in at least four separate studies, suggesting significant interest in this treatment approach. Efgartigimod appears in three trials, including a long-term safety extension study. Other medications being investigated include deucravacitinib, nipocalimab, sibeprenlimab, anifrolumab, and abiprubart, each representing different approaches to managing the immune system dysfunction underlying the condition.

The trials employ various treatment approaches. Most test biological medications given by injection, either under the skin or into a vein. Some studies examine combinations of established oral medications like hydroxychloroquine, leflunomide, and mycophenolate mofetil. One innovative trial in Denmark tests stem cell therapy injected directly into salivary glands to restore function.

Trial duration varies from 24 weeks to over a year, with some including long-term extension phases lasting several years. Most studies measure success using standardized scores like ESSDAI (disease activity) and ESSPRI (patient-reported symptoms), allowing consistent comparison of results across different treatments.

Participation requirements are generally similar across trials: adults typically aged 18-75 with confirmed diagnosis, positive specific antibody tests, minimum disease activity levels, and some remaining gland function. Common exclusions include pregnancy, recent infections, other serious health conditions, and recent participation in other trials.

These diverse approaches reflect the complexity of treating Sjögren’s syndrome and the medical community’s commitment to developing more effective therapies to improve patients’ quality of life.

Stargardt’s Disease

Stargardt’s disease is a rare genetic eye condition that causes progressive vision loss, usually beginning in childhood or adolescence. It affects about 1 in 10,000 people and is the most common form of inherited juvenile macular degeneration.

Table of contents

• What is Stargardt’s disease?
• Other names for the condition
• Affected parts of the eye
• Symptoms
• Causes and inheritance
• Diagnosis
• Disease stages
• Treatment and management
• Current research
• Living with Stargardt’s disease

What is Stargardt’s disease?

Stargardt’s disease is a genetic eye disorder that causes the gradual breakdown of cells in the central part of the retina called the macula (the small area of the retina responsible for sharp, central vision)^[1]. This is why healthcare providers sometimes call it juvenile macular degeneration or juvenile macular dystrophy^[2].

The disease happens when a fatty yellow substance called lipofuscin (a waste product left over from normal cell activity) builds up abnormally in the retina^[4]. Over time, this buildup damages special cells called photoreceptors (cells in the retina that convert light into signals the brain can process), particularly the cone cells that help you see fine details and colors^[2].

Stargardt’s disease typically develops during childhood or adolescence, with many people first noticing symptoms between ages 6 and 12^[3]. However, some people don’t experience vision problems until later in life. There is a late-onset form of the disease that can begin in adulthood^[3].

The condition affects about 30,000 people in the United States and approximately 1 in 10,000 individuals worldwide^[3][4]. It affects both males and females equally^[3].

Stargardt disease, Stargardt dystrophy, fundus flavimaculatus, juvenile macular degeneration, juvenile macular dystrophy

Other names for the condition

Stargardt’s disease is also known by several other names. The condition is sometimes called fundus flavimaculatus, especially when it affects the edges of the retina beyond just the central macula^[2][3].

Affected parts of the eye

• Macula
• Retina
• Retinal pigment epithelium (RPE)
• Photoreceptor cells (cone cells)

The disease primarily affects the macula, which is part of the retina responsible for central vision needed for detailed tasks such as reading, writing, and recognizing faces^[7]. The retinal pigment epithelium (a layer of cells that supports the photoreceptors) is also affected by the accumulation of lipofuscin^[3][4].

While Stargardt’s disease usually affects central vision only, some people may also experience changes to their side vision as the condition progresses^[1][2].

Symptoms

The most common symptom of Stargardt’s disease is a slow, progressive loss of central vision in both eyes^[1]. In the early stages, vision may be near normal, which can sometimes delay diagnosis^[7]. As the condition progresses, symptoms become more noticeable.

Common symptoms include^[1][2][3]:

• Gray, black, or hazy spots in the center of vision (blind spots or cloudy areas)
• Blurry or distorted vision
• Difficulty reading or seeing in dim light
• Sensitivity to light (finding bright light uncomfortable)
• Difficulty adapting when moving between bright and dark places, such as entering a darkened room or going outside at dusk
• Changes in color vision or new color blindness
• Worsened night vision

Children often first notice difficulty reading or adapting from dark to light environments^[3]. The rate at which vision is lost varies for each person. Some people lose their central vision more quickly than others^[1][7].

Eventually, most people with Stargardt’s disease have 20/200 to 20/400 vision, which cannot be corrected with prescription eyeglasses, contact lenses, or refractive surgery^[7]. However, in the vast majority of cases, people do not lose all their sight^[3]. Peripheral vision is usually preserved, allowing people to maintain some independence^[3].

Causes and inheritance

Stargardt’s disease is a genetic condition caused by changes in specific genes. Most commonly, the disease is caused by mutations in a gene called ABCA4^[1][2]. This gene provides instructions for making a protein that helps the body process vitamin A in the retina.

The body uses vitamin A to make molecules in the photoreceptor cells that enable vision. After these molecules are used, they break down into fatty waste products. The protein made by the ABCA4 gene normally helps clean up these waste materials^[1]. When the ABCA4 gene doesn’t work properly, the fatty material (lipofuscin) builds up in yellowish clumps on the macula. Over time, this buildup kills the light-sensitive cells and destroys central vision^[1].

A less common form of Stargardt’s disease is caused by changes in another gene called ELOVL4^[3].

Stargardt’s disease is most often inherited in an autosomal recessive pattern^[2][3][7]. This means that both biological parents must carry one copy of the changed gene for their child to develop the disease. Parents who are carriers (having one normal gene and one changed gene) typically do not have symptoms themselves^[3].

When two carriers have children, each child has a 25 percent (1 in 4) chance of inheriting two copies of the changed gene (one from each parent) and developing Stargardt’s disease^[3][7]. This chance is the same for each child, regardless of whether they are male or female, and regardless of birth order^[3].

The less common form caused by ELOVL4 gene changes has a dominant inheritance pattern, meaning only one changed gene from one parent is needed for the disease to develop^[3].

Diagnosis

An eye doctor can check for Stargardt’s disease through a comprehensive eye examination. The process typically begins with a dilated eye exam, which is simple and painless^[1]. The doctor gives you eye drops to dilate (widen) your pupils and then examines the back of your eye for signs of Stargardt’s disease, such as yellowish flecks on the macula^[1][7].

In many cases, your eye doctor may be able to detect Stargardt’s disease by examining your retina and macula, where characteristic yellowish flecks are often visible^[7]. These flecks are deposits of lipofuscin that accumulate abnormally in people with the condition^[4][7].

Your doctor may perform additional tests to diagnose Stargardt’s disease or track your symptoms^[1][2][7]:

• Color vision testing: Stargardt’s disease can cause color blindness, so your eye doctor may test your ability to see colors
• Fundus photography or fundus autofluorescent photography: Your doctor takes detailed photos of your retina to check for yellowish flecks on your macula and assess the extent of changes
• Optical coherence tomography (OCT): This test uses light waves to create a detailed picture of your retina, showing its structure and any damage
• Fluorescein angiography: A test that may be recommended to obtain more detailed images of your retina
• Electroretinography (ERG) or multifocal ERG: These tests measure how well your retina responds to light
• Genetic testing: Your doctor may suggest a genetic test using a blood sample or saliva sample to confirm the diagnosis of Stargardt’s disease and identify the specific gene mutation

Tell your doctor when you first noticed changes in your vision or other symptoms, as this information helps with diagnosis^[2].

Disease stages

Eye care specialists may classify Stargardt’s disease into stages as it progresses^[2]:

Stage 1: Flecks of excess lipofuscin begin to form in your macula. You might have mild symptoms during this stage.

Stage 2: The flecks have built up enough to spread beyond your macula to other areas of your retina around it. Symptoms will become more noticeable at this stage.

Stage 3: The flecks have been absorbed back into your macula and caused damage (a process called atrophy, which means the tissue has wasted away). This causes worsening symptoms.

Stage 4: The atrophy in your macula is severe enough to erase some or all of your central vision.

Understanding these stages helps doctors monitor disease progression and plan appropriate support and management strategies.

Treatment and management

Currently, there is no treatment available that can reverse Stargardt’s disease or repair the damage it causes^[1][2][7]. However, there are steps you can take to slow vision loss and ways to make the most of your remaining vision.

Protecting your vision

You can take several protective steps^[1]:

• Wear a hat and sunglasses to protect your eyes from sunlight when you go outside. Ultraviolet light exposure may accelerate vision loss
• Don’t take dietary supplements that contain more than the daily recommended amount of vitamin A. Excess vitamin A may contribute to the buildup of harmful fatty deposits
• Don’t smoke cigarettes, and try to avoid secondhand smoke. Some research suggests that avoiding smoking may help slow down vision loss for people with Stargardt’s disease

Vision aids and support

While there is no cure, vision rehabilitation and supportive care can help people perform everyday tasks^[1][7]. Your eye care specialist will suggest ways to manage symptoms and adapt to vision changes^[2].

Vision aids and technology are invaluable tools that enable people with Stargardt’s disease to live as normally as possible. Without them, many daily activities like working, reading, using a phone, or reading cooking instructions would be much more difficult^[19].

Low-vision services, mobility training, and other supportive care can help you adapt to vision changes and maintain independence^[7].

Current research

Although no FDA-approved treatments are currently available for Stargardt’s disease, researchers are actively working to develop therapies. Several companies are conducting clinical trials for potential treatments^[10][15].

Emerging therapies being studied

Six companies are actively developing therapies for Stargardt’s disease using various approaches^[15]:

• Vitamin A modification therapies: One promising approach involves using a modified form of vitamin A that produces less waste when processed in the retina. A drug called gildeuretinol (ALK-001) has received special recognition from the US Food and Drug Administration. This daily tablet treatment showed in clinical trials that it could slow retinal damage by more than 20 percent over two years^[12][16]. Early-stage patients taking the drug appeared to maintain stable vision for up to seven years. The treatment was safe and well-tolerated with no serious side effects^[12]
• Gene therapy approaches: Several companies are developing gene therapies that aim to correct or compensate for the faulty ABCA4 gene^[10][15]
• Protein splicing therapy: SpliceBio has dosed the first person in a Phase 1/2 clinical trial for a protein splicing therapy, marking the first FDA-authorized clinical trial for this type of treatment for Stargardt’s disease^[10]
• mRNA trans-splicing gene therapy: VeonGen has received FDA authorization to launch a clinical trial for an emerging therapy^[10]
• Stem cell therapy: Research is exploring whether stem cells could replace damaged retinal cells^[11]

Interested patients may be able to receive experimental treatments by joining a clinical trial^[7]. Talk to your eye doctor about whether participating in research might be appropriate for you.

Initial funding from organizations like BrightFocus Foundation has been crucial in supporting the development of these novel treatments^[16].

Living with Stargardt’s disease

Being diagnosed with Stargardt’s disease can be distressing, but with the right information and support, people can cope very well and lead fulfilling lives^[3]. Many people find that being diagnosed at a young age has enabled them to adapt, and their condition has never stood in the way of achieving their goals.

Finding a supportive work environment is important. Some employers are understanding and accommodating, making it possible for people with Stargardt’s disease to have successful careers^[19].

People with Stargardt’s disease and their families often adapt over time. Family members and friends automatically make small adjustments, such as reading menus aloud or reading subtitles^[19]. The people you surround yourself with may not even notice the disease after a while.

Many people with Stargardt’s disease report that their life is none the worse for having the condition. While certain things like not being able to drive may cause initial disappointment, not dwelling on these limitations helps people maintain a positive outlook^[19].

Vision loss can present challenges in dating and relationships. Being open about your condition upfront can help, although it may take time to find understanding partners^[19].

For children and teenagers with the condition, using assistive devices at school is important, even though young people may initially resist because they don’t want to appear different from their peers^[18].

Support services, counseling, and connecting with others who have the condition can help people adjust emotionally and practically to living with Stargardt’s disease^[17].

Stargardt disease is a rare genetic eye condition that slowly steals central vision, usually beginning in childhood or adolescence, leaving thousands of young people facing daily challenges that most cannot see.

Understanding Stargardt Disease

Stargardt disease is the most common form of inherited macular degeneration that affects children and young adults. Unlike age-related macular degeneration that typically develops after age 60, Stargardt disease usually appears much earlier in life, which is why healthcare providers sometimes call it juvenile macular degeneration or juvenile macular dystrophy. This genetic condition causes progressive damage to the macula, which is the central part of the retina (the light-sensitive tissue at the back of the eye) responsible for sharp, detailed vision needed for activities like reading, recognizing faces, and seeing fine details.^[1][2]

The disease happens when fatty material called lipofuscin builds up abnormally in the retina. In healthy eyes, this yellowish waste product forms naturally during normal cell activity, but the body cleans it away. In people with Stargardt disease, lipofuscin accumulates in the macula and the retinal pigment epithelium (a layer of cells that supports the light-sensing photoreceptor cells). Over time, these deposits damage and eventually kill the photoreceptor cells, leading to permanent vision loss that cannot be corrected with glasses, contact lenses, or refractive surgery.^[4][7]

Epidemiology

Stargardt disease affects approximately one in every 8,000 to 10,000 people, making it a rare condition. In the United States, roughly 30,000 to 60,000 individuals live with this disease. It affects both males and females equally, showing no preference for either sex. The condition has been identified across all ethnic and racial groups worldwide.^[3][4][13]

The typical age of diagnosis is under 20 years, with many children first experiencing symptoms between ages 6 and 12. However, the disease does not always follow this pattern. Some individuals do not develop any noticeable vision problems until adulthood, sometimes not until their 30s or 40s. This late-onset form of Stargardt disease can sometimes be mistaken for early-onset age-related macular degeneration, which makes proper diagnosis particularly important in younger adults presenting with macular problems.^[1][3][7]

Causes

Stargardt disease is caused by changes or mutations in a specific gene called ABCA4, which is located on chromosome 1. This gene provides instructions for making a protein that plays a crucial role in how the body processes vitamin A. The body uses vitamin A to create light-sensitive molecules in photoreceptor cells, which enable vision. When these molecules break down after being exposed to light, they create fatty byproducts as waste material. The protein made by the ABCA4 gene normally cleans up this waste, preventing it from building up in the retina.^[1][4]

In people with Stargardt disease, mutations in the ABCA4 gene result in a defective or missing cleanup protein. Without proper functioning of this protein, the fatty waste material (lipofuscin) cannot be removed efficiently. Instead, it accumulates in yellowish clumps or flecks in the macula and surrounding retinal areas. These deposits are toxic to the delicate photoreceptor cells, gradually destroying them and creating areas of damage called atrophy. As more photoreceptor cells die, central vision progressively deteriorates.^[12][16]

In rare cases, Stargardt disease can be caused by mutations in another gene called ELOVL4. This form of the disease has a different inheritance pattern and accounts for a much smaller number of cases.^[3]

Risk Factors

The primary risk factor for Stargardt disease is having inherited the genetic mutations from biological parents. The disease most commonly follows an autosomal recessive pattern of inheritance. This means that a child must inherit one copy of the mutated ABCA4 gene from each parent to develop the disease. Both parents are typically “carriers” of one mutated gene paired with one normal gene, which means they do not have the disease themselves but can pass the mutation to their children.^[2][7]

When both parents are carriers, each of their children has a 25 percent chance (one in four) of inheriting two copies of the mutated gene and developing Stargardt disease. Each child also has a 50 percent chance of being a carrier like the parents, and a 25 percent chance of inheriting two normal genes. The inheritance pattern means that siblings of someone with Stargardt disease may be at risk of either having the condition or being carriers themselves.^[7][13]

Once someone has Stargardt disease, certain environmental and lifestyle factors may influence how quickly vision deteriorates, though they do not cause the disease. Exposure to bright light and sunlight may accelerate damage to the retina. Taking vitamin A supplements in amounts exceeding the daily recommended dose may worsen the condition by providing more material that gets converted into the toxic lipofuscin deposits. Smoking and exposure to secondhand smoke may also contribute to faster vision loss, though the evidence is still being studied.^[1][21]

Symptoms

The hallmark symptom of Stargardt disease is a slow, progressive loss of central vision in both eyes. Central vision is what allows people to see details directly in front of them, whether reading text, watching television, recognizing faces, or performing tasks requiring precision. The rate at which vision deteriorates varies significantly from person to person. Some individuals lose their central vision relatively quickly over a few years, while others experience a much slower decline over decades. Eventually, most people with Stargardt disease have vision that ranges from 20/200 to 20/400, which means they are legally blind for tasks requiring detailed vision.^[1][4][7]

In the early stages of the disease, vision may be near normal, which can delay diagnosis. As the condition progresses, people begin to notice specific problems. Blurry vision often develops, making it increasingly difficult to see fine details clearly. Gray, black, or hazy spots may appear in the center of the visual field, interfering with whatever the person is trying to look at directly. These blind spots can be particularly frustrating because peripheral (side) vision usually remains intact, meaning people can see movement and objects around them but cannot focus clearly on anything they look at directly.^[2][7]

Many people with Stargardt disease experience increased sensitivity to light, a condition called photophobia. Bright lights can be uncomfortable or even painful, and may temporarily worsen vision problems. Related to this is difficulty adapting when moving between environments with different lighting. It may take much longer than normal for the eyes to adjust when stepping from bright sunlight into a darkened room, or when going from indoor lighting to the dark outdoors at dusk. This adaptation problem, known as dark adaptation difficulty, can affect independence and safety.^[1][2]

Color perception may also become impaired, with some people developing color blindness as the disease progresses. This happens because the macula contains a high concentration of cone photoreceptors, which are responsible for color vision as well as sharp central vision. As these cones die, the ability to distinguish colors accurately may diminish. Night vision may worsen as well, making it difficult to navigate in dimly lit spaces.^[1][3]

While central vision deteriorates, peripheral vision is usually preserved in most cases. This means people with Stargardt disease can typically move around independently and navigate spaces, but struggle with tasks requiring detailed vision. The contrast between functioning peripheral vision and failing central vision creates unique challenges in daily life.^[3][4]

Prevention

Because Stargardt disease is an inherited genetic condition present from birth, there is no way to prevent someone who has inherited the mutated genes from developing the disease. However, people who have been diagnosed with Stargardt disease can take several steps to potentially slow the progression of vision loss and protect their remaining vision.^[1]

Protecting the eyes from excessive light exposure is one of the most important preventive measures. Wearing a wide-brimmed hat and sunglasses that block ultraviolet (UV) rays whenever going outdoors can help shield the retina from potentially damaging light. This is particularly important because people with Stargardt disease often have increased light sensitivity, and bright light may accelerate retinal damage. The sunglasses should ideally block 100 percent of UVA and UVB rays.^[1][21]

Avoiding vitamin A supplements that contain more than the daily recommended amount is crucial. Because the disease involves problems with vitamin A processing in the retina, taking excess vitamin A through supplements may actually worsen the accumulation of toxic lipofuscin deposits. People with Stargardt disease should maintain a normal, healthy diet but avoid high-dose vitamin A supplementation unless specifically directed by their healthcare provider for another medical reason.^[1][21]

Not smoking and avoiding secondhand smoke may help slow vision loss, though the research is still ongoing. Some studies suggest that smoking could accelerate the progression of retinal damage in Stargardt disease, similar to its effects in age-related macular degeneration. People who currently smoke should consider quitting, and support resources are available to help with smoking cessation.^[1][21]

Regular eye examinations are important for monitoring the progression of the disease. Even though the underlying genetic problem cannot be fixed, tracking changes in vision helps healthcare providers adjust support strategies and introduces patients to helpful low vision aids and rehabilitation services at the appropriate times. Early intervention with low vision services can significantly improve quality of life and help people maintain independence as vision changes.^[2]

For families with a history of Stargardt disease, genetic counseling before having children can provide valuable information about risks and options. Genetic testing can identify whether someone is a carrier of the ABCA4 gene mutation, which helps couples understand the likelihood of having a child with the disease and make informed family planning decisions.^[2]

Pathophysiology

The pathophysiology of Stargardt disease centers on the abnormal accumulation of lipofuscin in the retina and the resulting destruction of photoreceptor cells. The process begins at the molecular level with the visual cycle, which is how the eye converts light into electrical signals that the brain interprets as vision. This cycle requires vitamin A in the form of retinoids. When light hits photoreceptor cells in the retina, it triggers a chemical reaction involving these retinoid molecules. After the reaction, byproducts must be cleared away before the photoreceptors can respond to light again.^[4][12]

In healthy eyes, the ABCA4 protein acts as a transporter, moving these byproducts out of the photoreceptor cells so they can be broken down and recycled. In Stargardt disease, mutations in the ABCA4 gene produce a defective or insufficient amount of this transporter protein. As a result, the byproducts cannot be removed efficiently. They accumulate inside the photoreceptor cells and then spill over into the retinal pigment epithelium layer below.^[4][16]

In the retinal pigment epithelium, these accumulated byproducts form lipofuscin, a yellowish-brown pigment composed of clumped proteins and lipids. Lipofuscin is toxic to the delicate cells of the retina. As it builds up, it appears as yellowish flecks that eye doctors can see when examining the back of the eye. These flecks are one of the characteristic signs used to diagnose Stargardt disease during an eye examination.^[2][4]

The progressive stages of Stargardt disease reflect the increasing damage from lipofuscin accumulation. In Stage 1, flecks of lipofuscin begin forming in the macula, and symptoms may be mild. In Stage 2, the deposits have built up enough to spread beyond the macula into surrounding retinal areas, causing more noticeable vision problems. During Stage 3, the accumulated lipofuscin causes atrophy (cell death) in the macula as photoreceptors and retinal pigment epithelium cells die. By Stage 4, severe atrophy has developed, erasing much or all of central vision as large areas of the macula no longer function.^[2][9]

The macula contains the highest concentration of cone photoreceptors, which are responsible for sharp central vision, color perception, and vision in well-lit conditions. As these cones die from lipofuscin toxicity, people lose the ability to see fine details, distinguish colors, and adapt to bright light. Rod photoreceptors, which are responsible for peripheral vision and night vision, are typically less affected in most cases of Stargardt disease, which explains why peripheral vision often remains relatively preserved even as central vision deteriorates.^[4]

The rate of progression varies depending on several factors, including the specific mutations in the ABCA4 gene, environmental factors like light exposure, and possibly other genetic factors that are not yet fully understood. Some mutations result in a complete absence of the ABCA4 protein, while others produce a protein that works partially. The severity of the genetic defect often correlates with how quickly the disease progresses and how severe the vision loss becomes.^[4]

Stargardt disease is a genetic eye condition that gradually damages the central part of the retina, leading to vision loss over time. The main goal of managing this disease is to slow down the damage and help patients maintain their independence and quality of life despite the changes in vision. Treatment approaches include protective lifestyle measures, vision aids, and emerging therapies being tested in clinical research studies.

How Treatment Helps People With Stargardt Disease

When someone is diagnosed with Stargardt disease, the focus shifts quickly to protecting what vision remains and learning to live well with the condition. The treatment path depends on many factors, including when the disease was discovered, how fast it is progressing, and what symptoms the person is experiencing. While doctors cannot yet reverse the damage this disease causes, they can offer guidance on protecting the eyes from further harm and improving daily functioning.^[1]

Medical experts have developed standard recommendations based on years of observing patients and understanding how the disease works. These guidelines help families know what steps to take right after diagnosis. At the same time, scientists around the world are testing new drugs and therapies in clinical trials, hoping to find treatments that can truly slow or stop the disease. Some of these experimental approaches are showing early promise and may become available to patients in the coming years.^[10]

The treatment journey for Stargardt disease is not just about medications or procedures. It involves learning new ways to read, work, and move through the world. It requires support from eye care specialists, rehabilitation professionals, and often emotional counseling. Each person’s experience is different, and treatment plans are tailored to individual needs and life circumstances.^[17]

Standard Treatment Approaches

Currently, there is no approved medication that can reverse or cure Stargardt disease. However, eye doctors provide clear advice on protective measures that can help slow the progression of vision loss. These recommendations are based on understanding how the disease damages the retina and what factors might make that damage worse.^[1]

One of the most important protective steps is avoiding excessive sunlight. The harmful rays from the sun can speed up the accumulation of toxic material in the retina. People with Stargardt disease are advised to wear sunglasses that block ultraviolet light and a wide-brimmed hat whenever they are outdoors. This simple habit can make a real difference in protecting the fragile cells of the macula.^[1]

Another key recommendation involves vitamin A supplements. In Stargardt disease, the body has trouble processing vitamin A properly, and this leads to a buildup of fatty deposits called lipofuscin in the retina. These deposits damage the light-sensitive cells over time. Taking high doses of vitamin A supplements can actually make this problem worse, so doctors strongly advise patients to avoid supplements that contain more than the daily recommended amount of vitamin A.^[1][2]

Beyond these protective measures, standard treatment focuses heavily on vision rehabilitation. This involves working with specialists who teach people how to use their remaining vision more effectively. Low-vision aids such as magnifying devices, special lighting, and screen-reading software can help maintain independence in reading, working, and managing daily tasks.^[1][2]

Vision rehabilitation programs also include orientation and mobility training. Since Stargardt disease mainly affects central vision, people often retain good peripheral vision and can learn techniques to navigate safely. Training helps patients develop strategies for crossing streets, using public transportation, and moving confidently through different environments.^[17]

Eye doctors typically monitor the disease through regular examinations. During these visits, they perform tests to track changes in the retina and measure how vision is changing over time. Tests such as optical coherence tomography (OCT), which creates detailed images of the retina, and electroretinography (ERG), which measures how the retina responds to light, help doctors understand the pace of the disease and adjust recommendations accordingly.^[1][7]

Genetic testing is also considered part of standard care. Confirming the genetic cause of the disease helps families understand inheritance patterns and can be important for family planning. Most cases of Stargardt disease are caused by changes in a gene called ABCA4, and genetic testing can identify these changes. This information is also becoming more important as new gene-based therapies are developed.^[1][2]

Emerging Treatments in Clinical Trials

While standard care focuses on protection and adaptation, the real hope for people with Stargardt disease lies in the new therapies being developed and tested in clinical trials. Several different approaches are being explored, each targeting a different aspect of how the disease damages the retina. These trials represent years of scientific work and offer the possibility that future patients may have real treatment options.^[10]

Modified Vitamin A Therapy

One of the most advanced experimental treatments is a drug called gildeuretinol, also known by its code name ALK-001. This medication is a modified form of vitamin A that has been engineered to work differently in the body. Scientists replaced some of the hydrogen atoms in vitamin A with a heavier form called deuterium. This change makes the vitamin “burn cleaner” in the retina, producing far less of the toxic waste material that builds up in Stargardt disease.^[10][12]

The drug is taken as a daily tablet, making it convenient for patients. In Phase 2 clinical trials, gildeuretinol showed promising results. The studies found that the drug slowed the growth of damaged areas in the retina by more than 20 percent over two years compared to patients who received no treatment. In some patients with early-stage disease who had not yet developed symptoms, the drug appeared to stabilize the condition, allowing them to maintain stable vision for up to seven years.^[12]

The safety profile of gildeuretinol has been encouraging. Patients in the trials tolerated the drug well, with no serious side effects reported. The U.S. Food and Drug Administration has granted this therapy special designations, including Rare Pediatric Disease designation and Fast Track status, which help speed up the approval process. These recognitions signal that regulators see significant potential in this approach.^[12][16]

This same drug is also being tested for geographic atrophy, a late-stage form of age-related macular degeneration that shares some similarities with Stargardt disease. The results in that population have also been positive, showing that the underlying mechanism may help multiple forms of retinal disease.^[12]

Gene Therapy Approaches

Another exciting area of research involves gene therapy, which aims to correct the genetic defect that causes Stargardt disease. Since most cases are caused by mutations in the ABCA4 gene, scientists are developing ways to deliver a working copy of this gene to the retinal cells.^[10][15]

Several companies are pursuing different gene therapy strategies. One approach involves injecting a treatment called VG801 developed by VeonGen. This therapy uses a technique called mRNA trans-splicing to correct the genetic error. The U.S. Food and Drug Administration has authorized a Phase 1/2 clinical trial for this treatment, which will test its safety and early signs of effectiveness. Similar authorization is being sought in Europe so that patients in multiple countries can participate.^[10]

Another gene therapy called SB-007, developed by SpliceBio, uses protein splicing technology. This is a new approach that helps cells produce the missing protein even when the gene is damaged. The first patient was dosed in a Phase 1/2 trial called ASTRA in early 2025. This trial represents the first time the FDA has authorized a protein splicing therapy for any condition, marking an important milestone in the field.^[10]

A company called Ocugen is developing OCU410ST, a subretinal gene therapy that is delivered through a surgical procedure. The therapy is injected under the retina, where it can directly reach the affected cells. Other companies, including Ascidian Therapeutics with their therapy ACDN-01, are also pursuing similar subretinal gene therapy approaches.^[15]

Gene therapies are typically administered only once or a limited number of times, unlike medications that must be taken daily. The goal is for the corrected genes to continue producing the needed protein for many years. However, these are complex treatments that require specialized surgical procedures and carry risks that are still being studied in the early-phase trials.^[10]

Optogenetic Therapy

A different experimental approach involves optogenetic therapy, which aims to make surviving retinal cells sensitive to light even after the normal light-sensing cells have been damaged. A therapy called MCO-010, developed by Nanoscope Therapeutics, uses this approach. The treatment involves delivering genetic instructions to retinal cells that help them respond to light in new ways. This therapy is given through an injection into the eye.^[15]

Optogenetic therapy is particularly interesting because it doesn’t require the original light-sensing cells to be intact. Instead, it reprograms other types of retinal cells to take over some of the light-sensing function. This could potentially help patients who already have significant vision loss, not just those in the early stages of disease.^[15]

Oral Visual Cycle Modulators

Another drug being tested is called tinlarebant (LBS-008), developed by Belite Bio. This medication works by modulating the visual cycle, which is the process by which the retina regenerates light-sensing molecules. By adjusting this cycle, the drug aims to reduce the buildup of toxic byproducts. Like gildeuretinol, tinlarebant is taken orally as a pill, which makes it convenient for long-term use.^[15]

The drug is currently being studied in Phase 3 clinical trials, which is the final stage before seeking approval from regulatory authorities. Phase 3 trials involve larger numbers of patients and compare the new treatment directly against standard care or a placebo to definitively determine whether the treatment works and is safe.^[15]

Stem Cell Therapy

Research into stem cell therapy for Stargardt disease is also underway, though it is in earlier stages compared to drug and gene therapies. The concept involves growing healthy retinal cells in the laboratory and transplanting them into the eye to replace damaged cells. This approach aims to restore the retinal pigment epithelium (RPE), a layer of cells that supports the light-sensing cells and is also damaged in Stargardt disease.^[11]

Stem cell therapy is technically challenging because the cells must survive transplantation, integrate properly into the existing retina, and avoid being rejected by the immune system. Scientists are working on methods to overcome these obstacles. While this approach holds long-term promise, it will likely be several years before stem cell treatments for Stargardt disease become available to patients.^[11]

How Clinical Trials Work

Understanding the phases of clinical trials helps explain how these treatments are being tested. Phase 1 trials are the first tests in humans and focus mainly on safety. Researchers give the treatment to a small number of people to see if it causes harmful side effects and to determine the best dose. Phase 2 trials involve more patients and begin to measure whether the treatment actually works as intended. Researchers look for improvements in vision tests or slowing of retinal damage. Phase 3 trials are large studies that compare the new treatment to current standard care to definitively prove it works and is safe enough for widespread use.^[10]

Participating in a clinical trial can give patients access to cutting-edge treatments before they are widely available. However, trials also involve uncertainty, as the treatments are still being proven. Some patients receive a placebo or standard care as part of the comparison group. Trial participants are closely monitored and receive extensive medical attention throughout the study.^[10]

Most Common Treatment Methods

• Protective Lifestyle Measures
  • Wearing sunglasses and hats to protect eyes from ultraviolet light
  • Avoiding vitamin A supplements above the daily recommended amount
  • Stopping smoking and avoiding secondhand smoke
  • Regular monitoring with eye examinations including OCT and ERG tests
• Vision Rehabilitation
  • Low-vision aids such as magnifying devices and special lighting
  • Screen-reading software and assistive technology
  • Orientation and mobility training
  • Vision therapy to maximize use of remaining peripheral vision
• Modified Vitamin A Therapy (Clinical Trials)
  • Gildeuretinol (ALK-001): deuterated vitamin A taken as daily tablet
  • Tinlarebant (LBS-008): oral visual cycle modulator
  • Shown to slow retinal damage by 20-30% in Phase 2 trials
• Gene Therapy (Clinical Trials)
  • VG801: mRNA trans-splicing therapy
  • SB-007: protein splicing therapy
  • OCU410ST: subretinal gene therapy
  • ACDN-01: subretinal gene therapy
  • Aim to correct the underlying genetic defect in ABCA4 gene
• Optogenetic Therapy (Clinical Trials)
  • MCO-010: therapy to make retinal cells light-sensitive
  • Delivered through injection into the eye
• Stem Cell Therapy (Research Stage)
  • Transplantation of laboratory-grown retinal cells
  • Aims to replace damaged retinal pigment epithelium
  • Currently in early research stages
• Genetic Testing
  • Confirms diagnosis by identifying ABCA4 gene mutations
  • Helps with family planning and understanding inheritance
  • Important for eligibility in gene therapy trials

Sjögren’s syndrome is a chronic autoimmune disease where the body’s own immune system mistakenly attacks the glands that produce moisture, leading to widespread dryness that can affect not only the eyes and mouth but the entire body and internal organs.

Understanding Sjögren’s Syndrome

Sjögren’s syndrome, pronounced “SHOW-grins,” is a condition that occurs when your immune system turns against your own body instead of protecting it. This autoimmune disease—meaning a disease where the immune system attacks healthy cells—primarily targets the glands responsible for producing moisture throughout your body. The most commonly affected glands are those that create tears in your eyes and saliva in your mouth, but the condition can reach far beyond these areas^[1].

The disease was first identified in the early 1900s by Swedish physician Henrik Sjögren, who noticed a pattern among women whose chronic arthritis came alongside persistent dry eyes and dry mouth. Today, medical professionals understand that this syndrome is more complex than originally thought, often affecting multiple body systems and presenting differently from one person to another^[5].

Sjögren’s syndrome can develop in two distinct ways. Primary Sjögren’s syndrome occurs on its own, without any other underlying condition causing it. Secondary Sjögren’s syndrome develops when another health issue, particularly another autoimmune disease, triggers the condition. About half of all cases occur alongside other autoimmune disorders such as rheumatoid arthritis, lupus, or scleroderma^[2].

Epidemiology: Who Gets Sjögren’s Syndrome?

Sjögren’s syndrome affects approximately two million people in the United States, with estimates ranging from one to four million depending on the source. The condition can strike anyone regardless of race or ethnicity, but certain groups face significantly higher risk than others^[3][7].

Women bear the overwhelming burden of this disease. More than 90 percent of people diagnosed with Sjögren’s syndrome are women, creating a female-to-male ratio of approximately 10 to 1. While men can and do develop the condition, it remains far less common in the male population. This dramatic gender difference suggests that hormonal factors may play an important role in the disease’s development^[4][13].

Age also matters considerably when it comes to Sjögren’s syndrome. Although the condition can develop at any age, including in children, most people receive their diagnosis between the ages of 45 and 55. Some sources indicate that the majority of patients are older than 40 at the time of diagnosis, with a second peak occurring after menopause when estrogen levels naturally decline and dryness becomes more pronounced throughout the body^[1][4][10].

People who already have other autoimmune diseases face elevated risk of developing Sjögren’s syndrome. Around half of all people with Sjögren’s syndrome have at least one other autoimmune condition. This connection is so strong that healthcare providers specifically monitor patients with rheumatoid arthritis, lupus, and similar diseases for signs of developing Sjögren’s syndrome^[3].

Causes of Sjögren’s Syndrome

The exact cause of Sjögren’s syndrome remains a mystery that scientists continue to investigate. What is known is that the disease represents a malfunction of the immune system, where the body’s defense mechanism begins attacking its own moisture-producing glands instead of protecting them from genuine threats^[3].

Primary Sjögren’s syndrome appears without any identifiable trigger or preceding condition. Researchers believe that several factors likely work together to create the perfect storm for disease development. Genetic factors appear to play a significant role—several genes have been identified that may make certain individuals more susceptible to developing the syndrome. However, having these genes does not guarantee that someone will develop the disease^[7].

Environmental factors may also contribute to triggering the disease in genetically vulnerable individuals. Some scientists theorize that Sjögren’s syndrome might be sparked by a previous infection with a virus or bacteria. Once activated, the immune system becomes confused and continues attacking the body’s own tissues long after any infection has cleared^[7].

Secondary Sjögren’s syndrome has clearer triggers, developing in response to other existing health conditions. Certain viral infections have been linked to triggering the syndrome, including hepatitis C, cytomegalovirus, Epstein-Barr virus, Human T-lymphotropic virus 1, and even COVID-19. Any autoimmune disease can potentially trigger secondary Sjögren’s syndrome, with rheumatoid arthritis, psoriatic arthritis, and lupus being particularly common culprits^[3].

Risk Factors

Several factors increase the likelihood of developing Sjögren’s syndrome, though having risk factors does not mean someone will definitely develop the disease. Understanding these risk factors helps individuals and healthcare providers remain vigilant for early signs of the condition.

Being female represents the single strongest risk factor for Sjögren’s syndrome. Women are nine to ten times more likely than men to develop the condition. This dramatic difference suggests that sex hormones, particularly estrogen, may influence the disease’s development. The two age peaks—one during childbearing years between 20 and 30, and another after menopause—further support the connection between hormonal changes and disease onset^[4][10].

Age plays a significant role in risk assessment. While Sjögren’s syndrome can develop at any age, including in children, the risk increases substantially for people between 45 and 55 years old. However, a growing number of patients are being diagnosed under age 18, indicating that the disease does not exclusively target older adults^[2].

Having another autoimmune disease dramatically increases the risk of developing Sjögren’s syndrome. Approximately half of all people with Sjögren’s syndrome have at least one other autoimmune condition. The presence of rheumatoid arthritis, lupus, scleroderma, or similar diseases should prompt both patients and doctors to watch carefully for signs of developing dryness and other symptoms characteristic of Sjögren’s syndrome^[3].

Previous viral infections may also elevate risk, though the exact mechanisms remain under investigation. Infections with hepatitis C, cytomegalovirus, Epstein-Barr virus, Human T-lymphotropic virus 1, or COVID-19 have all been associated with triggering secondary Sjögren’s syndrome in some individuals^[3].

Symptoms of Sjögren’s Syndrome

The symptoms of Sjögren’s syndrome vary dramatically from person to person. Some individuals experience only mild discomfort that barely interrupts their daily routine, while others suffer debilitating symptoms that profoundly impact their quality of life and ability to function. The condition affects people differently, and symptoms can fluctuate over time, with periods when they worsen—called flare-ups—alternating with times when they improve, known as remission^[6].

The two hallmark symptoms that define Sjögren’s syndrome are dry eyes and dry mouth. These occur because the immune system attacks and damages the lacrimal glands (which produce tears) and the salivary glands (which produce saliva). People with dry eyes often describe a burning, itching, or gritty sensation, as if sand or gravel is trapped in their eyes. The eyes may appear red and feel irritated. Dry mouth creates a feeling as though the mouth is stuffed with cotton, making swallowing and speaking difficult. The tongue may feel dry and cracked, and some people notice an unpleasant taste in their mouth caused by stomach acid reflux^[1][4].

Beyond the eyes and mouth, dryness can affect many other parts of the body. The skin may become dry and itchy. The nose can feel dry, leading to frequent nosebleeds. The throat may feel parched, triggering a persistent dry cough. Women commonly experience vaginal dryness, which can cause discomfort during intercourse. These widespread moisture problems occur because Sjögren’s syndrome can attack any of the body’s moisture-secreting glands^[3][6].

Chronic dryness brings its own set of complications. A persistently dry mouth dramatically increases the risk of tooth decay, cavities, tooth loss, gum disease, and oral infections including thrush. The lack of saliva makes chewing and swallowing difficult, potentially leading to weight loss and malnutrition. Dry eyes increase vulnerability to eye infections, corneal damage, and vision problems. Some people become unusually sensitive to light^[4][22].

Many people with Sjögren’s syndrome experience symptoms beyond dryness. Joint pain, swelling, and stiffness are common, as are muscle pain and weakness. The salivary glands may become visibly swollen, particularly those located behind the jaw and in front of the ears. Profound fatigue—a bone-deep exhaustion that doesn’t improve with rest—affects many patients and can be one of the most challenging symptoms to manage. Some people develop brain fog, experiencing difficulty thinking clearly or focusing on tasks. Skin rashes may appear, and some individuals lose their sense of taste^[1][3].

Up to half of all people with Sjögren’s syndrome develop extraglandular involvement, meaning the disease affects organs and tissues beyond the moisture-producing glands. The lungs, gastrointestinal tract, kidneys, liver, pancreas, blood vessels, and nervous system can all be impacted. This may cause symptoms such as shortness of breath due to lung inflammation and scarring, digestive problems including heartburn, numbness or tingling in the hands or feet due to neuropathy (nerve damage), and swollen lymph nodes. Rarely, people with Sjögren’s syndrome face an increased risk of developing lymphoma, a type of cancer affecting the lymphatic system^[2][4][5].

Prevention

Currently, there is no known way to prevent Sjögren’s syndrome from developing. Because the exact causes remain unclear and likely involve a combination of genetic predisposition and environmental triggers, specific prevention strategies have not been identified. However, individuals with risk factors—particularly those with other autoimmune diseases—can benefit from awareness and early detection.

For people who already have Sjögren’s syndrome, preventing complications and managing symptoms becomes the focus. Regular dental check-ups every six months are crucial for preventing tooth decay and gum disease that can result from chronic dry mouth. Brushing teeth two or three times daily with fluoride toothpaste and flossing regularly helps protect oral health^[4][6].

Regular eye examinations with an ophthalmologist help detect and prevent corneal damage and eye infections before they become serious. Protecting the eyes from environmental factors that worsen dryness—such as wind, dust, and dry air—can reduce symptoms and complications. Wearing sunglasses with enclosed sides when outdoors helps shield the eyes from drying elements^[4][6].

Maintaining overall health through a balanced diet, adequate hydration, sufficient sleep, and regular exercise may help reduce the frequency and severity of flare-ups. Avoiding smoking is particularly important, as tobacco use can irritate the eyes and mouth while causing saliva to dry up faster. Identifying and managing stress, which can trigger or worsen symptoms, also plays a valuable role in managing the disease^[6][16].

Pathophysiology: How Sjögren’s Syndrome Affects the Body

Understanding what happens inside the body during Sjögren’s syndrome helps explain why symptoms develop and progress the way they do. At its core, the disease involves a malfunction of the immune system, specifically the cells that normally defend the body against infections and other threats.

In Sjögren’s syndrome, certain white blood cells called lymphocytes become confused and begin attacking the body’s own moisture-producing glands. These lymphocytes infiltrate the lacrimal glands (which make tears) and salivary glands (which make saliva), causing inflammation and damage. Over time, this ongoing attack leads to scarring of the gland tissue, which progressively reduces the glands’ ability to produce moisture. Eventually, tear and saliva production can decline dramatically or even cease altogether^[1][5].

The inflammation and scarring process doesn’t stop with the tear and salivary glands. The same immune malfunction can affect other exocrine glands throughout the body—glands that secrete substances through ducts. This explains why people with Sjögren’s syndrome experience dryness in multiple locations: the nose, throat, skin, digestive system, and vagina all contain glands that can be targeted by the misdirected immune response^[3].

In approximately half of patients, the disease extends beyond the glands to affect internal organs and body systems. The immune system may attack the joints, causing inflammation that leads to pain, swelling, and stiffness similar to arthritis. The lungs can develop inflammation and scarring, which impairs breathing. The kidneys may be affected, altering their ability to filter waste from the blood. The nervous system can be damaged, resulting in neuropathy with numbness, tingling, or pain in the hands and feet. The gastrointestinal system may malfunction, causing digestive problems^[2][5].

The chronic inflammation throughout the body contributes to systemic symptoms like profound fatigue, muscle pain, and brain fog. The immune system remains constantly activated, essentially keeping the body in a continuous state of alert that exhausts physical and mental resources. This helps explain why rest alone often fails to relieve the deep fatigue that many patients experience^[2].

The immune system’s attack on the salivary glands creates a cascade of problems beyond simple dryness. Saliva plays numerous protective roles in the mouth: it helps wash away food particles and bacteria, neutralizes acids produced by bacteria, provides disease-fighting substances, and enhances the ability to taste and digest food. Without adequate saliva, the mouth becomes vulnerable to tooth decay, gum disease, oral infections, and difficulty eating and speaking. The loss of these protective functions explains why dental problems become so common and severe in people with Sjögren’s syndrome^[22].

Similarly, tears do more than simply moisturize the eyes. They provide essential nutrients to the cornea, wash away irritants and debris, and contain antibodies that fight infection. When tear production diminishes, the eyes become vulnerable to infections, the cornea can be damaged, and vision problems may develop. The gritty, painful sensation many patients describe results from the eye’s surface becoming dry and irritated without the protective tear film^[22].

Richter’s syndrome is a rare but serious complication where chronic lymphocytic leukemia suddenly transforms into an aggressive form of lymphoma, changing the course of treatment and outlook for patients who were previously managing a slow-growing cancer.

Understanding the Prognosis and What to Expect

When someone living with chronic lymphocytic leukemia, which is a type of slow-growing blood cancer affecting white blood cells, develops Richter’s syndrome, the medical situation changes significantly. This transformation means the body is now dealing with a much more aggressive form of cancer that grows and spreads rapidly. The outlook becomes more challenging, and understanding what this means can help patients and their families prepare emotionally and practically for the road ahead.^[1]

The prognosis for Richter’s syndrome is generally difficult, and it’s important to approach this reality with both honesty and sensitivity. Research shows that people with this condition typically face a median survival time of approximately one year after diagnosis when the aggressive lymphoma is related to their original chronic lymphocytic leukemia cells. This shortened timeframe represents a significant change from the often years-long management possible with chronic lymphocytic leukemia alone.^[3][20]

However, not all cases of Richter’s syndrome follow the same path. About one in five patients develop a form of aggressive lymphoma that is not genetically connected to their original leukemia. These individuals, whose aggressive lymphoma arose independently rather than transforming from existing leukemia cells, tend to have a better prognosis similar to people diagnosed with that type of lymphoma without a history of chronic lymphocytic leukemia.^[2]

Survival expectations also depend on the patient’s treatment history before the transformation occurred. Studies indicate that people who had not yet received treatment for their chronic lymphocytic leukemia when Richter’s syndrome developed generally have better outcomes than those who had already undergone therapy. This suggests that the biology of the cancer cells and how they respond to treatment plays an important role in determining outlook.^[5]

The goal of treatment when Richter’s syndrome occurs is to achieve a remission strong enough to allow patients to proceed to potentially curative therapies like stem cell transplantation. This procedure currently represents the only treatment approach associated with the possibility of long-term survival. Without successful transplantation, remissions achieved through initial treatments tend not to last for extended periods.^[5]

How the Disease Progresses Without Treatment

Understanding the natural progression of Richter’s syndrome helps explain why prompt medical attention becomes so critical when this transformation occurs. Unlike the slow and often manageable course of chronic lymphocytic leukemia, which can sometimes be monitored without immediate treatment through a strategy called “watch and wait,” Richter’s syndrome behaves very differently.^[2]

The transformation itself can happen quite rapidly. Patients may notice that symptoms which had been stable or slowly worsening suddenly become much more severe over a matter of days or weeks. Lymph nodes that were previously small or moderately enlarged can grow dramatically in size, sometimes becoming several centimeters across and causing visible swelling in the neck, underarms, or groin areas.^[2]

Without treatment, the aggressive lymphoma cells multiply quickly throughout the lymphatic system, which is a network of vessels and nodes that normally helps fight infection. Because this system reaches throughout nearly every part of the body, the cancer can spread to multiple locations rapidly. The spleen, which is an organ involved in filtering blood and supporting immune function, often becomes significantly enlarged, potentially causing abdominal discomfort or pain.^[2]

The rapidly growing cancer cells also place increasing demands on the body’s resources and can interfere with normal organ function. Patients may experience progressive fatigue as their energy reserves become depleted. Weight loss often accelerates as the body struggles to keep up with the metabolic demands of the cancer. Night sweats can become increasingly severe, sometimes soaking through clothing and bedding.^[5]

As the disease advances without intervention, complications become more likely. The bone marrow, where blood cells are produced, may become increasingly infiltrated with cancer cells, leading to declining production of healthy blood cells. This can result in worsening anemia, increased susceptibility to infections, and problems with blood clotting.^[3]

Possible Complications and Unexpected Developments

Richter’s syndrome brings with it a range of potential complications that can significantly affect a patient’s health and quality of life. Understanding these possibilities helps patients and families recognize warning signs and seek timely medical attention when needed.

One significant complication involves the blood system itself. As cancer cells crowd the bone marrow, the production of normal blood cells becomes impaired. This can lead to thrombocytopenia, which means having too few platelets in the blood. Platelets are small cell fragments that help blood clot properly, so when their numbers drop, patients may experience unusual bruising, bleeding gums, or nosebleeds that are difficult to stop.^[3]

Anemia, or low red blood cell counts, often worsens when Richter’s syndrome develops. Red blood cells carry oxygen throughout the body, and when their numbers fall, patients may feel increasingly tired, weak, dizzy, or short of breath even with minimal physical activity. Some patients develop visible signs like pale skin or a rapid heartbeat as their body tries to compensate for reduced oxygen delivery.^[3]

The immune system becomes significantly compromised, leaving patients vulnerable to serious infections. White blood cells that normally fight bacteria, viruses, and fungi are either reduced in number or don’t function properly. This means infections can develop more easily and may become severe quickly. Common infections can become life-threatening, and patients need to be vigilant about fever or other signs of infection.^[2]

Organ involvement represents another category of complications. The rapidly growing lymph nodes can press on nearby structures, potentially causing breathing difficulties if nodes in the chest become very large, or swallowing problems if neck nodes compress the esophagus. The enlarged spleen can become uncomfortable and may sometimes rupture if it grows too large, though this is uncommon.^[2]

Laboratory test results often show abnormalities that reflect the aggressive nature of the disease. Lactate dehydrogenase, an enzyme released when cells are damaged, typically rises to very high levels. Calcium levels in the blood may become elevated, a condition called hypercalcemia, which can cause confusion, excessive thirst, and kidney problems if not addressed.^[4]

Treatment complications also deserve consideration. The intensive chemotherapy regimens used to treat Richter’s syndrome can cause significant side effects including severe nausea, hair loss, mouth sores, and further temporary suppression of blood cell production. Managing these treatment-related complications requires careful medical supervision and supportive care.^[5]

Impact on Daily Life and Learning to Adapt

Living with Richter’s syndrome affects virtually every aspect of daily life, bringing physical, emotional, and practical challenges that extend beyond the medical symptoms themselves. Understanding these impacts can help patients and families develop realistic expectations and find ways to maintain quality of life during treatment.

Physical limitations become increasingly apparent as the disease and its treatment progress. The profound fatigue that often accompanies Richter’s syndrome is not the kind of tiredness that improves with rest. It can make even simple tasks like getting dressed, preparing a meal, or walking short distances feel exhausting. Many patients find they need to significantly reduce their activity levels and accept help with tasks they previously managed independently.^[15]

Work and career considerations present difficult decisions. Some patients may need to reduce their work hours, take medical leave, or stop working entirely depending on their symptoms and treatment schedule. The unpredictability of how one will feel from day to day makes it challenging to maintain regular commitments. Financial concerns often accompany these employment changes, adding stress during an already difficult time.

Social relationships and activities undergo significant changes. The increased risk of infection means patients often need to avoid crowds, limit visitors, and skip social gatherings, especially during periods when their immune system is particularly compromised by treatment. This isolation can feel frustrating and lonely, particularly for people who drew energy and joy from social connections.^[15]

Hobbies and recreational activities may need to be modified or temporarily set aside. Physical activities that were once enjoyable might become too tiring or risky during treatment. However, gentle activities like short walks, light stretching, or seated exercises can often continue and may help maintain some physical function and emotional well-being when energy permits.^[15]

Emotional and mental health effects are substantial and completely normal. Receiving a diagnosis of Richter’s syndrome often brings feelings of shock, fear, anger, sadness, or a sense of unfairness, especially for patients who had adjusted to living with chronic lymphocytic leukemia. Anxiety about the future, treatment outcomes, and survival is common and understandable. Some patients experience depression, which should be recognized and treated as a legitimate medical condition rather than a personal weakness.

Relationships with family members may become strained or closer, sometimes both. Loved ones may struggle with their own fears and grief while trying to provide support. Roles within the family often shift as the patient becomes less able to fulfill previous responsibilities. Open, honest communication about needs, fears, and feelings helps families navigate these changes together.

Practical matters demand attention at a time when energy and focus may be limited. Managing medical appointments, coordinating with multiple healthcare providers, understanding treatment plans, navigating insurance coverage, and making decisions about care all require significant mental energy. Many patients find it helpful to designate a family member or friend to help organize medical information and accompany them to important appointments.

Support for Family Members and Caregivers

Family members and close friends play crucial roles when a loved one develops Richter’s syndrome, but this journey affects them deeply as well. Understanding what families face and how they can best support their loved one while caring for themselves is essential for everyone’s wellbeing.

Learning about clinical trials becomes particularly important for families of Richter’s syndrome patients because standard treatments often have limited success. Clinical trials test new treatment approaches that might offer better outcomes than currently available options. Families can help by researching available trials, understanding eligibility requirements, and discussing options with the medical team.^[5]

Many research centers actively conduct clinical trials specifically for Richter’s syndrome, testing combinations of newer targeted drugs, immunotherapy approaches, and other innovative treatments. These trials may be available at specialized cancer centers even if they’re not offered at the patient’s local hospital. Families can search for trials through cancer research organizations, ask the treating doctor for recommendations, or contact major cancer centers to inquire about enrolling.

Understanding what participation in a clinical trial involves helps families support the patient in making informed decisions. Trials have specific requirements about who can participate, may require more frequent monitoring visits, and might involve travel to distant medical centers. However, they also provide access to cutting-edge treatments and very close medical supervision. The decision to participate is deeply personal and should be made after thorough discussion with healthcare providers about potential benefits and risks.

Practical support from family members takes many forms. Helping organize and attend medical appointments, taking notes during consultations, managing medications, preparing nutritious meals, assisting with household tasks, and providing transportation are all valuable contributions. Simply being present, listening without trying to fix everything, and offering comfort during difficult moments matters enormously.

Families should recognize signs that the patient may need additional medical attention, such as fever, severe pain, difficulty breathing, unusual bleeding, confusion, or other concerning symptoms. Knowing when to contact the medical team or seek emergency care helps ensure problems are addressed promptly.

Emotional support proves just as important as practical help. Allowing the patient to express fears, frustrations, and sadness without judgment creates space for honest communication. At the same time, families shouldn’t feel they need to always stay positive or hide their own emotions. Authentic connection and shared vulnerability often strengthen relationships during difficult times.

Respite and self-care for caregivers cannot be overlooked. Supporting someone with Richter’s syndrome is physically and emotionally exhausting. Family members need permission to take breaks, accept help from others, maintain their own health appointments, and acknowledge their own grief and stress. Caregiver burnout helps no one, and taking care of oneself enables better support for the patient.

Financial and legal planning may need attention, particularly given the serious nature of Richter’s syndrome. Families can help by ensuring important documents like advance directives, power of attorney, and wills are in place and reflect current wishes. Understanding insurance coverage, exploring financial assistance programs, and organizing medical bills and paperwork helps reduce stress.

Connecting with others facing similar situations provides valuable support for families. Caregiver support groups, online communities, and counseling services offer spaces to share experiences, learn coping strategies, and feel less alone. Cancer support organizations often provide resources specifically designed to help families navigate the emotional and practical challenges of supporting a loved one with serious illness.

Stargardt disease is a genetic condition that slowly takes away sharp, detailed vision — the kind you need for reading, recognizing faces, or watching your favorite shows. Vision loss usually begins in childhood or adolescence, though some people don’t notice changes until adulthood. While there is currently no cure or approved treatment to restore lost vision, understanding how the disease progresses and what to expect can help patients and families plan for the future and maintain quality of life.

Understanding What Lies Ahead: Prognosis

When a young person receives a diagnosis of Stargardt disease, one of the first questions that comes to mind is: what will happen to my vision? The truth is that Stargardt disease follows a progressive pattern, meaning symptoms gradually worsen over time. However, the speed and extent of vision loss varies considerably from person to person^[1][2].

Most people with Stargardt disease will eventually experience significant loss of central vision — the detailed vision needed for tasks like reading, writing, and driving. Many patients reach a visual acuity level between 20/200 and 20/400, which cannot be corrected with glasses, contact lenses, or surgery^[7]. This level of vision is considered legally blind in many countries, though it’s crucial to understand that this term reflects limitations in detailed tasks rather than complete darkness or inability to see anything at all.

The pattern of vision loss typically begins with difficulty reading or seeing in dim lighting. Some children first notice symptoms between the ages of six and twelve, while others may not experience problems until their twenties, thirties, or even later^[3][4]. There is even a late-onset form of the disease that can appear much later in life.

An important and reassuring aspect of Stargardt disease is that peripheral vision — your side vision — is usually preserved^[2][3]. This means that even as central vision deteriorates, most people retain the ability to navigate spaces, move around independently, and maintain awareness of their surroundings. Complete blindness, where someone cannot see anything at all, is extremely rare in Stargardt disease.

How the Disease Unfolds Naturally

Without any intervention, Stargardt disease follows a fairly predictable biological path, though the timeline varies. The condition is caused by mutations in a gene called ABCA4, which plays a crucial role in how the body processes vitamin A^[1][2]. Vitamin A is essential for creating light-sensitive molecules in the retina, but this process also generates fatty waste products. In a healthy eye, the ABCA4 gene produces a protein that efficiently cleans up this waste.

In Stargardt disease, the faulty gene cannot produce the cleaning protein properly. As a result, fatty material called lipofuscin accumulates in yellowish clumps on the macula — the central part of the retina responsible for sharp, detailed vision^[1][4]. Over months and years, this buildup damages and eventually kills the light-sensitive cells called photoreceptors, particularly the cone cells that allow us to see fine details and colors.

Eye doctors can observe the progression through stages. In Stage 1, small flecks of excess lipofuscin appear on the macula, and symptoms may be mild or barely noticeable. By Stage 2, the flecks have spread beyond the macula to surrounding areas of the retina. Stage 3 brings more serious damage as the flecks are reabsorbed into the macula, causing atrophy — a wasting away of tissue. Finally, in Stage 4, the atrophy becomes severe enough to significantly erase central vision^[2][9].

During this natural progression, people typically notice increasing blurriness in the center of their vision, blind spots or hazy areas, difficulty adapting when moving from bright to dark spaces or vice versa, new problems with color perception, and heightened sensitivity to light^[1][2]. These changes can be gradual or, in some cases, happen more rapidly.

Possible Complications That May Arise

Unlike some other eye conditions, Stargardt disease does not typically cause painful complications or lead to other serious health problems beyond the eyes. However, the progressive nature of vision loss itself presents challenges that can be considered complications in how they affect daily functioning.

One complication that develops in many patients is increased difficulty with color perception^[1][7]. Colors may appear washed out or difficult to distinguish from one another. This happens because the cone photoreceptors responsible for both detailed vision and color vision are damaged by lipofuscin accumulation. For someone who loves art, fashion, or any activity where color matters, this change can be particularly frustrating.

Another issue is the development of photophobia, or extreme sensitivity to light^[1][2]. Bright lights may become uncomfortable or even painful, making it difficult to be outdoors on sunny days or in brightly lit indoor spaces. This sensitivity can lead to avoiding certain environments or activities, potentially affecting social participation.

Some people with Stargardt disease also experience worsening night vision or difficulty adapting to changes in lighting^[2][3]. Moving from a bright outdoor area into a dim restaurant, or trying to navigate at dusk, becomes more challenging. This “dark adaptation” problem can create safety concerns, especially when navigating stairs, uneven surfaces, or unfamiliar environments.

In some cases, the disease also affects peripheral vision, though this is less common than central vision loss^[1][2]. When peripheral vision is impacted, mobility and spatial awareness become more difficult.

There is also the risk of psychological and emotional complications. Depression, anxiety, and feelings of isolation can develop as vision loss progresses and activities become more difficult^[17]. These emotional impacts are real complications that deserve attention and support.

How Stargardt Disease Affects Daily Life

Living with Stargardt disease means adapting to a world that was designed for people with full vision. The disease affects nearly every aspect of daily life, from the practical to the emotional.

Reading becomes one of the most immediately challenging tasks. Books, newspapers, computer screens, and smartphones all require detailed central vision. Many people with Stargardt disease need to use large-print materials, magnifying devices, or screen-reading software that converts text to speech^[17][18]. School assignments and work documents require accommodations. For students, this might mean having note-takers in class, using special glasses or electronic magnifiers, or receiving extended time on tests.

Work and career choices can be significantly affected. Some jobs simply cannot be performed safely or effectively with impaired central vision. Jobs requiring detailed visual work — like surgery, certain types of laboratory work, or operating heavy machinery — may be impossible^[19]. However, many people with Stargardt disease successfully build careers in fields like accounting, counseling, teaching, and various other professions, often with workplace accommodations and assistive technology.

Driving is typically not possible for people with advanced Stargardt disease, which affects independence and requires reliance on public transportation, family members, or ride services^[19]. This loss of driving ability is often cited as one of the most emotionally difficult aspects of the condition, particularly in areas where public transportation is limited.

Social situations present their own challenges. Recognizing faces becomes difficult, which can lead to awkward moments when you don’t acknowledge someone you know^[19]. Reading menus in restaurants, following subtitles on television or in movies, and participating in group activities like board games all require adaptations. Some people report that dating is more difficult because they cannot pick up on facial expressions and visual social cues^[19].

Sports and physical activities require modification. While someone might not be able to play sports that require tracking fast-moving objects, many activities remain accessible with adaptation^[18]. Swimming, yoga, walking, and certain team sports can still be enjoyed with appropriate support and awareness.

Daily household tasks like cooking, cleaning, managing medications, and organizing belongings all require new strategies^[17]. Using contrasting colors, proper lighting, organizational systems, and assistive devices can help maintain independence in these areas.

Despite these challenges, many people with Stargardt disease report living fulfilling, meaningful lives. They complete higher education, build careers, form relationships, raise families, and pursue hobbies and interests^[18][19]. The key is often early diagnosis, which allows time to learn coping strategies, acceptance of the condition rather than constant resistance, and building a strong support network.

Supporting Family Members Through Clinical Trials

For families dealing with Stargardt disease, clinical trials represent hope for future treatments. While there is currently no approved treatment to reverse or halt the disease, researchers around the world are actively testing new therapies. Several promising approaches are under investigation, including gene therapies, stem cell treatments, and drugs designed to reduce the toxic buildup in the retina^[10][15].

Family members can play a vital role in helping patients explore clinical trial opportunities. The first step is understanding what clinical trials are and how they work. Clinical trials are carefully designed research studies that test whether new treatments are safe and effective. Participants in these trials receive close medical monitoring and access to experimental treatments before they become widely available. However, trials also involve risks, as new treatments may not work or may cause unexpected side effects.

One way families can help is by researching available trials. Organizations like the Foundation Fighting Blindness maintain databases of ongoing clinical trials for retinal diseases, including Stargardt disease^[4]. The National Eye Institute and ClinicalTrials.gov also provide searchable databases of studies. Families can review eligibility criteria together, considering factors like the patient’s age, disease stage, genetic mutation type, and location.

Several types of treatments are currently being tested in clinical trials for Stargardt disease. Gene therapies aim to deliver a working copy of the ABCA4 gene to retinal cells. Companies like VeonGen, SpliceBio, and Ascidian Therapeutics are developing different approaches to gene therapy^[10][15]. Stem cell therapies attempt to replace damaged retinal cells with healthy ones grown in laboratories^[11]. Drug therapies, such as gildeuretinol (ALK-001) and tinlarebent (LBS-008), work by modifying vitamin A to reduce toxic waste buildup in the retina^[10][12][15].

Families can support participation by helping with practical aspects like transportation to study sites, which may require travel to specialized research centers. Clinical trials often involve frequent visits, detailed examinations, and careful documentation of any changes in vision or side effects. Having a family member to help coordinate appointments, keep records, and provide emotional support during the process can be invaluable.

It’s also important for families to help patients maintain realistic expectations. Clinical trials, especially early-phase studies, are primarily designed to test safety rather than effectiveness. Even if a treatment shows promise, it may take years before it becomes available to everyone. Some treatments may not work at all. Managing hopes while remaining optimistic about research progress is a delicate balance.

Families should also understand the concept of informed consent. Before enrolling in any trial, patients (or their legal guardians if the patient is a minor) must thoroughly understand the study’s purpose, procedures, potential benefits, and risks. Family members can help by attending consultation appointments, asking questions, and ensuring the patient feels comfortable with the decision.

Beyond clinical trials, families can support their loved ones by staying informed about research advances, connecting with advocacy organizations, and participating in patient registries like My Retina Tracker, which helps researchers understand disease patterns and recruit participants for future studies^[4].

Clinical Trials for Richter’s Syndrome

Richter’s syndrome is a serious transformation of chronic lymphocytic leukemia into a more aggressive form of lymphoma. Currently, 7 clinical trials are testing various treatment approaches for this condition across multiple European countries. These studies are investigating innovative therapies including targeted medications, immunotherapy combinations, and cell-based treatments to improve outcomes for patients whose disease has either returned after treatment or has not responded to previous therapies.

Clinical trial locations

• Austria
  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)
• Belgium
  • Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain
• France
  • Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter’s Syndrome Patients
  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)
• Germany
  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies
  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)
• Italy
  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies
  • Study on the Safety and Effectiveness of Venetoclax, Atezolizumab, and Obinutuzumab for Patients with Richter Syndrome from Chronic Lymphocytic Leukemia
  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)
  • Study on the Effects of Acalabrutinib in Patients with Chronic Lymphocytic Leukemia, Richter’s Syndrome, or Prolymphocytic Leukemia
• Netherlands
  • Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain
  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)
• Poland
  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies
• Spain
  • Study of Mosunetuzumab and Drug Combination for Untreated Patients with Richter’s Syndrome
  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)
• Sweden
  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

This trial is testing BGB-16673, an experimental BTK-degrader medication, in combination with other treatments for patients whose B-cell cancers have returned or not responded to previous therapies. The study is being conducted in Poland, Germany, and Italy.

Main inclusion criteria: Patients must be at least 18 years old with a confirmed diagnosis of relapsed or refractory B-cell malignancy. Participants need to have measurable disease and good physical function with an ECOG Performance Status of 0-1, meaning they can perform daily activities with minimal limitations. Adequate organ and kidney function is required. Women who can become pregnant must use effective birth control during the study and have a negative pregnancy test before starting treatment.

Main exclusion criteria: The study excludes patients under 18 years old and those with active central nervous system involvement from their cancer. Patients with uncontrolled infections, significant heart problems, severe kidney or liver issues, or who are pregnant or breastfeeding cannot participate. Those with a history of other cancers within the past 3 years, known HIV infection, active hepatitis B or C, or mental conditions that could interfere with study participation are also excluded.

Focus and goal: The study aims to find safe and effective treatment combinations for patients whose cancer has come back or did not respond to earlier treatments. It will be conducted in two parts: the first will determine the right dose of the drug combinations, while the second will further study how well these doses work and what side effects they may cause. Doctors will monitor patients’ health throughout, checking how well the treatment is working and tracking any side effects.

Investigational drugs: The trial uses BGB-16673, which works by breaking down a specific protein called BTK that is important in B-cell cancers. This medication is being studied in combination with other treatments including zanubrutinib, sonrotoclax, mosunetuzumab, obinutuzumab, and glofitamab. The medications are given as tablets taken by mouth or through intravenous infusion or subcutaneous injection.

Study of Glofitamab with Rituximab or Obinutuzumab and Drug Combination for Untreated Richter’s Syndrome Patients

This French trial evaluates a new treatment combination for patients who have not previously received treatment for Richter’s syndrome. The study is specifically designed for patients whose chronic lymphocytic leukemia has transformed into a more aggressive form.

Main inclusion criteria: Participants must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma that has transformed into diffuse large B-cell lymphoma. Patients must be between 18 and 80 years old with an ECOG performance status of 0 to 2. At least one measurable tumor or lymph node is required, or bone marrow involvement. Previous treatment for the underlying leukemia is allowed, but not for the transformation itself. Patients must have adequate blood health, liver function, heart health, and kidney function. A negative pregnancy test is required for women of childbearing potential, and all participants must agree to use effective birth control.

Main exclusion criteria: Patients who have already received treatment specifically for Richter’s syndrome cannot participate. Those who do not have the diffuse large B-cell lymphoma type are not eligible.

Focus and goal: The study aims to determine how well a combination treatment works in reducing the cancer. Participants will receive up to six cycles of treatment involving Glofitamab combined with either Rituximab or Obinutuzumab, along with the CHOP chemotherapy regimen (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). The medications are delivered through intravenous infusion, except for prednisone which is taken orally. Regular assessments will track the cancer’s response and monitor for side effects.

Investigational drugs: Glofitamab is a bispecific antibody that helps the immune system target and destroy cancer cells by connecting proteins on cancer cells with those on immune cells. Rituximab and Obinutuzumab also target specific proteins on cancer cells to help the immune system destroy them. The chemotherapy drugs (Cyclophosphamide, Doxorubicin, and Vincristine) work by slowing or stopping cancer cell growth, while Prednisone helps reduce inflammation and manage side effects.

Study of Mosunetuzumab and Drug Combination for Untreated Patients with Richter’s Syndrome

This Spanish trial explores the effectiveness of the M-CHOP treatment combination for patients who have not previously received treatment for Richter’s syndrome.

Main inclusion criteria: Patients must be adults between 18 and 79 years old with previously untreated Richter’s syndrome, specifically the diffuse large B cell variant, confirmed by medical criteria. Participants need to have CD20 positive disease confirmed by special tests. An ECOG performance score of 2 or less is required, meaning patients can perform most daily activities. Adequate bone marrow function and a creatinine clearance of at least 45 mL/min are necessary. Participants must have a life expectancy of more than 3 months and agree to use birth control to avoid pregnancy or fathering a child during the study.

Main exclusion criteria: Patients who have already received treatment for Richter’s syndrome cannot participate. Those outside the specified age range or who are part of a vulnerable population requiring special protection are not eligible.

Focus and goal: The study evaluates the M-CHOP combination, which includes mosunetuzumab, vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide monohydrate, and prednisone. The treatment is structured in cycles with regular monitoring through imaging tests such as PET/CT scans. The primary goal is to achieve complete remission, meaning no detectable disease in the body. The study includes a comparison with a placebo to determine treatment effectiveness.

Investigational drugs: Mosunetuzumab is an experimental immunotherapy medication that targets specific proteins on cancer cells to help the immune system recognize and destroy them. CHOP is a combination of four chemotherapy drugs (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) that work together to kill cancer cells or stop them from growing. Most medications are given intravenously, except prednisone which is taken orally.

Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain

This trial in the Netherlands and Belgium studies Golcadomide for treating lymphoma that affects the brain, including cases where the cancer has returned or not responded to previous treatments.

Main inclusion criteria: Patients must be at least 18 years old with a diagnosis of secondary central nervous system lymphoma, relapsed primary large B-cell lymphoma of the central nervous system, or refractory primary large B-cell lymphoma of the central nervous system. Cohort A participants must have received prior high-dose methotrexate-based chemotherapy. Cohort B participants must have aggressive malignant B-cell lymphoma with specific subtypes and central nervous system involvement confirmed by cerebrospinal fluid analysis, MRI evidence, or biopsy. A WHO performance status of 2 or less is required, along with adequate blood counts and willingness to follow study requirements.

Main exclusion criteria: The study excludes patients with secondary central nervous system lymphoma, relapsed primary large B-cell lymphoma of the central nervous system, and refractory primary large B-cell lymphoma of the central nervous system who do not meet the specific inclusion criteria.

Focus and goal: The study aims to evaluate whether Golcadomide can help reduce the cancer or achieve complete remission. Participants will receive the medication as a capsule taken by mouth. Regular assessments including blood tests and imaging will monitor treatment effects. The study will continue until 2028, examining how the medication behaves in the body, including its presence in spinal fluid compared to blood, and investigating genetic factors that might influence treatment response.

Investigational drugs: Golcadomide (CC-99282) is an experimental medication that interferes with specific pathways cancer cells use to grow and survive, thereby inhibiting their proliferation. It is being tested specifically for brain lymphomas and is administered orally.

Study on the Safety and Effectiveness of Venetoclax, Atezolizumab, and Obinutuzumab for Patients with Richter Syndrome from Chronic Lymphocytic Leukemia

This Italian trial tests a three-drug combination for patients with Richter syndrome, focusing on both safety and effectiveness of this treatment approach.

Main inclusion criteria: Participants must be 18 years or older with a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma with biopsy-confirmed transformation to diffuse large B cell lymphoma consistent with Richter’s Syndrome. An ECOG performance status of 2 or less is required. Patients must meet specific blood health criteria at screening, including adequate neutrophil counts, platelet counts, and hemoglobin levels, unless bone marrow involvement affects these values. Adequate blood clotting, kidney, and liver function are necessary. Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control for specified periods after treatment.

Main exclusion criteria: Patients with other types of cancer unrelated to Richter syndrome, those who have had recent different cancer treatment, pregnant or breastfeeding women, and those with severe uncontrolled medical conditions are excluded. Patients with recent participation in other clinical trials, allergies to study medications, uncontrolled infections, or inability to follow study procedures are also not eligible.

Focus and goal: The study evaluates the combination of venetoclax, atezolizumab, and obinutuzumab to see if it can achieve a significant response rate. The study aims for at least 67% overall response rate by the end of the sixth treatment cycle. Regular assessments will monitor for side effects and treatment effectiveness, including complete remission rate, duration of response, progression-free survival, and overall survival.

Investigational drugs: Venetoclax is taken orally as tablets and works by targeting and blocking a specific protein that cancer cells need to survive. Atezolizumab is given through intravenous infusion and helps the immune system recognize and attack cancer cells by blocking a protective protein. Obinutuzumab, also given intravenously, targets specific proteins on cancer cell surfaces to help the immune system destroy these cells.

Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Richter Transformation (RT)

This multi-country trial (Netherlands, Austria, Germany, France, Spain, Italy, and Sweden) investigates a specialized cell therapy for adults whose disease has returned or not responded to previous treatments.

Main inclusion criteria: Participants must be 18 years or older with a confirmed diagnosis of relapsed or refractory Richter Transformation. At least one measurable lesion is required, and lesions previously treated with radiation can only be counted if they have grown again. Previous treatment side effects must be stable and improved to a mild level. An ECOG performance status of 0 or 1 is required, along with adequate blood and organ function. Patients must have confirmed CLL with transformation to diffuse large B-cell lymphoma. The disease must have returned or not responded after one line of therapy. Those who can have children must agree to use specific birth control methods.

Main exclusion criteria: Patients with different types of cancer unrelated to Richter Transformation, those with severe allergic reactions to similar treatments, uncontrolled infections, pregnancy or breastfeeding, significant heart problems, active hepatitis B, C, or HIV, recent other cancer treatments, or any medical condition making participation unsafe are excluded.

Focus and goal: The study evaluates brexucabtagene autoleucel, a CAR T-cell therapy that uses genetically modified immune cells to target and destroy cancer cells. The treatment involves taking a patient’s own T-cells, modifying them in a laboratory, and infusing them back to fight the cancer. The study monitors response rates, duration of response, time to disease progression, and overall survival.

Investigational drugs: Brexucabtagene Autoleucel is a CAR T-cell therapy involving modified immune cells specifically designed to recognize and attack cancer cells. Preparatory medications like cyclophosphamide and fludarabine may be given before the main treatment. The therapy is administered through intravenous infusion.

Study on the Effects of Acalabrutinib in Patients with Chronic Lymphocytic Leukemia, Richter’s Syndrome, or Prolymphocytic Leukemia

This Italian trial explores acalabrutinib for treating several types of blood cancers, including Richter’s Syndrome, focusing on finding the safest and most effective dose.

Main inclusion criteria: Participants must be 18 years or older with confirmed diagnoses of chronic lymphocytic leukemia, small lymphocytic lymphoma, Richter’s syndrome, or prolymphocytic leukemia that has relapsed or been resistant to at least two previous treatments. For certain groups, patients whose condition is worsening after initially responding to ibrutinib or who did not respond well to ibrutinib can participate. Patients must have measurable disease with at least one lymph node 2 cm or larger and active disease meeting specific criteria for needing treatment. An ECOG performance status of 2 or less is required, along with agreement to use highly effective birth control methods.

Main exclusion criteria: While the trial includes patients with Richter’s Syndrome, specific exclusion criteria relating to this condition were not detailed in the provided information beyond general exclusions for the study.

Focus and goal: The study aims to determine the safety and appropriate dosage of acalabrutinib through dose escalation. Participants receive the medication in increasing doses to find the most effective and safe amount. The study looks at how the body processes the medication and its effects on the disease, with regular monitoring including check-ups and tests to ensure safety and gather information on the medication’s impact. The trial is expected to continue until June 2027.

Investigational drugs: Acalabrutinib (ACP-196) is provided as film-coated tablets and hard capsules taken orally. It works by inhibiting Bruton’s tyrosine kinase, a protein crucial for cancer cell growth and survival. The medication is classified as a kinase inhibitor and represents a targeted therapy option for specific types of leukemia.

Summary

The seven clinical trials for Richter’s syndrome reflect diverse therapeutic approaches across Europe. A notable concentration of trials is occurring in Italy, which hosts four studies, while multiple trials are also active in Germany, France, the Netherlands, and Spain. This geographic distribution suggests strong European commitment to addressing this challenging condition.

The trials can be broadly categorized into three treatment approaches. First, several studies focus on combination immunotherapy and chemotherapy for newly diagnosed patients, such as the glofitamab and mosunetuzumab trials in France and Spain. Second, multiple trials target relapsed or refractory disease with innovative approaches including the venetoclax combination in Italy and the BGB-16673 study spanning Poland, Germany, and Italy. Third, an advanced cell therapy trial using brexucabtagene autoleucel is being conducted across seven countries, representing the most widespread study.

The investigational treatments vary considerably, from targeted oral medications like venetoclax and acalabrutinib to intravenous immunotherapies like glofitamab and obinutuzumab, and finally to sophisticated CAR T-cell therapy. Most trials focus on patients whose disease has returned or not responded to previous treatments, though some specifically target treatment-naive patients. This diversity of therapeutic options and trial designs offers hope for improved treatment outcomes across different patient populations and disease stages.

Raynaud’s phenomenon is a condition where small blood vessels in your fingers and toes suddenly narrow in response to cold or stress, cutting off normal blood flow and causing dramatic color changes, numbness, and pain. Though it affects millions of people worldwide, many live with mild symptoms that can be managed with simple lifestyle changes.

Understanding Raynaud’s Phenomenon

Raynaud’s phenomenon happens when the tiny blood vessels that supply your fingers and toes react too strongly to certain triggers. Instead of slightly narrowing to conserve heat—which is a normal body response—these vessels clamp down much more than they should. This excessive narrowing, called vasospasm (a temporary tightening of blood vessels), severely restricts blood flow to the affected areas. The result is a sequence of distinct color changes that can be alarming if you don’t know what’s happening.^[1]

The condition was first described by a French physician named Maurice Raynaud back in 1862, which is why it bears his name. While the phenomenon can affect any part of your body where small vessels exist, it most commonly strikes the fingers and toes. Some people also experience episodes in their ears, nose, lips, or even nipples.^[2][3]

During an attack, your affected body parts typically go through three distinct stages. First, they turn white or very pale as blood flow drops dramatically. This happens because oxygen isn’t reaching the tissues. Next, they may turn blue or purple as the limited blood present loses its oxygen. Finally, as the blood vessels relax and blood rushes back in, the area turns bright red and often throbs or tingles intensely. This classic three-color progression is known as a triphasic color change.^[3][7]

An episode usually lasts around 15 minutes, though some attacks may be shorter—just a few seconds or minutes—while others can stretch on for hours. The discomfort is typically worst during the final red phase, when blood returns and brings with it a burning, throbbing sensation along with pins and needles.^[2]

Types of Raynaud’s Phenomenon

Medical professionals divide Raynaud’s into two main categories: primary and secondary. Understanding which type you have is important because it affects both the severity of symptoms and the approach to treatment.^[2]

Primary Raynaud’s phenomenon, also called Raynaud’s disease, is the most common form. It occurs on its own without any underlying disease or condition to explain it. The cause remains unknown, though researchers believe genetics may play a role. This type tends to be milder, causing uncomfortable symptoms like color changes and numbness but rarely leading to serious complications such as tissue damage. Most people with primary Raynaud’s can manage their symptoms through lifestyle adjustments alone.^[2][4]

Secondary Raynaud’s phenomenon, also known as Raynaud’s syndrome, develops as a result of another medical condition, medication, or environmental exposure. This form is less common but tends to be more severe. People with secondary Raynaud’s face a higher risk of complications, including painful skin ulcers (open sores) and, in rare cases, tissue death called gangrene. The underlying cause might be an autoimmune disease, blood vessel problems, occupational hazards, or certain medications.^[2][5]

How Common Is Raynaud’s Phenomenon?

Raynaud’s phenomenon affects approximately 4 to 10 percent of people worldwide, though the exact numbers vary depending on the population studied and the climate where people live. It is notably more common in regions with colder weather, where people are frequently exposed to temperature drops.^[8][14]

Women are significantly more likely to develop Raynaud’s than men. In fact, women are about nine times more likely to experience primary Raynaud’s. The condition often begins during adolescence or young adulthood, with most cases of primary Raynaud’s starting before age 30, typically in the teenage years. Secondary Raynaud’s, on the other hand, usually develops later in life, often after age 30, and sometimes affects people over 60.^[1][2][5]

Having a family member with Raynaud’s increases your likelihood of developing the condition, suggesting that genetic factors may contribute to its development. People living in colder climates are also at higher risk, likely because they’re exposed to cold temperatures more frequently, which can trigger episodes.^[1][2]

What Causes Raynaud’s Phenomenon?

The exact cause of primary Raynaud’s phenomenon remains a mystery. Researchers don’t fully understand why some people’s blood vessels react so dramatically to cold or stress. However, they do know how the attacks unfold. When you’re exposed to cold, your body naturally tries to preserve heat by narrowing blood vessels near the skin’s surface. This moves blood away from your extremities and toward your core, protecting vital organs. In people with Raynaud’s, this normal protective mechanism goes into overdrive. The blood vessels narrow far more than they should and stay narrowed for an extended period.^[4][5]

Secondary Raynaud’s has clearer origins, as it’s linked to specific underlying conditions or exposures. The most common cause is an autoimmune disease—a condition where the immune system mistakenly attacks healthy tissue. Diseases like scleroderma (a condition that causes skin and connective tissues to harden), lupus (when the immune system attacks healthy tissues throughout the body), rheumatoid arthritis, and Sjögren’s syndrome frequently cause secondary Raynaud’s. These conditions can damage blood vessels, making them inflamed and more prone to spasms.^[3][5]

Certain medications can also trigger or worsen Raynaud’s symptoms. Beta blockers, used to treat high blood pressure and heart conditions, are known culprits. Migraine medications, interferon drugs, and some medications used for attention deficit hyperactivity disorder can also cause problems. Stimulants, including those found in some cold medicines and diet pills, may narrow blood vessels and bring on attacks.^[5][6]

Occupational exposures represent another important cause of secondary Raynaud’s. People who regularly use vibrating machinery—such as jackhammers, chainsaws, or other power tools—can develop what’s called hand-arm vibration syndrome. Repeated exposure to vibrations damages the nerves and blood vessels in the hands. Workers exposed to certain chemicals, including polyvinyl chloride, or those who experience cold injuries on the job are also at increased risk.^[5]

In older adults, especially those over 60, obstructive vascular disease becomes a more frequent cause. Conditions like atherosclerosis (buildup of fatty material in arteries), diabetes-related blood vessel problems, and other circulatory disorders can all contribute to Raynaud’s symptoms. Rarely, certain infections such as hepatitis B, hepatitis C, or parvovirus B19 have been associated with the condition.^[5]

Risk Factors for Developing Raynaud’s

Several factors can increase your likelihood of developing Raynaud’s phenomenon. Understanding these risk factors can help you recognize whether you might be at higher risk.^[4]

Your biological sex plays a significant role. Women and people assigned female at birth are far more likely to develop Raynaud’s than men. The reasons for this aren’t entirely clear, but hormones, particularly estrogen, may influence how blood vessels respond to cold and stress.^[1][2]

Age matters too, though differently for the two types. Primary Raynaud’s typically appears in young people under 30, often beginning during the teenage years. If you’re over 30 and developing Raynaud’s symptoms for the first time, it’s more likely to be secondary Raynaud’s, which warrants medical investigation to identify any underlying conditions.^[1][7]

Family history is another important factor. If you have close relatives with Raynaud’s, you’re more likely to develop it yourself. This genetic connection suggests that inherited traits affecting blood vessel function may make some people more susceptible.^[1][2]

Having certain autoimmune or connective tissue diseases dramatically increases your risk of developing secondary Raynaud’s. Scleroderma is particularly strongly associated with Raynaud’s—most people with scleroderma will experience Raynaud’s symptoms. Other conditions linked to secondary Raynaud’s include lupus, rheumatoid arthritis, Sjögren’s syndrome, and thyroid disorders.^[3][5]

Lifestyle habits can contribute as well. Smoking is a major risk factor because nicotine causes blood vessels to narrow, making attacks more likely and more severe. Repetitive hand motions, especially those involving vibration from power tools, can damage blood vessels and nerves over time. Even typing or playing piano for extended periods has been suggested as a possible contributor in some cases.^[7][13]

Where you live matters too. People living in colder climates face more frequent exposure to cold temperatures, a primary trigger for Raynaud’s attacks. This repeated exposure may increase both the likelihood of developing the condition and the frequency of episodes.^[8]

Recognizing the Symptoms

The hallmark symptom of Raynaud’s phenomenon is the dramatic color change in your fingers and toes when exposed to cold temperatures or emotional stress. These changes follow a predictable pattern, though not everyone experiences all three phases.^[1]

The first phase brings paleness or whiteness to the affected digits. Your fingers or toes become very pale or white because blood flow has been severely restricted. At this stage, you’ll likely notice that the affected areas feel cold and numb. The lack of sensation can be unsettling, and you might find it difficult to use your hands for detailed tasks.^[3][7]

In the second phase, the affected areas may turn blue or purple. This happens because the small amount of blood remaining in the tissues has been depleted of oxygen. The blue coloration indicates that your tissues aren’t getting the oxygen they need. This phase may not be as noticeable in people with darker skin tones, though the areas may appear somewhat paler or ashen compared to unaffected skin.^[7]

The third phase occurs as blood flow returns. Your fingers or toes become bright red as blood rushes back into the previously starved tissues. This is typically the most uncomfortable phase. You may experience intense throbbing, burning sensations, tingling, or a feeling of pins and needles. Some people describe it as feeling like their fingers are on fire. The pain can be quite sharp and may last several minutes as normal blood flow is restored.^[3][7]

While fingers and toes are most commonly affected, Raynaud’s can also impact other body parts. Your nose, ears, lips, or nipples may experience similar color changes and sensations, though this is less common. Some people find that only one or two fingers are affected during an attack, while others experience symptoms in all digits on both hands.^[2][3]

The frequency and severity of attacks vary widely from person to person. Some people have occasional mild episodes that are more annoying than painful. Others experience frequent, severe attacks that significantly interfere with daily activities. Cold weather is the most common trigger, but even minor temperature changes can cause problems—grabbing something from the freezer, washing hands in cold water, or entering an air-conditioned building on a warm day can all trigger an episode.^[4]

Emotional stress is another powerful trigger. Anxiety, fear, or excitement can cause your nervous system to release chemicals that make blood vessels constrict, bringing on an attack even when the temperature is comfortable.^[2][4]

People with severe secondary Raynaud’s may develop more serious complications. Small, painful ulcers can form on the fingertips or toes when tissues don’t receive adequate blood flow over time. These sores are slow to heal and can become infected. In very rare cases, prolonged lack of blood flow can lead to gangrene, where tissue actually dies. This is most common in people with underlying autoimmune diseases that have damaged the blood vessels.^[2][3]

Prevention and Managing Triggers

While there’s no cure for Raynaud’s phenomenon, you can take many practical steps to prevent attacks and reduce their frequency. For most people with primary Raynaud’s, lifestyle modifications are enough to keep symptoms manageable.^[7]

Staying warm is the most important preventive measure, but it’s not just about keeping your hands and feet warm. You need to keep your entire body warm because Raynaud’s attacks occur when your body’s core temperature drops. Your body responds by restricting blood flow to your extremities to protect vital organs. Dress in layers when going outside, and don’t forget a hat—you lose significant body heat through your head. Wear thick socks and insulated, waterproof boots in cold weather.^[7][16]

For your hands, mittens provide better protection than gloves because they keep your fingers together, allowing them to share warmth. Consider wearing thin gloves inside the mittens for extra insulation. Keep chemical hand warmers on hand—you can slip these into your mittens, pockets, or socks when you know you’ll be exposed to cold for extended periods. Some people find battery-powered heated gloves or socks helpful during winter months.^[3][15]

Be prepared for indoor temperature changes too. Wear oven mitts or thick gloves when reaching into the freezer or refrigerator. Air conditioning can trigger attacks, so consider keeping a light sweater or jacket at your workplace or in the car. Some people find it helpful to warm their hands under a faucet with lukewarm (not hot) water before going outside in cold weather.^[3][15]

If you smoke, quitting is crucial. Nicotine causes blood vessels to constrict, making Raynaud’s attacks more frequent and more severe. Many people find their symptoms improve significantly after quitting smoking. Your doctor can help you find smoking cessation programs and medications to support your efforts.^[7][13]

Limit your caffeine intake. Caffeine can narrow blood vessels and may trigger episodes in some people. This includes coffee, tea, energy drinks, chocolate, and some soft drinks. Pay attention to whether caffeine seems to worsen your symptoms, and consider reducing or eliminating it if you notice a connection.^[7][19]

Managing stress is another important preventive strategy. Since emotional stress can trigger attacks just as effectively as cold temperatures, finding ways to reduce stress can help. Techniques like deep breathing exercises, yoga, meditation, or regular physical activity can help you manage stress more effectively. Some people benefit from biofeedback therapy, which teaches you to control certain body functions, including blood flow to your hands and feet.^[3][7]

Regular exercise improves circulation throughout your body, which can help reduce the frequency and severity of Raynaud’s attacks. Even moderate activities like walking, swimming, or cycling can make a difference. Just be sure to dress warmly when exercising outdoors in cold weather.^[3][15]

Review your medications with your doctor. Some drugs can worsen Raynaud’s symptoms, including certain blood pressure medications, migraine drugs, birth control pills, and over-the-counter decongestants containing stimulants. Your doctor may be able to suggest alternatives that won’t trigger attacks.^[6][7]

For people whose Raynaud’s is related to workplace exposures, protective measures at work are essential. Use anti-vibration gloves when operating power tools, take frequent breaks, and keep your work area as warm as possible. Some people need to change jobs or modify their duties to avoid triggers.^[5]

What Happens During an Attack: The Body’s Response

Understanding what’s happening inside your body during a Raynaud’s attack can help you better manage the condition. The process involves a complex interaction between your blood vessels, nervous system, and various chemical messengers.^[12]

Your body has a sophisticated system for regulating temperature and blood flow. Small blood vessels called arterioles (tiny branches of arteries) and capillaries (the smallest blood vessels) normally adjust their width constantly in response to various signals. When you’re cold, these vessels naturally narrow a bit to conserve heat. When you’re warm, they widen to release heat. In Raynaud’s phenomenon, this adjustment system malfunctions.^[2][5]

The abnormal response in Raynaud’s involves several interconnected problems. First, the blood vessel walls themselves become overly sensitive to cold and stress. The smooth muscle cells that surround these vessels contract too forcefully and for too long. Second, the nerves that control blood vessel width send exaggerated signals, telling vessels to narrow far more than necessary. Third, various chemicals in the blood that normally help regulate blood flow become unbalanced.^[12]

In primary Raynaud’s, these problems are largely functional—the blood vessels structurally look normal, but they behave abnormally. The vessels can fully recover between attacks, which is why primary Raynaud’s typically doesn’t cause permanent damage.^[2][12]

Secondary Raynaud’s is more complex because it involves both functional and structural changes to blood vessels. The underlying disease—often an autoimmune condition—damages the vessel walls themselves. Inflammation can make vessel walls thick and stiff. Scarring may develop. The inner lining of vessels, called the endothelium, may not work properly. All these structural changes make it harder for blood to flow normally, and they explain why secondary Raynaud’s is more likely to cause tissue damage.^[12]

The balance between chemicals that narrow vessels (like endothelin and norepinephrine) and those that widen them (like nitric oxide) is disrupted in Raynaud’s. Too much of the narrowing chemicals or too little of the widening ones—or both—leads to the excessive vasoconstriction that characterizes the condition. Hormones, particularly estrogen, may influence this balance, which could help explain why women are more susceptible to Raynaud’s.^[5][12]

When blood flow is severely restricted during an attack, the affected tissues don’t receive enough oxygen. This oxygen deprivation, called ischemia, causes the numbness and color changes. If the ischemia is brief, as in typical Raynaud’s attacks, tissues recover completely when blood flow returns. However, if attacks are frequent and severe, or if underlying blood vessel disease is present, tissues may not get enough oxygen even between attacks. This can lead to permanent damage, including ulcers or, in extreme cases, tissue death.^[2][12]

Raynaud’s phenomenon is a condition where fingers and toes react dramatically to cold temperatures or stress, turning white, blue, and then red as blood flow changes. While it can be uncomfortable and sometimes painful, understanding how to manage this condition can help people maintain their quality of life and prevent complications.

Prognosis and Life Expectancy

The outlook for people with Raynaud’s phenomenon depends greatly on which type they have. Understanding the difference between primary and secondary forms helps set realistic expectations about the future.

For those with primary Raynaud’s disease (the most common form), the prognosis is generally very good. This type occurs on its own, without any underlying health condition causing it. Most people with primary Raynaud’s experience mild symptoms that can be managed through simple lifestyle changes^[1][2]. The condition does not shorten life expectancy and typically does not damage blood vessels permanently. While episodes can be uncomfortable and disruptive, they rarely lead to serious complications. Primary Raynaud’s affects more women than men and often begins in younger people, typically under age 30, sometimes starting during the teenage years^[1][4].

The situation differs for those with secondary Raynaud’s phenomenon, which occurs due to an underlying condition such as lupus, scleroderma, rheumatoid arthritis, or other autoimmune diseases^[2][3]. In these cases, the prognosis depends not only on the Raynaud’s itself but also on the severity and management of the underlying disease. Secondary Raynaud’s tends to be more serious because both functional and structural problems exist in the blood vessels. This means that in addition to the blood vessels narrowing too much in response to cold or stress, there may also be permanent damage to the vessel walls^[2].

People with secondary Raynaud’s face a higher risk of developing complications. These can include painful skin ulcers on the fingertips or toes, which are open sores caused by poor blood flow^[4][2]. In rare cases, severely reduced blood flow can lead to gangrene, which is tissue death, potentially requiring amputation. However, it’s important to emphasize that gangrene is rare and typically only occurs when the condition is severe and not properly managed^[2].

The good news is that with proper treatment and lifestyle modifications, most people with either form of Raynaud’s can manage their symptoms effectively and maintain good quality of life. Regular monitoring by healthcare professionals, especially for those with secondary Raynaud’s, helps catch any complications early when they are most treatable^[9].

Natural Progression of the Disease

Raynaud’s phenomenon follows different paths depending on whether someone has the primary or secondary form, and understanding what happens if the condition is left untreated helps people appreciate the importance of management strategies.

In primary Raynaud’s disease, the natural course is generally stable or even improving over time. Many people find that their symptoms remain about the same year after year, with occasional episodes triggered by cold weather or stress. Some individuals experience fewer and less severe attacks as they age, although the condition rarely disappears completely on its own^[1]. Without treatment, primary Raynaud’s continues to cause uncomfortable episodes where fingers and toes turn white, blue, and red, but these episodes do not progressively worsen or cause permanent damage to the affected areas.

The typical episode of primary Raynaud’s begins when someone is exposed to cold temperatures or experiences emotional stress. The blood vessels in the fingers and toes suddenly constrict much more than they should. This causes the affected areas to turn pale or white as blood flow decreases dramatically. The skin also becomes cold and numb during this phase^[2]. As the lack of oxygen continues, the skin may turn blue. When the blood vessels finally relax and blood flow returns, the affected areas turn bright red and may throb, tingle, or feel painful. This entire sequence usually lasts around 15 minutes, though it can occasionally last several hours^[2][4].

For those who don’t take steps to manage their condition, these episodes simply continue to occur whenever they encounter triggers. The frequency might increase during colder months and decrease in warmer weather. However, between episodes, the fingers and toes return to normal appearance and function^[1].

Secondary Raynaud’s phenomenon follows a more concerning path if left untreated. Because this form involves both functional problems (blood vessels constricting too much) and structural problems (actual damage to blood vessel walls), the natural progression can be more serious^[2]. The underlying disease causing the secondary Raynaud’s may progressively damage blood vessels over time, making attacks more frequent, more severe, and longer-lasting.

Without proper treatment, people with secondary Raynaud’s face increasing risk of tissue damage. The reduced blood flow during repeated episodes can eventually harm the skin and underlying tissues of the fingers and toes. Small cuts or injuries may heal very slowly or not at all. Over time, painful ulcers may develop on the fingertips or toes, which are essentially wounds that form because the tissue isn’t getting enough blood and oxygen to stay healthy^[3][4].

In severe cases of untreated secondary Raynaud’s, prolonged lack of blood flow can cause tissue death, known as gangrene. When this happens, the affected tissue turns black and must be removed surgically to prevent infection from spreading. This can ultimately lead to amputation of affected fingers or toes, though this outcome is rare when people receive appropriate medical care^[2].

The underlying autoimmune disease or other condition causing secondary Raynaud’s also continues to progress if not treated. For example, someone with undiagnosed scleroderma might experience increasing skin thickening and internal organ involvement alongside worsening Raynaud’s symptoms^[5].

Possible Complications

While many people with Raynaud’s phenomenon experience only temporary discomfort, complications can develop, particularly in those with the secondary form of the condition. Understanding these potential complications helps people recognize warning signs and seek timely medical attention.

The most common complication is the development of digital ulcers, which are open sores that form on the fingertips or toes. These ulcers occur when repeated episodes of reduced blood flow damage the skin and underlying tissue. The tissue simply doesn’t receive enough oxygen and nutrients to stay healthy, causing it to break down and form painful wounds^[3][4]. Digital ulcers are much more common in people with secondary Raynaud’s, particularly those with scleroderma or other connective tissue diseases.

These ulcers are not like typical cuts or scrapes. They tend to heal very slowly because the poor blood circulation that caused them also makes it difficult for the body to repair the damage. Even small ulcers can be extremely painful, making it difficult to use the hands for everyday tasks like buttoning clothes, typing, or holding objects. In some cases, these ulcers can become infected, adding another layer of complication that requires antibiotic treatment^[3].

Another potential complication is skin changes in the affected areas. Repeated episodes of Raynaud’s can cause the skin on the fingers and toes to become thin, tight, and shiny. The skin may lose its natural texture and elasticity. In some people, particularly those with underlying scleroderma, the skin may also thicken and become hard to the touch. These changes can affect dexterity and make the fingers and toes more vulnerable to injury^[5].

In rare but serious cases, prolonged severe reduction in blood flow can lead to gangrene, which is the death of body tissue. When tissue dies, it turns black and must be surgically removed to prevent infection. If gangrene affects a significant portion of a finger or toe, amputation may be necessary. It’s crucial to understand that this is an uncommon complication that typically only occurs in severe, untreated cases of secondary Raynaud’s^[2].

Some people develop complications related to their attempts to warm up during an attack. For instance, running very hot water over cold, numb fingers can cause burns without the person realizing it immediately because the fingers are numb and can’t properly sense temperature. Similarly, placing hands or feet too close to heaters or fires can result in burns^[23].

Chronic pain can become a complication in itself. Some people with severe Raynaud’s experience ongoing pain in their fingers and toes, even between attacks. This persistent discomfort can significantly impact quality of life and may require pain management strategies or medications^[3].

For those with secondary Raynaud’s, complications from the underlying disease can interact with or worsen the Raynaud’s symptoms. For example, someone with lupus might experience joint inflammation that makes it even harder to protect their hands from cold exposure. Someone with scleroderma might have difficulty moving their fingers due to skin tightening, making it challenging to perform warming exercises during an attack^[5].

Impact on Daily Life

Living with Raynaud’s phenomenon affects many aspects of everyday life, from simple household tasks to social activities and work responsibilities. The condition requires constant awareness of potential triggers and advance planning to avoid or manage attacks.

Physical activities and daily tasks become more challenging. Simple actions that most people take for granted require careful thought for someone with Raynaud’s. Opening a refrigerator or freezer can trigger an attack, so many people learn to use oven mitts or gloves when retrieving frozen items^[3][15]. Going grocery shopping means planning ahead to bring gloves for handling cold items in the frozen food section. Even holding a cold beverage can be problematic, leading people to use insulated sleeves or hold drinks with a napkin wrapped around them.

Weather and seasonal changes significantly impact daily life for people with Raynaud’s. Cold weather doesn’t just mean dressing warmly—it requires strategic layering of clothing, always carrying extra gloves, and sometimes avoiding outdoor activities altogether during winter months^[7]. Air conditioning in summer can also pose problems, as walking into a heavily air-conditioned building on a hot day can trigger an attack due to the sudden temperature change^[3][16].

The emotional and psychological impact of Raynaud’s should not be underestimated. Many people experience anxiety about having an attack in public or social situations. The visible color changes in fingers can draw unwanted attention and questions from others. Some people feel self-conscious about their hands looking different or worry about shaking hands in social or professional settings when their fingers are cold^[1].

Social activities often require modification. Going to outdoor events, concerts, or sports games in cold weather requires extensive preparation with multiple layers of clothing and hand warmers. Some people find themselves declining invitations to activities they used to enjoy because managing their condition in those settings feels overwhelming. Swimming, even in heated pools, can be problematic because the body cools down when getting out of the water^[16].

Work life can be significantly affected depending on the person’s occupation. Office workers may struggle with air conditioning or need to request workspace modifications. People who work outdoors or in cold environments face daily challenges that may affect their ability to perform their jobs. Those whose work involves fine motor skills with their hands may find that frequent attacks interfere with their productivity and accuracy^[23].

Hobbies and leisure activities may need adjustment. Gardening, crafts, playing musical instruments, or participating in winter sports all become more complicated when managing Raynaud’s. Many people find they must give up activities they once loved or find creative ways to adapt them to accommodate their condition^[16].

There are strategies for coping with these limitations that many people find helpful. Keeping the entire body warm, not just the hands and feet, is crucial because attacks happen when the body’s core temperature drops^[16]. Wearing layers of loose clothing allows for temperature regulation throughout the day. Chemical hand warmers tucked into gloves or pockets provide portable heat sources. When an attack begins, simple exercises like swinging the arms in circles or wiggling fingers and toes can help restore blood flow^[3][15].

Planning ahead becomes second nature. This means checking weather forecasts before going out, always having gloves accessible, warming up the car before getting in, and thinking through potential cold exposures before they happen. Many people develop detailed personal strategies that work for their specific situation and lifestyle^[23].

Regular exercise helps improve circulation overall and may reduce the frequency of attacks^[3][7]. Finding ways to stay active despite the challenges of Raynaud’s contributes to both physical and emotional well-being. Eating warm meals before going out in cold weather can help raise core body temperature^[23].

Support for Family and Caregivers

Family members and friends play an important role in supporting someone living with Raynaud’s phenomenon. Understanding the condition and how it affects daily life helps loved ones provide meaningful assistance and encouragement.

One of the most valuable things family members can do is learn to recognize the signs of an attack and understand how to help. When someone is experiencing an attack, their fingers or toes turn pale or blue, feel numb, and may become painful. Family members can assist by helping the person move to a warmer environment, finding warm water for them to soak their hands or feet in, or helping them put on extra layers of clothing. Knowing not to use very hot water, which could cause burns to numb fingers, is important safety information for caregivers^[23].

Understanding that Raynaud’s requires constant environmental awareness helps family members support practical adaptations at home. This might mean keeping the house warmer than they otherwise would, understanding why the person needs to wear gloves even for seemingly minor exposures to cold, or helping with tasks that involve handling cold items. Simple accommodations like retrieving items from the freezer, opening cold beverage containers, or handling other cold objects can make daily life easier for someone with Raynaud’s^[15].

Family members can help with advance planning for outings and activities. This includes reminding the person to bring gloves and hand warmers, helping them layer clothing appropriately, and being patient if they need to warm up before or during activities. Understanding that declining certain invitations isn’t personal rejection but rather necessary self-care helps maintain relationships^[16].

When it comes to clinical trials for Raynaud’s phenomenon, family members can provide crucial support in several ways. Clinical trials are research studies that test new treatments, medications, or management strategies for Raynaud’s. These trials are essential for advancing medical knowledge and developing better treatment options for the condition.

Family members can help their loved one find relevant clinical trials by searching medical databases, contacting medical centers that specialize in Raynaud’s or related conditions, or asking the person’s doctor about available trials. The search process can be time-consuming and sometimes confusing, so having help navigating websites and making phone calls to gather information can reduce the burden on the person with Raynaud’s^[4].

Understanding what participation in a clinical trial involves helps family members provide informed support. Trials typically require multiple visits to a research center, careful tracking of symptoms, and sometimes trying new medications or therapies. Family members can help by driving the person to appointments, helping them remember to record symptoms or take medications as directed by the trial protocol, and providing emotional support during the often lengthy trial process.

Family members should understand that participating in clinical trials is completely voluntary. The decision to join or leave a trial belongs to the person with Raynaud’s. However, discussing the potential benefits and risks together can help in making informed decisions. Benefits might include access to new treatments before they’re widely available and close monitoring by specialists. Potential concerns include time commitment, possible side effects of experimental treatments, and the possibility of receiving a placebo rather than the active treatment in some types of studies.

Emotional support throughout the trial process is valuable. Some people feel anxious about trying new treatments or worried about disappointing researchers if they need to withdraw from a study. Family members can provide reassurance and help maintain perspective about the person’s right to make decisions about their own healthcare.

Supporting someone with secondary Raynaud’s may involve additional considerations related to the underlying disease. This might mean attending medical appointments to help remember information the doctor provides, understanding the connection between the underlying condition and the Raynaud’s symptoms, and providing support for managing multiple health conditions simultaneously^[5].

Finally, family members benefit from learning about Raynaud’s support organizations and resources. Groups specifically focused on Raynaud’s and related conditions offer educational materials, support group connections, and updates on research advances. Sharing these resources can help both the person with Raynaud’s and their family members feel less isolated and more informed^[7].